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ABSTRACT

USING A NETWORK OF SINGLE SITE-SPECIFIC CYSTEINE MUTATIONS
COUPLED WITH CROSSLINKING MASS SPECTROMETRY (CX-MS) TO REFINE
THE STRUCTURE AND DYNAMICS OF THE HUMAN ALPHA 1 GLYCINE
RECEPTOR (GLYR)

By
Kayce Alexandra Tomcho
May 2021

Dissertation supervised by Dr. Michael Cascio
A network of site-specific single Cys-mutations coupled with CX-MS can be used
to elucidate a more refined structure of GlyR and obtain a more definitive understanding
of pentameric ligand-gated ion channel (pLGIC) allostery. Each Cys-mutant is introduced
into an α1 homomeric Cys null background (C41S/C290A/C345S), or in the same
background with F207G/A288G mutation that allows non-desensitizing GlyR activation
by ivermectin (IVM). State-dependent crosslinking with methanethiosulfonate
benzophenone (MTS-bzp) to a single thiol of purified, vesicle reconstituted GlyR are
conducted after enriching the receptor in different allosteric states: resting (no ligand),
open (F207G/A288G + IVM), or desensitized (excess glycine). Digested peptides are
analyzed via liquid chromatography mass spectrometry to identify sites of intra- and
intermolecular crosslinking. Tandem MS of mass-shifted precursor ions further refine
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these distance constraints. Independent comparative studies targeting different single Cys
GlyR (M287C, K116C, K206C) provides evidence of allosteric changes between the
three states, as well as direct topological information of regions that are unresolved in
other high-resolution structures of pentameric ligand gated ion channels (pLGICs), most
notably the M3-M4 loop. The unresolved loop is shown to interact with the rest of the
protein primarily in non-conducting states, possibly highlighting its role in structure in
those states. Regions of receptor mobility have also been identified and are both novel
and congruent with what is reported in literature. Reported mobile regions include the
M2-M3 loop, the C-loop, M3-M4 loop and very near the N-terminus. These findings can
be applied to further refinement of GlyR structure, and provide information on GlyR
molecular mechanism. Additionally, methods reported in this work can also be applied to
the understanding of other members of the pLGIC family, and other transmembrane
proteins that are waiting further structural information.
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CHAPTER 1. CROSSLINKING MASS SPECTROMETRY (CX-MS)
1.1 Introduction
The 1980s saw a surge of developments in mass spectrometry that paved the way
for mass spectrometry proteomics. The Nobel prize in chemistry was awarded to John
Fenn, Koichi Tanaka and Burt Wuthrich for the development and utilization of a “soft”
ionization source, electrospray ionization (ESI) which allowed for the study of “molecular
elephants”, or proteins.1 ESI and also MALDI (matrix-assisted laser desorption/ionization)
allow protein samples to become ionized while preserving both covalent and non-covalent
interactions that are crucial to the folding and assembly of proteins. These ionization
sources are usually coupled with time-of-flight (TOF) or quadrupole-time-of-flight (QTOF) mass analyzers to separate the ions to provide accurate mass measurements.2
A protein sample can be introduced to the mass spectrometer and is generally
analyzed in two ways, as a whole protein or as peptide fragments. This refers to either the
top-down or bottom-up approach, respectively. Both of these methods can provide
information on the sequence, structure, higher order assembly, binding properties and
kinetics of proteins and thus, are very useful.3
In bottom-up studies, the protein is enzymatically digested fully before being
separated by liquid chromatography, ionized by either ESI or MALDI and then shuttled to
the mass analyzer. Tandem MS (or MS/MS) allows selected peptide ions (in this case) to
be selected by m/z and be further fragmented before undergoing a second mass
spectrometric analysis. These precursor ions, the peptides chosen, are most commonly
fragmented using collision induced dissociation (CID) which typically breaks peptides at
their peptide bond, or at the alpha carbon, producing what is referred to as b, y and a ions
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(see Figure 1 for representations of these fragments) depending on which side of the
peptide (N or C-terminus) the charge resides.2 These ions are referred to as product ions,
and are used to match to predicted fragmentation patterns in databases. This can be used
for a variety of approaches such as de novo sequencing, protein identification, quantitation
of proteins, and most relevant to this work – protein structure determination.3,4
Over the last two decades, the ability to study protein structure using MS has further
evolved into several different techniques. Of particular interest here is crosslinking mass
spectrometry (CX-MS). CX-MS has emerged as a useful tool in determining protein
structure and dynamics,5–10 uncovering protein constituents in large protein assemblies,6,11–
13

identifying protein-lipid interactions,14–16 protein-DNA interactions useful in epigenetics

research,17 studying the interactome18,19 and analyzing proteins in situ.20
CX-MS still makes use of the soft ionization techniques spoken of previously, and
uses MS/MS with CID to produce fragmentation spectra in order to do this. A few of the
other mass spectrometric approaches to studying protein structure will be addressed in
Section 1.2.4. Continued advancements to a growing database of crosslinked peptides,7,21,22
and a better matching system that also identifies the confidence of a match,7 as well as
methods to better quantitate crosslinking6,7 will aid in the further popularity and usefulness
of CX-MS.
The overall principle of this technique relies on generating a covalent bond between
residues that are close in space. After crosslinking occurs, the sample is proteolytically
digested to allow for better ionization of these smaller peptide fragments and then analyzed
via mass spectrometry and various software databases. A series of generated crosslinks
give

rise

to

distance

constraints

and
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create

a

topological

map

of

the

complex/protein/interactome in question. The topological map can be used to aid in the
development or refinement of current structural models and can provide necessary details
into the molecular mechanisms of the protein in various conformations and its interactions
with its surroundings.
The crosslinker used to generate these distance constraints consists of at least two
parts; reactive groups that are either homo- or hetero-functional and a spacer connecting
the two that determines the distance between the proximal residues. The spacer can be
thought of as a ‘molecular ruler’ as its length can be variable, from zero-length to longer.
Using multiple sites of initial attachment of the crosslinker within the protein of interest
can provide a network of interactions that aid in model building and structural refinement.
Typical chemistries used based on limited reactive groups of 20 natural amino acids are
amine, carboxylate, thiol and photoreactive. Some crosslinkers also include additional
components such as moieties to allow for enrichment of crosslinked species.
CX-MS is a high-throughput and versatile technique. Though it has low-resolution,
it benefits from having complementarity to other structural techniques.10,19,23 CX-MS is
also highly sensitive, as only femtomolar amounts of total protein are required to generate
many detectable crosslinks using modern MS platforms.5,8 Sample purity, homogeneity
and solvent requirements for MS are more inclusive than x-ray crystallography or
NMR,10,24 and thus can be applied to larger proteins,13,23 membrane proteins5,25,26 and
protein assemblies,19,20 in their native environments. Perhaps most important,
conformational changes and protein dynamics can be analyzed as CX-MS allows
investigators to examine functional complexes under wide ranges of physiological
conditions. In other high-resolution structures, the protein is often truncated, bound with
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stabilizers, solubilized or mutated for stability, often resulting in a non-functional protein,
leaving the determined structure a static image that does not truly represent a dynamic fulllength protein in its native environment.27,28
1.2. Methodologies for Determining Structure - Why Choose CX-MS?
As previously mentioned, CX-MS is very versatile and lends itself to analyzing
proteins not only in native conformations and environments but also in the context of larger
systems. Since this will be a discussion about the utility of MS methodologies, particularly
CX-MS, as a useful complement to other methods for studying the structure of proteins
this section will first discuss some of the methods with a particular focus on membrane
proteins.
Membrane proteins represent approximately 25 to 30% of the entire proteome, but
a disproportionate amount of them are targets for therapeutics.29–31 However, the
characterization of integral membrane proteins, such as pentameric ligand-gated ion
channels (pLGICs, see Chapter 2), is particularly challenging as they are typically
expressed in low abundance, and because they are very hydrophobic, can only be purified
by solubilization in detergents.25,32,33 They are often hard to crystallize due to the need for
solubilizing detergents.33 The toolbox used by structural biochemists has a variety of
methods to deal with these complications, though there are limitations to each of them.
1.2.1. NMR
NMR (nuclear magnetic resonance) spectroscopy studies the quantum mechanical
properties of the nucleus of an atom by analyzing their behavior in a magnetic field and
quantizing their nuclear spin. These properties depend on the local environment in which
the atom is situated, and in the case of protein NMR, this information can be used to build
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a map of how the atoms in the protein are linked together chemically, how close they are
in space, and how they move with respect to one another.34 For proteins, the atom that is
analyzed is usually the unpaired spin states 1H, 13C, 15N, or a combination of them.34 There
are several different types of 2D-NMR techniques that are used in structural biochemical
studies, including; COSY (correlation spectroscopy), NOESY (nuclear Overhauser effect
spectroscopy), TOCSY (total correlation spectroscopy), HSQC (heteronuclear singlequantum correlation spectroscopy), among others, which are reviewed quite thoroughly in
these reviews.35–41 All of them require similar steps to gain structural information,
however; including sample preparation, which requires highly purified, stable and
concentrated protein,19,42,43 data acquisition, spectra processing which matches NMR
resonances to each atom in the protein and structural analysis which builds the structure
using either distance geographic methods or molecular dynamics.35,42,44
The major advantage to this technique is that protein structure can be determined
for soluble proteins in their natural state. Because of this, NMR structures are able to
represent protein dynamics.34,36,44 It is also a high-resolution technique, that provides good
details and insights into protein structure. The disadvantages, however; are that the sample
must be highly pure, in high concentration and stable, and be no larger than approximately
50 kDa.45–49 Also, membrane proteins, because of their large hydrophobic regions are
difficult to study due to large micelle size of solubilized proteins, whose slow tumbling
results in peak broadening.10,25,50 Solid-state techniques have been utilized to study some
membrane proteins, but NMR studies have limited success in studying full-length integral
membrane proteins, and instead has been used to examine smaller truncated soluble
domains of membrane proteins.
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1.2.2. X-ray Diffraction
X-ray diffraction uses x-rays to determine the arrangement and position of atoms
in a crystal. By exposing a crystalline sample with x-ray beams, the generated angles and
intensity of the diffracted x-rays as a function of sample orientation can be measured, and
deconvoluted to create a three-dimensional image of the electron density of the crystallized
molecule. This information can be used in fitting atom positions, chemical bonds, and
structural details of a protein in question.42,51,52
Major advantages to this methodology are the model building, high resolution and
broad molecular weight range. Furthermore, x-ray diffraction is well studied and has been
used for years.42 Though it can be used for a wide variety of protein types and for proteins
in complex with DNA or RNA, the preparation, diffraction and crystallization for the
technique is laborious and difficult.19,52 The samples used to generate structures must be
able to be crystallized and must have high purity.52 There is also difficulty in studying
membrane proteins, highly flexible proteins and large protein complexes.5,19,24,53 The
biggest disadvantage though to this technique, and thus, the drive to use CX-MS, is that
the structures generated do not represent proteins in their native environments and are
typically liganded, to reduce the energy state of the complex to promote crystallization. Xray structures are static images, and do not directly account for protein dynamics and
conformational changes.5 Furthermore, mutations, truncations and bound-stabilizers can
detract from native functionality and dynamics or render a protein non-functional.27,28 It is
imperative to apply CX-MS to these incomplete protein structures to gain insight into
protein dynamics and to refine structure in areas that are not well resolved.
1.2.3. Cryo-Electron Microscopy (cryo-EM)
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Similar to X-ray diffraction, cryo-EM works by measuring diffraction using an
electron beam, rather than x-rays, targeted at a cryopreserved sample in a vacuum. The
beam passes through a thin layer of amorphous ice and scatters, creating an image that is
magnified and detected. However, this high energy electron beam is highly destructive,
causing damage to proteins and necessitating low dose imaging. Technical and
computational limitations have only recently been surmounted. This information is used to
generate a three-dimensional image of the structure of the protein.51,52,54 The versatility of
this technique is immense, cryo-EM allows for small sample size and can be used on very
large molecules and molecular complexes, such as virions and ribosomes.54 And unlike its
predecessor, cryo-EM has the ability to study membrane proteins.55 The invention of
polymer-based or lipid-based systems, such as amphipols,56 styrene-maleic acid (SMA) 57
and lipid nanodiscs55,58 have made the analysis of membrane proteins easier.
Commonly, detergents are used to solubilize membrane proteins, but when used in
cryo-EM structure determinations, the detergents can cause significant issues, such as
decreasing the contrast of resulting images,59 disrupting the hydrophobic interactions
between protein-protein and protein-lipid interactions,55 and not providing a native
environment of lipids for the proteins. Amphipols, like detergents, have different physical
properties than a native lipid bilayer,60 and differ in their electrostatic potential and
dielectric constant as well. This can result in non-natively folded proteins.55,60,61 A study
by Efremov et al.62 showed that the rabbit ryanodine receptor (RyR1), when solubilized in
a lipid environment, compared to detergent environments such as Tween-2063 or CHAPS64
has a similar structure but represents a different conformation.55,62,65 This is an important
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point, as membrane proteins rely on direct interactions with certain lipids in their
environment to influence their function.55,66,67
Lipid nanodiscs provide a more optimal way to provide membrane protein
structures. Briefly, lipid nanodiscs are composed of a section of lipid bilayer surrounded
by a membrane scaffold protein (MSP), which is a derivative of apolipoprotein A-1, and
consists of short amphipathic helices.55,68 MSP molecules are arranged in either a parallel
or anti-parallel manner surrounding the piece of lipid bilayer which can be of variable
size.55 A membrane protein can be inserted into the nanodisc and then can be imaged using
cryo-EM. Though this tool has paved the way towards building the structural database of
membrane proteins, which currently only represent a small fraction in the PDB, it does
have some limitations. There are different biophysical properties between lipids used in
nanodiscs, and the lipids that are contacting the MSP show perturbations.55,58,69,70
Furthermore, a study analyzing an ABC transporter, MsbA, showed an increase of activity
in nanodiscs that contain a higher number of lipids.71 Another study using EPR showed
that lipids in nanodiscs are also more highly ordered and may resemble a lipid bilayer
environment in the presence of cholesterol.72
These drawbacks may be managed in time, as this technique is still fairly new.
However, the major disadvantages to this technique cannot be as easily addressed. CryoEM, despite its versatility, is very costly, and thus, not available for many researchers.51,52
Like cryo-EM, CX-MS is not hindered by the added detergents and membrane proteins can
be easily reconstituted into various lipid bilayer environments to allow for native or nearnative environments, but at a much more reasonable cost.
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The other main disadvantage is that cryo-EM does not provide a good context in
which to study protein dynamics, similar to x-ray diffraction, the resulting structures are
static. The protein must be first trapped in a conformational state before rapid freezing,
which makes studying dynamics involved in functional cycles, ligand or lipid binding, and
infrequently populated states harder to discern.29
1.2.4. Other Types of Mass Spectrometry
The structure of a protein can be analyzed through a bottom-up approach, meaning
the protein is subjected to proteolysis and its fragments are analyzed to obtain information
about the protein as a whole, or top-down analysis, where an intact protein is studied. CXMS, as well as hydrogen/deuterium exchange (HDX), and oxidative labeling are examples
of bottom-up proteomics, but they can also be performed in a top-down manner. Native (or
non-covalent) MS, often used in conjunction with ion mobility spectrometry (IMS) is a
good example of top-down proteomics.
Native MS (nMS) relies on keeping the non-covalent interactions intact when
subjected to electrospray ionization (ESI), which allows for tertiary and/or quaternary
structures to remain intact.73–75 This is particularly useful for the study of protein subunit
stoichiometry.29 The Robinson lab has been quite successful in obtaining structural
information for large membrane protein complexes using nMS methods, including
stochiometric information for V-type ATPases from T. thermophiles and E. hirae,76 an
ATP binding cassette (ABC) transporter,77–79 among others.12,80–83 When nMS is coupled
with IMS, protein complex connectivity can be determined, which has also been shown by
the Robinson lab,80,84–88 and others.89–92 Besides determining architecture and
stoichiometry, nMS with and without IMS has also helped developed the literature on the
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importance of lipids in membrane protein structure and function. Specific lipids provide
stability, alter function and can promote dimerization.67,73,93–95 Some challenges exist with
this technique, in regards to studying unstructured loop regions and intrinsically disordered
proteins,29,81–83,96 but these can be managed by using bottom-up techniques such as CXMS in tandem with nMS. There are also similar issues involving the use of detergents,
amphipols and lipid nanodiscs as seen in cryo-EM, reviewed by Calabrese and Radford.29
Using a bottom-up approach with HDX-MS, CX-MS or various other labeling
techniques such as oxidative labeling, one may study protein structure by following a
generic workflow; labeling the protein/protein complex, using proteolytic digestion, and
finally MS analysis. Usually, the MS analysis includes soft ionization techniques such as
ESI and either collision induced dissociation (CID) or surface induced dissociation (SID)
to create analyzable fragments that include the site of modification. These can then be used
to build a map to infer structural information, binding interfaces, and/or conformational
dynamics (See Section 1.4 for more details about the workflow of CX-MS).
1.2.4.1. HDX-MS
HDX-MS involves diluting a protein sample in deuterated buffer, allowing for
hydrogen atoms that are accessible to the solvent to be exchanged with deuterium. The
exchange rate between side chain amines and carboxylic acids is too fast to be measurable,
so these experiments focus on main chain amide hydrogens. The exchange between
hydrogen and deuterium is allowed to occur for defined periods of time and then the
reaction is quenched by lowering the pH of the solution to approximately 2.5, where the
exchange rate is negligible. As with any bottom-up approach, the sample is then digested,
separated by liquid chromatography (LC) and analyzed via MS.29,97,98
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Commonly, HDX-MS is used to study protein conformation, dynamics, ligand
binding sites and allosteric effects.29,99,100 Several studies have been conducted to study
conformational changes of membrane proteins including a study by Mehmood et al.101 of
a bacterial ATP-binding cassette (ABC) transporter in both an inward facing and outward
facing conformation. Their studies showed different flexibilities of regions between the
two states. Another study, focusing on the Na+/H+ antiporter from E. coli analyzed lithium
binding at physiological pH and provided a mechanism for ion translocation.102 Similarly,
Adhikary et al.103 analyzed LeuT a bacterial homolog of the neurotransmitter sodium
symporter family to discern a conformational mechanism for transport. Protein complexes
and their configurations are also a common target for HDX-MS studies. The β2-adrenergic
receptor has been studied in complex with a G protein coupled receptor (GPCR),104 GRK5,
a GPCR kinase,105 and β-arrestin.106
HDX-MS is also a useful technique for understanding protein folding,107,108 and
discovering motifs within proteins.109 An example of this is a study that analyzed human
green opsin, a GPCR, where researchers found a conserved Pro-Pro motif in an
extracellular loop.109 Loops that are unstructured are often difficult to crystallize and thus,
using methods like HDX-MS can help provide structural details not found in highresolution methods.
1.2.4.2. Oxidative Labeling
Other labeling techniques, such as oxidative labeling, are often coupled with MS to
provide similar results to HDX-MS and CX-MS. Labeling with hydroxyl radicals is
generally not very specific, and thus, multiple residues can be non-specifically targeted.
Like HDX-MS, the stipulation to labeling is that the residue must be solvent accessible,
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but it must also have intrinsic reactivity as well. Residues most likely to be labeled are
those with sulfur atoms, Met and Cys, followed by aromatic residues, Trp, Tyr and Phe.
Additionally, His, Arg, Lys, Gln, Glu, Leu, Ile, Val and Pro can also be modified.110
Oxidative labeling is most commonly used in much the same ways as both HDXMS and CX-MS, in that is provides constraints useful in modeling, specifically for proteins
that are not amenable to other methods,110–112 and maps protein-protein interfaces to show
connectivity and stoichiometry of protein complexes.113–118 Various studies have analyzed
the interface of monomeric subunits of galectin-1,112 unfolding properties of
apomyoglobin,117 and have characterized the tertiary structure of CD4 bound to an
envelope protein component of HIV, gp120.116 Of particular importance to this work is the
analyses of integral membrane proteins using this technique. Two studies by the
Konermann lab119,120 investigated structural characterization of bacteriorhodopsin in a
natural lipid environment. These studies focused primarily on labeling Met residues as they
are found in abundance in bacteriorhodopsin. They were interested in discerning which
Met residues were solvent accessible and comparing their results to native structures of
bacteriorhodopsin. They also analyzed the protein under semi-denatured conditions and
found that noncovalent contacts between bacteriorhodopsin and the bilayer provide
stability to certain helices within the structure.
There are some drawbacks to this technique, such as secondary oxidation reactions,
oxidation of non-solvent accessible residues, incomplete conversion and specificity.121 But,
overall, this technique provides complimentary to high resolution structures as does the
other bottom-up approaches and is thus, useful towards understanding the complex fields
of protein dynamics and protein-protein/lipid/drug interactions.
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Though not a complete discussion of all the methods used to study protein structure
and dynamics, this section has provided a glance into the toolbox a structural biochemist
uses. The next section will look deeper into the wide array of uses for CX-MS and why it
is the specific tool of choice for this work.
1.3. Applications of CX-MS
1.3.1. Protein Structure and Modeling
Determinations of tertiary protein structure are most commonly solved using NMR,
x-ray crystallography and now, cryo-EM. As of 2018, x-ray crystallographic and NMR
structures totaled 98% of all structures found in the Protein Data Bank (PDB).19 Most of
the structures in the PDB are of soluble proteins, however; this is changing, and more
membrane proteins are being included due to recent advancements in cryo-EM. Though
these methodologies provide good structural details, they do have disadvantages as was
previously discussed. One common way to utilize CX-MS was to aid in structural
refinements as CX-MS can help mitigate some of the issues seen in other methodologies
and provide structural refinements important towards understanding conformational
dynamics in native-like environments.
Recent successes of the technique, towards structure determination are derived
from crosslinking data, resulting from computational or experimental studies. There have
also been publications that focused on using crosslink data from the literature with software
tools to assess how to best analyze and understand the crosslinking results in terms of
protein structure.122–125 Kahraman et al.126 and Hoffmann et al.127 used simulated crosslinks
with various analytical software tools to provide information on visualization and
validation and scoring solvent-accessible crosslinking, respectively.128
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Analysis of the bovine basic fibroblast growth factor with intramolecular CX-MS
identified the fold of the protein using sequence threading and Lys-Lys crosslinking with
bis-sulfosuccinimidyl suberate.129 A study by Brodie et al.130 analyzed myoglobin and
FK506 binding protein using CX-MS and discrete molecular dynamic simulations to create
distance constraints. They were particularly interested in comparing the ability of CX-MS
to identify proteins made up of mostly α-helices versus β-sheets.130 Belsom et al.131 used
high-density CX-MS to analyze human serum albumin and compared their results to
available crystal structures. The study used a photoactivatable crosslinker, sulfo-SDA
(sulfo-NHS-diazirine or sulfosuccinimidyl 4,4’ – azipentanoate), which benefits from
being able to react with any amino acid on the diazirine end, thus providing more
crosslinking data. A particular focus of this study was to see how this methodology
performed in terms of identifying unknown structures.131 This study, as well as a study by
Fischer et al.132, compared the success of analyzing α-helices versus β-sheets. According
to these studies, CX-MS has greater success solving protein structures that were mostly αhelical in nature.131,132 This may be due to crosslinker length, which has a relative distance
from Cα to Cα of approximately 20 to 25 Å, whereas; the distance between β-strands in a
β-sheet is only 5 Å.10,131 However, a good way to combat this would be through the use of
different length crosslinkers, to create a network of constraints to hone in on minute
structural details.
Structural refinement, through the means of protein-protein interactions within a
singular protein will be the focus of this work. A heterobifunctional MTS-benzophenone
crosslinker will be used (details on common crosslinkers used can be found in Section 1.5)
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and the target will be a transmembrane protein, which as previously covered, have unique
complications involved when studying their structure.
1.3.2. Protein-Protein, Protein-Lipid and Protein-DNA Interactions
Outside of using protein-protein interactions to determine structure and refine
models, protein-protein interactions, as well as proteins crosslinked to other
macromolecules can provide context into the protein’s native environment.
Protein-protein interactions can be studied between multiple proteins in multisubunit complexes, or between binding partners. Two of the most well-known examples
are the elucidation of the nuclear pore complex24,133,134 and RNA polymerase II and its
binding partners.13,135–137 The architecture of the entire pore complex was determined by
using several techniques, including a low-resolution cryo-EM density map as a starting
point, affinity purification and pull-down assays, MALDI MS, immunoblotting, constraint
mapping and computational studies.24 Predicted locations of proteins in the pore complex
as well as protein folds typical of coat proteins that were close to the nuclear membrane
surface, such as clathrin were assigned.133,134 Pore spokes were arranged in vertical
columns and it was hypothesized to be due to gene duplication for these types of
structures.24 RNA polymerase II was shown to interact with TFIIF through over 250
crosslinks between the two proteins,13 which visualized their orientation towards each
other. Before this study, the understanding of transcription initiation was provided via
docking studies, which can be inaccurate when used alone.24 This work has led to the
investigation via CX-MS of other systems, including the eIF1-eIF3 translation initiation
complex,138 transcription and DNA repair factor TFIIH,139 and a modulator of the TORC1
pathway, the SEA complex.140
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Protein-lipid interactions can be helpful in elucidating protein structure and also
provides information, specifically when studying membrane proteins, regarding local
membrane environment. According to a review by Yeagle67 in 2014, 70 membrane proteins
have

been

crystallized

in

the

presence

of

lipids,

including

cholesterol,

diphosphatidylglycerol (cardiolipin), phosphatidic acid (PA), phosphatidylglycerol (PG),
phosphatidylethanolamine (PE), phosphatidylcholine (PC), phosphatidylinositol (PI) and
phosphatidylinositol bisphosphate (PIP2). Furthermore, studies have shown that different
lipids have an effect on both protein structure and function.93,95,141–144 Studies using CXMS and analyzing protein and lipid interactions, like those conducted by Ferraro et al.,14
have shown that cholesterol concentration results in different apo-states of the glycine
receptor and has elucidated specific binding sites for cholesterol in a state dependent
manner.14 DeMarco et al.145 showed cholesterol binding to the N and C-terminus of the
serotonin transporter, regions absent in all crystal structures of monoamine transporters. A
large-scale study by Wang et al.15 looked at protein-lipid interactions using an alkynecontaining choline head group and a diazirine modified fatty acid to crosslink in situ, with
phospholipid interacting proteins identified by MS. The field of protein-lipid interactions,
unlike protein-protein interactions is still unexplored and needs further studies to develop
the lipidomics side of CX-MS.
Interactions between protein and DNA can show the dynamics of binding,
structural details related to these conformations and the bigger picture regarding the local
environment. Because the interactions between nucleic acids (DNA or RNA) are
noncovalent interactions, and thus weak, trapping them via crosslinking can facilitate
analysis. Formaldehyde is most commonly used,146,147 but photoactivatable crosslinkers
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that produce pyrimidinyl radical are also used.148,149 Both of these are zero-length
crosslinks.146,149 This protein and nucleic acid crosslinking was later applied to MS
analyses,150–153 including a study where a fibroblast growth factor was crosslinked to
uracil.153

Later

advancements

in

protein

pull-down

assays

and

chromatin

immunoprecipitation (ChIP) led to more large-scale studies.
Qiu and Wang154 searched for unknown DNA repair and regulation proteins using
formaldehyde crosslinking and LC/MS-MS. A study analyzing histone proteins in intact
nuclei used protein-protein and protein-DNA interactions to help aid in understanding the
total landscape of the nuclei.155 ChIP, with added MS-based analysis and Chromatin
enrichment proteomics (ChEP) both use a crosslinking step with formaldehyde that
crosslinks DNA to proteins.17,156,157 These methods are gaining popularity as they provide
a way to better understand the role of PTMs, particularly in chromatin, in affecting DNA
binding, which is useful for the growing field of epigenetics.
1.3.3. The Interactome and Studying Proteins in Situ – The Future of CX-MS
More recently, CX-MS has been used to study larger interaction networks and
proteins in situ, within their crowded physiological context. This is ideal for studying
protein-protein and protein-macromolecule interactions, as it provides the most authentic
environment.
A study by Ryl et al.20 in 2019, analyzed the human mitochondria for protein
network interactions. They used a non-cleavable Lys-Lys crosslinker, disuccinimidyl
suberate (DSS) and identified over 5000 distance constraints, and had crosslinking between
over 700 proteins. Studies similar to this have also been conducted on murine mitochondria
with cleavable crosslinkers18,158 and several other large systems already mentioned,
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including the 26S proteasome,135 components of RNA polymerase I, II, III,13,136,137 and the
nuclear pore complex133,134 have been elucidated structurally by CX-MS. Other large-scale
protein-protein interaction studies focus on intact cells, including P. aeruginosa cells,159
E.coli cells,160 MR-1 cells,161 and HeLa cells.162 There are also studies that have used
viruses.163 These studies highlight the future territory of CX-MS and its role in discovering
the molecular machinery of large-scale systems and how proteins interact in situ.
Fürsch et al.164 conducted a proteome-wide study to analyze the propensity for
high-abundant protein crosslinking. They used an in vitro mimic of a crowded cell
environment and compared it to eukaryotic cell lysates as they hypothesized that by
optimizing analysis parameters towards a first order kinetic model would allow for more
low-abundant protein crosslinking sites to be determined. The importance of their work is
to show limitations in current CX-MS analysis techniques (see Section 1.5) and to provide
better methodologies to improve these techniques.
The use of crosslinkers that are cleavable inside the mass spectrometer also offers
new insights into understanding proteins in their natural environment. These include
incorporation on unnatural amino acids in proteins using photoactivatable amino acids,
such as photo-leucine and photo-methionine,165,166 oxidative crosslinkers,167 and
photoactivatable crosslinkers,168,169 such as disuccinimydal dibutyric urea (DSBU) and
disuccinimidyl sulfoxide (DSSO).5,10 A study by Arlt et al.170 analyzed the full-length
tumor suppressor protein, p53, used DSBU and mapped distance constraints applying it to
p53 crystal structures bound with DNA.10,171–173 It is noted that the length between Cα –
Cα using DSBU is approximately 27Å, and the group found that the majority of both intraand intermolecular crosslinking matched what was found in the crystal structure.10,170,173
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Of particular importance, p53 is an intrinsically disordered protein,174 and thus has a very
flexible protein structure, so using CX-MS is ideal for studying it in a native context.
Regardless of the protein being analyzed, its size, its environment and what it is
being crosslinked to, CX-MS has the ability to aid in structural refinement, modeling, and
understanding protein dynamics. Of particular interest to this work is the availability of
CX-MS to analyze membrane proteins, which have proven difficult to study by other
methods. CX-MS is a versatile, cost-efficient, and high-throughput method that is a
valuable tool in fully developing the structure of a protein. It is becoming increasingly
important in understanding proteins in a larger setting, something that was unforeseen a
mere decade or two ago. Because of its affordability and accessibility, it will continue to
be a well-sought-after tool in the structural biochemist’s toolbox.
1.4. Workflow of CX-MS
As previously discussed, CX-MS can be used to study a protein/protein complex
either by a top-down or a bottom-up proteomic approach. Because the focus of this work
uses the bottom-up approach, this section will discuss only this one at length. The general
workflow of a bottom-up CX-MS experiment (Figure 1) consists of primarily three parts;
(1) crosslinking, (2) proteolytic digestion and (3) MS/MS analysis. The overall goal of this
type of experiment is to map protein interfaces or determine low-resolution structures of
proteins. This section will focus on the more specific workflow involved in using CX-MS
to determine and refine protein structure.
Before beginning this type of experiment, it is essential that the sequence of the
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protein(s) that are being analyzed is completely known, allowing them to be matched using
databases. It is also ideal to optimize all conditions such as crosslinker concentrations,
protein concentrations, buffer pH and reaction times to maximize sequence coverage, and
Figure 1. General Workflow of CX-MS. The general workflow of CX-Ms is split into several parts: 1)
crosslinking, which in this example, shows intrasubunit crosslinking in yellow and intersubunit
crosslinking in green, 2) proteolytic digestion, which maintains the covalent crosslinking, 3) MS analysis
via ESI-Q-TOF, which identifies precursor ions, 4) MS/MS analysis which allows mass-selected
precursor ions to be targeted for fragmentation with CID, creating product ions which are then matched
with predicted fragmentation patterns to build crosslinking maps and refine structure.

more fully characterize the protein(s) in question.5 Control samples that have not been
crosslinked should be used as controls to rule out any possible protein aggregate formation
occurring that would be confused for crosslinking.5
The chosen crosslinker will determine the specificity of what residues are being
crosslinked as well as the graphic scale of the crosslinking map. This information is a
crucial step towards refining structure (see Section 1.5 for common crosslinkers used in
CX-MS experiments). For this work, methanethiolsulfonate benzophenone (MTS-bzp) will
be used as the molecular ruler, because the benzophenone group does not show specificity
towards any amino acid, and because the MTS functional group can be targeted towards
recombinantly introduced single cysteines as a point of initial attachment. In general, a
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crosslinking experiment occurs in solution, after enrichment of a protein in a desired
conformational state. Depending on the protein or protein complex and the crosslinker
used, the end result may give both intra- and intermolecular/subunit/protein crosslinks.
In a bottom-up approach, the next step is proteolytic digestion. In order to do this,
first the crosslinked protein must be separated from the rest of the reaction mixture which
can be done by SDS-PAGE or by size-exclusion chromatography.5 If SDS-PAGE is used,
the piece of the gel containing the crosslinked protein can be excised and be subjected to
in gel proteolytic digestion. If size-exclusion chromatography is used, the digestion
happens in solution. In the case of multi-subunit or protein complexes, there are different
bands or fractions, consisting of a single protein (or subunit) with only crosslinks within
itself, and those containing crosslinking between one protein and another protein or one
subunit to another subunit. Different proteases can be used for digestion, depending on the
sequence and/or buffer conditions. Sometimes, multiple proteases are used.7,8
The crosslinked peptides can now be analyzed via MS. This can be done using
MALDI or ESI in a bottom-up approach. This section will focus only on the latter. Usually
the peptide mixture is introduced into the mass spectrometer by first allowing LC
separation. Then, in ESI, the liquid sample is sprayed into the instrument while being
subjected to an electric field which produces small, highly charged droplets. These ionized
samples are then introduced to the mass analyzer. Identifying the crosslinked residues from
the produced data happens in a two-step process; (1) identifying the peptides that were
crosslinked and (2) refining the area to a single residue (or close to single) of that peptide
where the crosslinker bound. In the first step, a series of spectra are obtained and precursor
ions are selected. These precursor ions are the peptides that have been mass-shifted by the
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mass of the crosslinker. ESI-MS/MS can then be used to further refine these precursor
peptides.5 The precursor ions are targeted for dissociation, in the case of these studies CID
was used, to produce product ions of reduced mass that may be subsequently separated by
their respective m/z by further MS. Identifying fragments with or without the covalently
attached crosslinker allow for the refinement of crosslinking sites to an exact or
approximate site within the precursor mass ion. Successful refinement of the site of
crosslinking is dependent on the quality and dynamic range of the spectra produced.7
Peptide fragmentation by CID generally occurs at the peptide bond, produces two main
fragment types, N-terminal b-ions and C-terminal y-ions, depending on which species
retains the charge.175–177 An alternative to CID is electron transfer dissociation which
generally gives N-terminal c-ions and C-terminal z-ions. Because peptides and proteins
fragment in these expected ways, this methodology is very useful towards identification of
peptides.7,175–177
The extracted data from the fragmentation spectra must be matched at a certain
level of confidence with a theoretical crosslinked peptide match. This leads to
unambiguous matches that can refine structure. A large component of using CX-MS is
computer software data analysis programs. This aspect of the workflow, more than any
other, is laborious and time consuming due to the complexity and sheer size of the data
produced. This is overall, the biggest limitation to CX-MS.5,7,131,178–180 There are many
different computer algorithms that can be used to match spectra with potential crosslinked
peptides,21,22,126,181–185 and ultimately, that is the main goal. Many of the publicly available
software for crosslink identification, visualization, modeling and quantitation can be found
in the review by Yu and Huang.19 More complete searchable databases and a generally
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acceptable method for CX-MS experiments, in addition to new, better equipped software
programs will increase the usability and popularity of this technique.
The final aspect of this technique is mapping the distance constraint data onto
available crystal structures or designing structures based on the distance constraints.
Structural modeling techniques can assist with this, once a suitably sized network of
crosslinks is obtained. This information can be used to guide complex protein arrangements
and stoichiometry, tertiary structural modeling, and conformational changes.
1.5. Crosslinkers used in CX-MS
The location of a crosslinker imposes a distance restraint of known length, which
after enzymatic digestion, crosslinked peptides can be analyzed with mass spectrometry.
This information can be used to help construct a three-dimensional structural image of the
protein.10 These distance restraints can also be applied to help narrow down the likeliness
of a preexisting model, generated from crystallography or by computational studies.8 Some
important considerations that can be used to reduce the number of predicted structures
include the accuracy of the probe to limit interatomic distances, the nature of the
approximations used in making the models, and the similarities and dissimilarities in the
examined models.8
Another important consideration is what crosslinker is chosen. Several factors
contribute when choosing a crosslinker; its reactivity, its functionality and its length.
Common reactivities used are sulfhydryl, amine and photoreactive. Sulfhydryl reactive
compounds include maleimides, haloacetyls and pyridyl disulfides.186,187 Their reaction
mechanism includes the formation of either a thioether bond or a disulfide bond to Cys
residues in proteins.186 Because of their specific reactivity, using this type of crosslinker
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can limit the structural details obtained, and the need to reduce disulfide bonds could also
lead to a distortion of structure.187 The abundance of Cys residues in proteins is quite small,
only about 2.3 – 3.3%,188,189 so structural information using just the Cys available in the
protein minimizes the amount of information that can be obtained.
Amine reactive crosslinkers most commonly used are N-hydroxysuccinimide
(NHS) esters, imidoesters, and carbodiimides.186 All of these react with primary amines,
which can be found at the N-terminal end of a protein and at the side chain of Lys
residues.190,191 Lys-Lys crosslinking is commonly used with this type of crosslinker.192–197
An example of a commonly used carbodiimide is EDC (1-(3-dimethylaminopropyl)-3ethyl-carbodiimide hydrochloride), which is a zero-length crosslinker.198 The abundance
of Lys residues in proteins, is higher than Cys, at 7.2%.199–202 , so there are more available;
however, they are usually only solvent exposed. The main disadvantage, though, to using
these types of crosslinkers is that tryptic cleavage sites are removed.5,8
Photoreactive crosslinkers are those that are induced to react when exposed to UV
light. Common ones are diazirines, aryl azides and benzophenones. What makes these
molecules ideal is their high reactivity, low selectivity, stability, and reactivity within a
range that is not destructive to biological samples.5,198 Because of their non-selectivity or
low-selectivity, they are not limited to binding specific amino acid residues and thus are
useful for unbiased structural determinations.198 Aryl azides are the most commonly used
crosslinker of this type, and work by forming short-lived nitrenes after photoactivation that
can insert into target molecules through active hydrogen bonds at C-H and N-H sites as
well as through addition reactions at double bonds.191,203,204 Diazirines, when induced by
UV light, generate a carbene that inserts into C-H bonds or heteroatom-H bonds.5 This type
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of crosslinker is used often to analyze protein-DNA/RNA interactions,205–207 as well as for
structural studies.208–210 Finally, benzophenones differ from the previous types because
they are produced via a non-photo-dissociative mechanism and thus reversible. After being
activated via light, a biradical is formed. The oxygen radical abstracts a hydrogen radical
from a bond of the reaction partner. The created alkyl radicals form a new C-C bond
between the photoactive molecule and the protein target.5,211,212 Several structure
determination studies have been conducted using benzophenones as the crosslinker of
choice.213–217
An additional affinity tag can also be applied to crosslinkers, such as biotin,218 or
an alkyne or azido group which can be used to enrich crosslinks by covalently attaching
them to a solid phase support.198 There are also anti-crosslinker antibody based enrichment
tags.198 The incorporation of these tags can help increase the signal-to-noise ratio by
providing for enrichment of crosslinked peptides before MS.218
Crosslinkers of all reactivities can also be under the umbrella of cleavable
crosslinkers. Both photo-219 and chemical-reactivities220 can be cleaved by various means
depending on their unique properties before MS analysis. But there are also MS-inducible
cleavages that result from fragmentations that happen inside the mass spectrometer,
including via CID and ETD.19 The advantages to using crosslinkers that are cleavable in
the MS are two-fold: one, there is effective correlation between separated crosslink
constituents and the parent ion, as each fragment caries a piece of the fragmented
crosslinker, and two, this results in simplification of data processing and analysis.19 An
important consideration for these crosslinkers is that their cleavable bonds are more labile
than peptide bonds and that their fragmentation should be independent of peptide charge
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and/or sequence.19 Several important ones to note, designed in the Huang lab are DSSO
(disuccinimidyl sulfoxide),19,221 DMDSSO (dimethyl disuccinimidyl sulfoxide),19,222 and
DHSO (dihydrazide sulfoxide).19,223 All of these are sulfoxide containing crosslinkers
which are commonly utilized reactive groups in other heterobifunctional crosslinkers.
Functionality is another factor used when choosing a crosslinker. These fall under
two general categories; homo- or heterofunctional. Homofunctional crosslinkers have
identical reactivity groups on each side of the spacer arm. This allows for the crosslinking
between identical functional groups, such as Lys-Lys or Cys-Cys crosslinking. Though
these crosslinkers are very common and used often, there are some issues associated with
using them. First, amino acids may be distributed unevenly throughout a protein, and thus,
if crosslinking to only a specific type, it may lead to lack of global information.197 Also,
there can be a tendency to form protein aggregates through intermolecular crosslinking.
This can be mitigated by using less concentrated protein samples or by performing a twostep reaction where a single protein is crosslinked first before adding a second protein of
interest.5,190 This is only useful though if the study is targeting a protein interface between
multiple proteins, instead of looking at a singular protein.
Heterobifunctional crosslinkers will have at least two different reactive groups, but
can also have more than that. These are useful as they target more than one functional
group and thus are benefitted naturally by a multi-step process that decreases the chance of
forming higher-order aggregates. Photoreactive crosslinkers are especially useful in that
they are stable until induced with UV light.5 Methanethiosulfonate-benzophenone (MTSbzp) is a good example of a heterobifunctional crosslinker that targets both Cys residues
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one reactive end, and has no specificity on the benzophenone site, allowing it to target any
amino acid.211,212 Of particular note, this work will use MTS-bzp.
Often, crosslinkers will have more than one reactivity, which can help to provide
less selectivity and thus a better chance of reacting with more of the protein providing more
distance constraint information. For example, it is common that photoreactive groups are
also paired with amine- or sulfhydryl groups, making them multi-functional.5
Lastly, the length of the crosslinker provides another level of classification. As
stated previously, there are zero length crosslinkers like formaldehyde (commonly used to
fix cells and in DNA-protein interactions studies). This class of crosslinkers require both
functional groups being crosslinked to be in close enough proximity to form a covalent
bond. MTS-bzp is approximately 25Å from Cα to Cα. Regardless of the crosslinker chosen,
it is important to consider the range of flexibility of the crosslinker as well as protein
dynamics. This defines the proximity between the two points, but this distance can vary
over time, which is useful for structural mapping. Studies by Ryl et al.,20 Merkley et al.224
and Kahraman et al.123 showed that many crosslinks formed exceed the length of the
crosslinker used. It is also useful to use multiple length crosslinkers to expand or shrink the
grid scale of the map, to provide additional details related to structure from a particular
point of reference.
1.6. Limitations and Challenges of CX-MS
CX-MS is a valuable tool for the structural biochemist, however; there is room for
improvement. The limitations and challenges of this technique can be split into two
categories: technique-based and data analysis-based, specifically for the purpose of
modeling.
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1.6.1. Technique-based
Proteolytic digestion is most commonly performed with trypsin, and because it
cannot cleave a modified C-terminal Lys or Arg residue, this results in missed cleavages.5
Also, there are many crosslinkers that employ the modification of a primary amine, and so
trypsin cannot be as effective here, either.5,122,130,198 Many data analysis algorithms account
for missed cleavages, and this will mitigate missing peptides that have modified Lys
residues. However, missed cleavages also result in larger peptides, which is another issue
altogether.
The larger the peptide piece is, the greater the likelihood of it being harder to detect
with the mass spectrometer. Large peptides may also result from crosslinked products with
low charge states. ESI can create these peptides from a loss of positive charge after
modification of Lys residues.5,122 There is also an issue with an increase in the number of
peptides that have the same mass. This is increased as the number of amino acids in the
peptide increases.5
Using in-gel digestion of crosslinked peptides via excised gel pieces can result in a
loss of sample.5 This could result from proteins not being well-resolved and thus not
excising them properly. Size exclusion chromatography could be used to mitigate this.
However, because of the high sensitivity of the mass spectrometer, not much sample is
needed.
1.6.2. Data Analysis – How is this information best used for modeling?
Crosslinking data can provide a wealth of distance constraints, that can then be
applied to model building or model validation. While CX-MS is not the only tool that
creates distance constraints, it does create a multitude of them that can be used for modeling
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purposes. This means that some consideration and care should be taken when applying this
information towards building models.
The distance between two crosslinked residues should be limited by the distance of
the crosslinker between them. However, this does not take into account that both the protein
and the crosslinker will have inherent flexibility.7 The crosslinker will have rotations of
bonds as well as vibrations that cause a variability in its length. And the protein, as a
dynamic molecule, will sample energy states that may not be representative of its lowest
energy state and differ from available high-resolution structures. One way to provide
additional information refining the available conformational states is by using multiple
crosslinkers of variable lengths.
Matching fragmentation spectra with expected fragments of peptides in databases
yield unambiguous data. There is also evidence that supports very little experimental error
in regards to misassigned crosslinks,13 as data is only interpreted from fits with a very high
confidence match. Since CX-MS is able to look at protein dynamics, whereas crystal
structures do not, it makes sense that the variability in conformation and flexibility will be
larger.7 This is also seen in peptides that cannot be resolved to a single residue; it may be
due to flexibility of the region, or alternative conformations, instead of lack of
fragmentation spectra due to hard to ionize species. Thus, there is value to allowing lowerconfidence matches being taken into account. This is also important in terms of showing
multiple structures as a result of lower confidence matches, as these might be indicative of
multiple conformational states in a singular sample.
Depending on the crosslinker used, as well as the accessibility of the crosslinker to
various regions in the protein, there may be missed data. If a crosslinker is only targeting
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Lys residues, there may be an uneven distribution of them in the protein; the same can be
said for any crosslinker with certain specificities.7 Photoactivatable crosslinkers, that do
not have residue specificity are a good alternative. However, depending on the
hydrophobicity or hydrophilicity, there may be issues penetrating the transmembrane
regions of the protein or the solvent accessible regions,225–228 this is particularly important
when studying membrane proteins. Similar to the distance issue, this can be mitigated by
choosing a crosslinker that best suits the protein of interest being analyzed, or by using
multiple types of crosslinkers to obtain global information.
As previously mentioned, larger peptides are harder to detect in the mass
spectrometer. Also, if these larger peptides are picked up, they may be hidden by
background noise due to their lack of ionizability.177 There are also issues of hydrophobic
peptides being lost through sample preparation.7 This means that not all peptides that are
crosslinked are represented in the data. The interpretation of this can be two-fold; as the
absence of crosslinked peptides either means that it is not in close proximity to the initial
point, or that the two pieces would crosslink, but it is not represented in the sample. These
difficulties are reduced by having good mass coverage in control studies. A developed
network of various points can also help mitigate this. This way, not only is new information
valuable, but also reciprocity between regions. If A crosslinks to B and B crosslinks to C,
it is important to see if A also crosslinks to C.
Another setback of CX-MS data analysis is quantitation. Mass spectra peaks
represent the intensity of an ionizable peptide, not its abundance. MS quantitation has been
typically done using a labeling technique, by using stable isotopes, either introducing them
to the protein sample through the growth media (SILAC – stable isotope labeling by/with
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amino acids in cell culture)229–231 or the crosslinker.232 But comparing the yield of
crosslinked peptides between samples is difficult, and because their ‘flyability’ the
intensity in which a given peptide is observed, differs between experiments, individual
peptides cannot be compared between samples.7 Another issue with quantitation is low
signal intensity.233 This means if peaks are even visible to be detected, it is much harder to
produce reliable fragmentation spectra. Often an Orbitrap mass spectrometer is used to trap
a precursor ion and produce fragmentation spectra through tandem MS.179,233 The biggest
issue with analyzing quantitation data is the software is currently not equipped to handle
such complex data. In 2016, Chavez et al.234 proposed using an open source software
package Skyline to analyze quantitative CX-MS data. It is available to researchers who
have LC-MS capabilities, and works with the already available quantitative methods, like
SILAC. There are other packages like this one that have been proposed to help with the
vast amount of data produced.179,233 In 2019, Muller et al.179 discussed a data-independent
acquisition of analyzing quantitation CX-MS data.
1.7. Summary.
Crosslinking-mass spectrometry (CX-MS) is a sensitive and useful tool to
characterize spatial relationships of proteins. It is a preferred technique to study membrane
proteins as it is not hindered by their mass or their hydrophobicity. By using CX-MS, a
network of distance constraints will be obtained, and these can be used to build more highly
resolved and accurate molecular models. This will provide complementary information of
a full-length, functional protein in a near-native environment, which cannot be achieved
using high resolution structural techniques. Ultimately, as protein structure is intimately

31

linked to protein function, these studies will aid in future modulation of this protein and
the development of targeted therapeutics.
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CHAPTER 2. PENTAMERIC LIGAND GATED ION CHANNELS
2.1 Introduction
Pentameric ligand gated ion channel (pLGICs) proteins are transmembrane channel
proteins that allow cells to respond quickly to external changes in their environment,
particularly by mediating fast neurotransmission in the nervous system.235–237 When a
presynaptic nerve is excited or stimulated, it releases a neurotransmitter that then binds its
target protein on the post synaptic nerve.235–237 As a result of neurotransmitter, or ligand,
binding, a conformational change results which opens a pore in the pLGIC and allows
either cations (Na+, K+, Ca2+) or anions (Cl-) to enter the cell. The resulting ion flux is
driven by the electrochemical gradient and is thus passive.235 The result of this
communication between neurons via electrochemical response is an action potential, which
is when the membrane potential rapidly rises and falls from its normal ‘resting’ state, often
referred to as ‘firing’.
Figure 2. The Synaptic Cleft. The glycine receptor is located at the post-synaptic cleft and responds to
glycine binding. Its role is to allow the entry of chloride ions into the cell to hyperpolarize the cell, which
decreases the likelihood of an action potential. The image below shows the release of glycine from
synaptic vesicles into the cleft, where it can find its target receptor and bind. Chloride ions can then move
into the cell.
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The path along which action potentials occur starts approximately at -60 millivolts
(mV), slightly more negative than its threshold potential, and as voltage-gated sodium
channels open, and positive ions pass into the cell, the potential rises to the threshold
potential, where at that point, an action potential will either happen or not. If it does pass
the threshold, there is a surge of more sodium ions entering the cell, and the potential
increases to approximately 40 mV. This is called depolarization and is an excitatory
response. As the sodium channels begin to close and potassium channels open,
repolarization occurs. Instead of settling around the potential in which it started, it becomes
more negative, as a result of efflux of potassium and influx of chloride ions. This
hyperpolarizes the cell, and is known as the refractory period, which prevents another
action potential from happening too quickly; this is the inhibitory response. Both the
excitatory and inhibitory responses are controlled by pLGICs.238,239
There are several members that belong to this family, that also goes by the name of
Cys-loop receptors, named as such due to a defining loop of residues formed by a disulfide
bond in the extracellular domain (ECD) of these receptors,235,240–242 which will be detailed
later during the discussions about structure. In mammals, there are the excitatory cationpermeable: nicotinic acetylcholine receptors (nAChRs) and serotonin type 3 receptors (5HT3Rs), and the inhibitory anion-permeable γ-aminobutyric acid type A receptors
(GABAARs) and glycine receptors (GlyRs), as well as zinc-activated ion channels.238,243
There are also pLGICs found in bacteria and archaea,242,244 including a proton-gated ion
channel found in cyanobacteria, Gloeobacter violaceous (GLIC)245,246 and a
GABA/cysteamine-gated channel isolated from Erwinia chrysanthemi (ELIC),247–249
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though these do not have the characteristic disulfide bridge found in their eukaryotic
relatives.
pLGICs are distributed throughout many parts of the body and by mediating fast
neurotransmission, and thus, neural communication, they play an important role in sensory,
motion, metabolism, memory and attention, cognition, sleep and wakefulness, pain, and
mood.243,250,251 nAChR’s are located in the central and peripheral nervous system, in the
muscles, and other tissues,252,253 and are the most well-understood in the family. Their
primary agonists are acetylcholine and nicotine,252 and they are primarily responsible for
the depolarization of muscle fiber by Na+, K+ and Ca2+ ions,254,255 mediating post-synaptic
neurotransmission in the autonomic ganglia, and triggering intracellular metabolism,252
due to their high permeability to calcium.256 Medically important, nAChRs are targets of
pharmaceuticals used to treat several diseases, including, schizophrenia,257 ADHD,258
Alzheimer’s disease,259 Parkinson’s disease260 and Crohn’s disease,261 as well as others,
and they are also targets of drugs treating smoking cessation.262,263
5-HT3Rs, the only ionotropic member of 5-HTRs subtypes (the others are G-protein
coupled receptors264) are found distributed throughout the CNS, particularly in the
hippocampal formation, amygdala, and cerebral cortex,265,266 but also are found in the
gut.267,268 In the CNS, they mediate the release of many neurotransmitters such as
dopamine, acetylcholine, GABA and glutamate,243,269,270 and in the gut they play an
important role in gastrointestinal motility and survival and development of dopaminergic
neurons.267,268 Due to their role in the gut, these receptors are drug targets for irritable bowel
syndrome271,272 as well as treating emesis, particularly in cancer patients.273,274
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GABAA Rs are located throughout the CNS, in many parts of the brain, but also are
found in the retina, liver cells and immune cells.275,276 They are the predominant source of
fast inhibitory neurotransmission,243,277 and contribute to the subsequent integration of
neuronal excitation.276 Defects to the receptor can cause epilepsy.278 They also respond to
a wide variety of drugs, including benzodiazepines and other anesthetics.275
GlyRs, to contrast, are more localized and are found in specific regions, such as the
brainstem, spinal cord, and substantia nigra, as well as the retina.236 They have also been
found in non-neuronal tissues, such as immune cells, endothelial cells, hepatocytes, and
renal cells, though the significance of non-neuronal expression is not yet understood, but
could potentially play a role in disease.279 In CNS, GlyRs also play a role in inhibitory
neurotransmission,236,237 and like GABAARs are hot spots for many pharmaceutical targets,
including anesthetics and cannabinoids,280,281 and thus, play a role in pain management,282–
284

a topic that will be discussed in more detail in Section 2.3.3.
The stoichiometry of subunits in pLGICs varies widely depending on the protein

type, the region where it is found, the developmental stage of the organism, the specific
job intended for the pLGIC and influences how many ligands bind to the receptor to open
the channel. A total of 17 subunits have been identified for nAChRs, α1-10, β1-4, γ, δ, and
ε, and with the exception of α8 which is found in avian receptors, all are found in
mammals.235,243,285 In adult somatic neuromuscular junctions, the stoichiometry is
(α1)2β1γε, whereas, in embryonic and denervated skeletal muscles the stoichiometry is
(α1)2β1γδ.235 Also, some of the subunits do not form functional pentamers, α5 and β3, as
homomers or as pairs,235,285 whereas; α7 and α9-nAChRs can form functional
homopentamers.243
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For 5-HT3Rs there are five different subunits, A-E.235,243,286–288

Heteromeric

subunits containing 5-HT3 A and B subunits are well-characterized, and it is known that the
receptors containing A subunits form homomers,289 and that heteromers containing A and
B differ in their allosteric regulation of several anesthetics and alcohols.289–291 5-HT3C, D
and E subunits, however; cannot form functional homomers, and must be combined with
5-HT3A to function; heteromers containing these subunits are expressed in the submucosal
plexus of the large intestine, the colon, and in the cell bodies of myenteric neurons and are
important in gut mobility. 235,286–288
GABAA receptors consist of many different subunits, α1-6, β1-3, γ1-3, ρ1-3, δ, ε,
π and θ.243,292–294 Many GABAARs contain α, β, and γ subunits, with the α1β2γ2 pentamer
contributing to the largest percentage in the CNS, followed by α2β3γ2 and α3β3γ2.235
Functional homopentamers can be formed with ρ1-3 subunits.235 In addition to these
homopentamers, approximately ten other GABAARs have been characterized and wellstudied. There are a multitude of specific examples of positive allosteric modulators for
GABAA Rs, but some noteworthy ones are diazepam and flunitrazepam which are not
selective on α4 or α6 subunits.235 Ligands that bind in the benzodiazepine binding site can
distinguish α subunits from γ subunits.292
GlyR can be expressed as either a homopentamer of α subunits of which there are
four varieties (α1-4, though α4 is not detected in humans), or as a combination of α and β
subunits.235,243 The most commonly found stoichiometry in adult mammals is 2α subunits
and 3β,295 and the homopentameric α1 and α3 are both well-characterized and have been
crystallized.296,297 α2 can also form homopentamers in neonates.235,243 The β subunit is
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known to anchor the receptor to gephyrin through an amphipathic sequence found in the
intracellular loop, and it also reduces channel conductance and alters pharmacology.298–300
2.2. The Structure of pLGICs
Figure 3. Architectural Structure of a pLGIC. A. Represented by the schematic is the structural
components in a single subunit of a pLGIC and its orientation in the membrane. A large N-terminal
domain preceding M1, four TM domains labeled M1-M4 that have α-helical secondary structure. M2 is
in green as it, forms a side of the pore. Also shown is a large intracellular loop connecting M3 and M4, as
well as other loops connecting the TM regions. B. Top down view of the TM domain. Four α-helices per
subunit for a total of twenty. M2, in green, one from each of the five subunits, lines the pore of the channel.
C. A typical stoichiometric assembly of GlyR, with two α-subunits, and three β-subunits.

In recent years, due to advances in crystallography and cyro-EM techniques, many
structures of pLGICs have been solved. The first structures of a pLGIC was from x-ray
crystallography experiments in 2001, by Brejc et al., 301 of a soluble acetylcholine binding
protein (AChBP), and electron microscopy experiments by Cartaud et al. and Miyazawa et
al., 302,303 using nAChR found in the electric organ of Torpedo marmorata. Nigel Unwin
solved the full-length nAChR structure in 2005, also using the electric organ of the eel.304
The structure solved by Unwin and the structure of AChBP represent a closed structure
and a ligand-bound structure, respectively.303,304 Later, in 2016, a human nAChR structure
was determined via cyro-EM.305
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Recent successes in studying eukaryotic members of the pLGIC family were
preceded and aided by crystallographic determinations of simpler prokaryotic members,
ELIC243,306,307 and GLIC,308,309 which, aided by the assessment of nAChRs in different
conformations, gave broader information on the family as a whole. The overall layout of
these proteins is described as urn-like in appearance,296 with a wider ECD region composed
of a mainly β-sheets, a narrower α-helical TMD region and a partially resolved intracellular
region.238,304 Each pLGIC consists of a ring of five subunits of various types, that pack
Figure 4. pLGIC Conformational States. Typical conformational dynamics of a pLGIC
involves three allosteric states: resting (blue) where ligand is not bound and the channel is
closed. The ECD (blue ovals) is a “bloomed” conformation. The open, or active state, (green)
is short-lived and responds to ligand binding by allowing the passage of ions through a now
open pore. The desensitized state (pink), is non-conducting and longer lived. The receptor
has higher affinity for its ligand in this state.

together to form a central pore, lined by M2 in each of the five subunits in which to allow
ion flow in response to channel opening via neurotransmitter binding. The ECD also
contains the ligand-binding domain (LBD) in which two to five ligands bind between
subunits, depending upon receptor type.238,304,310
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Successively, other eukaryotic pLGIC structures were solved, including: the 5HT3Rs from Mus musculus;311 a glutamate gated chloride channel (GluCl) from
invertebrate Caenorhabditis elegans;312 human homomeric β3-GABAA R,313 human
homomeric α3-GlyR297 and homomeric α1-GlyR from zebrafish (Danio rerio).296 These
structures represent various conformations of the receptors that contribute to the overall
knowledge of pLGIC structure and dynamics.
A review article by Nemecz et al. 235,243 characterized several crystal structures into
their likely conformational states. The conformational stages a pLGIC goes through, are
resting (apo-) when no ligand is bound and the central pore is closed, and thus nonconducting; a transient open or active state, as ligand binds and channel is gated open, and
a long lived desensitized state, where ligand is more tightly bound, but the central pore is
closed, and the receptor is once again non-conductive. It is important to note, as mentioned
in Chapter 1, that crystal structures do not truly represent a native environment of
membrane proteins, as they are crystallized in a de-lipidated environment (important
especially as pLGICs are transmembrane proteins) with stabilizers such as antibodies or
other molecules bound. They also do not represent the dynamics of a protein, as they are
static representations, but they do provide structural information, and an understanding of
a conformation that represents a low-energy well in a protein’s allosteric transitioning.
These structures can provide a starting point to guide towards complete structural
knowledge and thus future modulation of function via targeted therapeutics.
As noted,9 to date, the resting-like structures are: GLIC apo,243,308,309,314 GLIC
LC,243,308,309,314

GluClα

apo,243,312,315

α1-GlyR

strychnine,243,296

α3-GlyR

strychnine.243,297,316 The resting state structures are either apo- or bound with antagonist.243
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In all of these structures, the pore region shows a constriction point at a hydrophobic
residue, which points towards a closed non-conducting conformation. This is due to the
unfavorable interactions between the hydrophobic residue and water, which creates an
impassable energy barrier for solvated ions.243
The open or active-like structures are: α1-GlyR glycine,243,296 α1-GlyR
glycine/ivermectin,243,296 GluClα ivermectin,243,312 and GLIC pH 4.243,308,309 The open state
structures are bound with agonist or a potentiator.243 The hydrophobic based closure seen
in the resting state structures is no longer visible in open state structures, leading to a wider
diameter pore. There is some debate to whether this is due to the existence of a hydrophobic
“activation gate”, especially in terms of the α1-GlyR glycine/ivermectin structure.243,296
According to Nemecz et al.,243 though, more work is necessary to further understand the
dynamics of the cytoplasmic border in the TMD.
Only one of the current structures is thought to be desensitized-like, which is β3GABAA R.243,313 And, additionally, not all of the structures were able to be characterized
with respect to conformation, notably, ELIC,243,306,307 5-HT3 A243,311 and POPC-GluClα.243
The transitions between conformational states, as well as a discussion of how lipids
affect conformational states will be revisited further as it pertains to GlyR in Section 2.3
and in Chapter 3.
2.2.1. The Extracellular Domain (ECD)
The ECD of pLGICs is approximately 190-200 amino acids per subunit and has a
β-sandwich fold, composed of paired antiparallel inner and outer β-sheets.301,317 The Nterminal domain is at the top of the protein and consists of a variable-length short α-helix,
that is absent in prokaryotic relatives.243
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Ten β-strands comprise the β-sandwich

fold.238,301,317 The ECD also contains the ligand-binding domain (LBD), in which the
binding pocket is between neighboring subunits. The ligand or neurotransmitter binds in
between subunits, and interacts with loops and β-strands from subunits on either side, and
Figure 5. Extracellular Domain of pLGICs. The extracellular domain of a pLGIC is represented by
AChBP (PDB: 1ux2). a. A single subunit with labeled beta strands, β1 – 10. b. Two subunits are shown
to highlight the loops that form the LBD, loops A-C on the principle subunit (left), colored red, orange
and yellow, respectively, and loops D-F on the complementary strand (right) are colored blue, green
and purple, respectively. The colored residues represent the general area of the loops and not the distinct
positions that contact the ligand, as it differs depending on the receptor.
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the C-loop plays a role in binding. The C-loop is thought to move in a hinge-like fashion
and cap over the bound ligand, resulting in a long-lived higher affinity desensitized
state.238,240,304,318 Though the C-loop is perhaps the most mobile region within the
ECD,238,240,245,296,297,319 proposed to move as much as 7Å in nAChRs317,318 , the other βstrands, particularly β1, β2, β3, part of β5, β6 and β8 are proposed to move as a result of
ligand binding241 (See Figure 5a). The five individual subunits together of the ECD form a
water-filled vestibule that provides the ions access to the channel.238
2.2.1.1 The Ligand-Binding Domain (LBD) and the C-Loop
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The ligand-binding domain (LBD) or the orthosteric site for the endogenous
neurotransmitter is located about halfway from the top of the ECD to the membrane, in
between two subunits.243 Once ligand binds, the receptor allosterically shifts to a
conformation that stabilizes the channel towards the open state. This is the first step
towards receptor activation, which is followed by coupling and finally, gating.238 Agonist
binding occurs between subunits, at loops A-C on the principal subunit face and loops DF on the complementary subunit face238,320–323 (see Figure 5b). As discussed previously,
the number of binding sites depends on the particular subunit distribution and is diverse
among the pLGIC family. Heteromeric receptors require usually at least two ligandbinding sites for full activation,238,321,324,325 but homomers seen in GlyR and GABAA Rs, do
not require total ligand binding for activation.238,322,323
The agonist situates itself between the loops; these loops contain critical aromatic
residues that allow for cation-π interactions, and hydrogen bonding, which stabilizes the
interaction.317,326 This interaction primarily involves loop-B in nAChRs, 5-HT3Rs, and
GlyRs, and loop-A in GABAARs.238,318,327 However, the other loops involved in the LBD,
also have conserved aromatic residues that are crucial. Loop-A and the C-loop also have
conserved aromatic residues, mostly Tyr.238,328–330 On the complementary subunit face,
Loop-B and Loop-D contains a conserved tryptophan (Trp) residue in nAChRs and 5HT3Rs; this is replaced for a phenylalanine (Phe) or tyrosine (Tyr) in GlyRs and
GABAA Rs, respectively.238,317,318 It was later found that loops D and E are actually βstrands.243
The conformational structural changes due to ligand binding are required to
transmit the signal to the other parts of the receptor; the ECD-TMD interface and the
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relatively distant gating region (>40 Å away from the LBD296,304) in the TMD, in order to
trigger the opening of the channel. The C-loop, as mentioned, is thought to play a role in
this signal transmittance by its capping motion, which hinges over the bound ligand. This
has been shown in experiments with AChBP, which highlighted that residues within the
C-loop (consisting of β-strands 9 and 10, as well as a short loop between them, Figure 5b)
may move as much as 7 Å.317 Due to its location, being in close proximity to the other
loops participating in cation-π interactions with the neurotransmitter, it is a likely candidate
for means of transmitting signal to the other loops and the inner β-sheets and activating the
channel for gating.238,331 Loop-B is shown to rotate to close around the agonist and it also
makes contacts with loops A and C, and loop-A also changes conformation due to ligandbinding.331–333 Notably, a conserved Asp residue in loop A also signifies its potential
importance in ligand binding, and it may also make contacts with loop B.333–337 A study
conducted by Miller et al.338 also shows loop-A in GlyRs can trigger activation through a
connection in the hydrophobic core. Furthermore, many studies have mapped mutations in
GABAA Rs and GlyRs to the loops in the LBD that lead to spontaneously opening
channels.339–342
Other studies confirm the importance of the C-loop in triggering activation; a study
analyzing electron micrographs of nAChRs showed that in the absence of agonist, the Cloop is in the uncapped formation,343 and hydrogen-deuterium exchange mass spectrometry
confirmed that in agonist-bound receptors, the C-loop is less accessible.344 The proposed
movement of the C-loop is a twisting motion of the β9-β10 hairpin that shifts the base of
β9 inwards; this likely diminishes the space between the inner β-sheet which forces the
sheet to move as well.238,310 This movement of the inner β-sheet is thought to signal
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downstream activation of the receptor. Similarly, it has also been proposed that movements
due to ligand-binding occur early in the activation process and happen close to the binding
site, yet still contribute to a downstream effect.345,346 These studies highlight the feedback
communication between C-loop motion and channel gating.238,331
Functional studies have shown that closure of the C-loop does not have to come
from ligand binding, but there is seemingly a connection between how many ligands bind
and the duration of the active or open state. Because of this, it is thought that C-loop
capping might be a pre-activation step, or a “priming” step before the channel
opens.238,347,348 This pre-activation step has also been referred to as a ‘flip’ state, in regards
to studies performed on nAChRs and GlyRs using agonists of different binding affinities.
Agonists that stabilize the ‘flip’ state with high affinity would cause a longer active state,
meaning that if the pre-activation and/or ‘flip’ state is equivalent to the capped state, then
an agonist can be characterized as full or partial depending on whether it is able to promote
C-loop capping.238,349 Regardless of the studies conducted, this is still a mechanism that is
not fully understood and may not be universally applied to all pLGICs. Though evidence
does suggest that C-loop capping is the probable means of transmitting signal, it is not
known whether or not this is the initiation step of receptor activation.238 It may, instead be
a means of providing stabilization to allow other nearby loops to trigger downstream
channel activation, as studies on GABAARs have suggested.350,351
2.2.2 The ECD-TMD Interface
The interface between the ECD and TMD is responsible for communicating the
signal of ligand-binding in the ECD to the TMD region where gating will occur. It also
houses the Cys-loop, an important region that gives these receptors their name; often a
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synonym of pLGIC. As stated previously, the prokaryotic relatives of pLGICs do not
contain the disulfide bridge of the Cys-loop which is also known as the β6-β7 loop.
Furthermore, this region is wholly important in terms of receptor malfunctions, as
mutations to this area are the cause of diseases associated with pLGICs.
The interface consists primarily of three different loops; the β1-β2 loop, the M2M3 loop, and the Cys-loop (Figure 6), but is also the region where the C-terminal tail, the
pre-M1 linker and the loop linking β8 and β9 are located. The β1-β2 loop and the Cys-loop
are situated at the base of the ECD; the β1-β2 loop is part of the inner β-sheet, and the Cysloop connects the inner and outer β-sheets. In studies analyzing nAChRs, these loops form
arcs which make contacts using their sidechains with the M2-M3 loop, which is facing
upwards from the TMD, connecting M2 and M3. The β1-β2 loop is closest to the M2
channel.238,304 What is interesting is that in non-α subunits of nAChRs, these loops are
situated approximately 2 to 3 Å away from the pore,304 which suggests the importance of
these loops transmitting signal in active subunits.
The β1-β2 loop in GlyRs has also been shown to be important in signaling. In a
single channel study analyzing the mutation A52S in the α1 subunit of glycine receptors in
spasmodic rats, results showed a reduction in the affinity of a ‘flipped’ conformation and
in apparent cooperativity.352 This suggests that this loop, like the C-loop discussed in the
previous section, may affect ligand binding. Further studies of GlyRs, this time analyzing
the M2-M3 loop have shown that different agonists (taurine and glycine) evoke almost
identical motions of this loop, perhaps suggesting that this loop moves in a pre-determined
fashion.238,353 Yet, other studies by Lynch et al. and others354–358 have shown that mutations
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to the M2-M3 loop in GlyRs, particularly those that cause hyperekplexia (see Section 2.3),
affect channel gating, and becomes more accessible during the open state.359,360
In the prokaryotic relatives, ELIC and GLIC, a comparison of the open and closed
states revealed movement of the β1-β2 loop downwards towards M2, and displacement
outwards of both the Cys-loop (β6-β7 loop) and the M2-M3 loop.238,246,247,306,361 Studies
targeting these ancient relatives suggest that they are not only employed in signaling
mechanisms long before the origin of the animal nervous system, but that they are
Figure 6. ECD-TMD Interface. The ECD-TMD interface, inset in black,
of a pLGIC (GlyR, PDB: 3jad). The primary loops are color coordinated;
the β1-β2 loop is shown in blue, the Cys-loop is shown in green and the
M2-M3 loop is colored orange. Also visible is the C-terminal tail in red.
The TMD is also labeled, M1 – M4.

functioning in a similar
mechanistic manner.244,362
It

is

not

clear

whether or not the other
loops that are present in the
β1-β2 loop

interface, the β8-β9 loop and
the
Cys-loop

pre-M1

linker,

contribute to the activation
of the receptor or if they are
communicating

M1
M4
M3
M2

with

the

TMD. Though there are
M2-M3 loop

C-terminal tail

functional
suggest

studies

that

this.347,363,364

Overall, the residues that are
important for receptor activation interact through hydrophobic and electrostatic
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interactions, and the positions of these residues is quite reserved through pLGICs.238,303,365–
368

Pharmacologically significant, several diseases and disorders of pLGICs are due to
mutations located in this interface. Congenital myasthenic syndromes are a group of
disorders that cause decreased surface expression of muscle nAChRs, or slow or fast
channel syndrome. Slow channel syndrome is marked by prolonged channel openings and
fast channel syndrome by abbreviated openings.369,370 Many different mutations cause
these syndromes, and more information can be found in Engel et al.371 Epilepsy, a common
neurological disorder marked by seizures, is linked to malfunctions in GABAA Rs,372,373
and is caused by several different mutations, often dominant, affecting many of the
subunits. Some notable ones that are located in the interface are α1 A322D, β3Y302 and
γ2R323.374,375 These mutations, and the others that cause epilepsy disorders, often result in
reduced whole cell current and decreased surface expression.373 Also, hyperekplexia is a
disorder that results due to mutated α1 GlyR, most commonly, and will be discussed in
Section 2.3.3.
2.2.3. The Transmembrane Domain (TMD)
The last step in the activation process is, of course, channel opening, which occurs
in the TMD. There are four transmembrane α-helices per subunit, contributing to a TMD
region of twenty α-helices per receptor. The α-helices, M1 – M4, are positioned so that M2
from each subunit is lining the pore. M4 is the outermost helix. The M2 helix, regardless
of subunit type, in a single receptor, is very homologous and is composed of identical or
very similar residues.238 The helices are not aligned perfectly parallel, and are instead wider
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at the extracellular end. To stabilize the channel, there are many contacts between the M2
helices of each subunit, as well as minor contacts between M1 and M3.238,310
In order to provide clarity when comparing the residues within the pore to other
members of the pLGIC family, a prime number system is used, defined by Miller in 1989,
starting at the cytoplasmic end at 0’ and moving up the helix to reach 20’ at the extracellular
end.376

In most of the channels, the middle of the helix, facing inwards contains

hydrophobic residues; 9’ Leu is consistent throughout the pLGIC members, and in the 13’
position, Ala, Thr, or Val are present.238,376 The ends of the M2 helices are most often
charged residues, often Glu and/or Asp.238,376
The channel gate has been studied extensively in nAChRs, and was found to be in
between the 9’ – 14’ residues, particularly at two places, at the 9’ and 13’ Leu.310,331 The
hydrophobic residues form a hydrophobic bubble, approximately 6 Å in diameter which is
sufficient to block hydrated Na+ and K+ ions from displacing further down the channel.304
Analyses of the members of the pLGIC family, specifically nAChR, GABAA R and
GlyR, using hydrophilic residue substitution have shown an increase in susceptibility for
the channel to open in response to agonist.377–381 This is consistent with hydrophobicity
providing stabilization for a closed channel.304,310 Other studies, however; suggest that the
channel gate is on the cytoplasmic side of the channel, and not the midpoint. These studies
used cysteine-modifying reagents in the absence of agonist, as well as picrotoxin (PTX).382–
385

There are also evidence that there is two distinct gates; this dual-gate model proposes

that there is a gate for the closed to open transition, and also a gate for desensitization.386
Several studies analyzing GlyR desensitization have proposed the gate is near the
cytoplasmic end,354,357,386,387 and other studies have shown that picrotoxin (PTX) blocks
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desensitization386 and that the M3-M4 loop plays a role in desensitization.388 This
controversy is still not completely resolved and further work needs to be conducted to
resolve this issue.
Much of the research focusing on channel opening, however; agrees that pLGICs
open by a tilting of M2 helices.304,308,309,389–393 The channel has to widen for opening to
occur, and this is most likely done through M2 moving back towards M1 and M3, which
is thought possible because M2 only makes limited contacts to these other two helices, and
is also partially separated from them due to a space between them that is thought to be
filled with water and cholesterol.360,394–396 Furthermore, since most of the stabilization
comes from M2-M2 interactions, C-loop capping due to ligand binding is thought to
provide enough destabilization to the closed gate to allow widening of the hydrophobic
bubble and opening the channel.238,397–399
In addition to the TMD region being important in regards to channel gating, the
region also plays a huge part in the binding of allosteric modulators. It is modulated by
several compounds, such as alcohols and anesthetics, endogenous neurosteroids and zinc
ions, which will be further discussed in Section 2.3.1.
2.2.4. The Intracellular Domain (ICD)
The intracellular domain contains both the M1-M2 loop and the M3-M4 loop which
is in some ways the hallmark of each individual channel, as this region varies widely
between the family members in length and sequence variation.388 The M1-M2 loop, in
GlyRs, is also important in terms of hyperekplexia, a disorder linked to the receptor.400 A
commonly studied mutation P250T, located in the M1-M2 loop, is a dominant mutation
that causes the disorder,357,358,401 and will be discussed in the next section.
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The M3-M4 loop, however; is much more diverse in terms of its importance. This
intracellular loop has many different functions and modulations, including mediating
specific

interactions

with

intracellular

binding

partners,388

post-translational

modifications,388,402 channel structural integrity,403 gating,404 desensitization,405–407
modulation by positive allosteric ligands408 and receptor surface expression.402 Studies of
pLGICs have shown that if the loop is severely truncated, or if the receptor is lacking the
loop entirely, this leads to non-functional receptors.388,409–411 The M3-M4 loop is also a
defining characteristic of the eukaryotic pLGIC members, as it is very short in prokaryotic
ELIC and GLIC.308,412,413 Because of the variation of size and amino acid sequence in each
eukaryotic loop, and based on chimeric studies that showed full pentamers could form with
a loop that was not subunit-specific, it is known that the loop determines the specific ion
channel properties.388,414–416 The information available on this defining loop comes from
experimental studies and not from structural studies, as members of the pLGIC family can
only crystallized successfully by truncating this loop and replacing it with a short
peptide.296,297,331,417,418 This lack of structural information provides a strong rationale into
the usefulness and importance of the MS studies undertaken in this work. Furthermore,
because this loop is so variable, this section will primarily focus on discussing the details
of the M3-M4 loop in the context of only glycine receptors.
The M3-M4 loop of α1-GlyR is nearly 70 residues, which is about 20% of the mass
of a single subunit. It is not as large as the M3-M4 loop in nAChRs, but it is comparable
in size to the GABAARs. There are several motifs within the loop of considerable
importance, such as the stretch of basic residues near M3. Mutations of the basic residues
in this region, conducted by Carland et al.,419 lead to a non-functional receptor, which
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suggested a role for this region to draw anions through the pore. This region is thought to
be important for insertion of M3 into the membrane,420 and also contains the nuclear
localization signal (NLS), which interact with intracellular proteins karyopherins α3/α4
and results in the transport of GlyRs into the nucleus.421 This stretch, particularly
316RFRKK320

along with a di-Lys region later in the loop, binds to the G-protein subunit

Gβγ.388,422 This interaction has been shown to enhance glycine induced chloride current.423
The basic stretch is also important in terms of binding allosteric modulators, such as ethanol
and endocannabinoids.424–427 Another region, located next to the basic stretch, residues 358
– 372, in α3-GlyRs has been shown to play an important role in desensitization, and also
folding stability of the region.405 There are two other motifs seen in GlyRs, a polyproline
region,

366

PPPAPS371 in α1-GlyRs, and a poly-asparagine region,

358

NNSNTTN364. The

poly-Pro region is thought to have helical structure, specifically as a poly-proline helix type
II (PPII) and has been analyzed via CD-spectroscopy.387,428 These PPII helices form the
SH3 (Src homology 3 domain) consensus sequence,429,430 which is a common binding motif
found in many proteins. Syndapin 1 is an intracellular protein that binds GlyRs via their
SH3 domains and plays a role in trafficking and possibly even anchoring.431,432 Currently,
the understanding of the basis of the poly-asparagine domain in GlyRs is severely
lacking.388
As stated previously, structural information of this region does not come from high
resolution crystal structures, but there is some information regarding the secondary
structure of certain regions of this loop. As described by Unwin et al.,331,388 most of the
secondary structural features are located at the ends of the loops, leaving the middle of the
loop unstructured or disordered. There is evidence of α-helices at the beginning and end of
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the M3-M4 loop in pLGICs, including nAChRs and 5-HT3Rs,311,331 and this has been
proposed to be true in GlyRs as well. CD-spectroscopy studies showed evidence of αhelices near M3 and M4.433 And there is evidence of a PPII helix, mentioned above, also
identified via CD-spectroscopy located between residues 365 and 371 of α1GlyRs.387,421,428
The M3-M4 loop is also targeted by many intracellular binding partners. An
important one to note is gephyrin. Gephyrin is a peripheral membrane protein that consists
of three domains; an N-terminal G domain, a C-terminal E domain and an unstructured
domain that links the two together.404 The E domain interacts with the β-subunit of GlyRs
and its function is primarily synaptic anchoring.404 This was proven due to its
copurification with both GlyR and tubulin,434–436 studies using gephyrin antisense
oligonucleotides that stopped formation of GlyR in the membrane,404,437 and via treating
rat spinal neurons with strychnine which inhibited GlyR and gephyrin clusters at
postsynaptic membranes which suggests that activation of the receptor is essential for the
proteins to cluster.404,438 Other roles for gephyrin is mediating synaptic inhibition and longterm potentiation.404,439–441 Additional intracellular binding partners were already
previously mentioned including G-protein subunits Gβγ, karyopherins α3/α4 and syndapin
1. Vesicular trafficking proteins, Sec8 and vesicular presynaptic marker VGLUT1, also
bind α3-GlyR intracellularly, and control its trafficking towards presynaptic terminals.442
A study by Del Pino et al.388,431 used mass spectrometry and identified two more binding
proteins that target the β-subunit of GlyRs, Vps35 and neurobeachin. Also, a GTP/GDP
exchange factor, CB and neuroligin 2 are known to play a role in formation and function
of inhibitory postsynapses via binding to GABAARs, but this interaction has not yet been
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shown in GlyRs.388,443 It is clear that while it is known that these intracellular binding
proteins are essential to GlyR function, there is still a lack of clarity on the mechanisms
behind these interactions. There is also a possibility that more interactions exist and will
be identified in the future.
Post-translational modifications (PTMs) also affect the M3-M4 loop, particularly
ubiquitination and phosphorylation. Ubiquitin is attached to Lys residues and signals that
the protein is ready for degradation; in GlyR, there is approximately ten Lys residues in the
M3-M4 loop and three of them are ubiquitinated to allow for protein internalization and
degradation.388 There are recessive mutations that result in hyperekplexia that lead to
accumulation of the receptor that then influences the degradation of the receptor through
the ubiquitination process.411,444 Phosphorylation of GlyR M3-M4 loop results from protein
kinase A or C (PKA, PKC), depending on the subtype. Residue S391 in α1-GlyRs is
phosphorylated by PKC, which is in a similar location to phosphorylation sites in other
pLGICs.445 β-GlyRs are also phosphorylated by PKC at S403.446 α3-GlyRs are
phosphorylated by PKA at position S346; this serine is not conserved in α1-GlyRs and
thus, PKA cannot modulate α1 subunits.447 The role phosphorylation plays on GlyRs has
been studied extensively. Research has shown phosphorylation of α1 receptors mediates
interaction with intracellular proteins, such as gephyrin.446,448,449 A study by Huang et al.450
analyzed PKC after being activated by a myristate and found that this led to increased
internalization of GlyR, except when a di-Leu region (L314/L315) of the M3-M4 loop was
mutated. Another study examined the effects of phosphorylation of GlyRs on ethanol
potentiation.451 Also, as described in Section 2.3.3.2., chronic pain is linked to GlyRs, and
the phosphorylation of α3-GlyRs by PKA plays an important role in pain sensitization.447
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Other studies show that kinases effect the desensitization of the receptors and also the
maximal chloride influx.452,453
In summary, the large intracellular loop in pLGICs serves to distinguish the
members from one other, contributing to their specific functions. It plays several roles that
affect gating, desensitization, trafficking, degradation, among others. Because there is a
lack of structural information on this region, CX-MS studies can lead towards a better
understanding of dynamics of this region and pinpoint what specific areas of the loop are
interacting with the membrane or are in close proximity to the channel.
2.3 The Structure-Function Relationship of GlyR
The glycine receptor is found in localized regions, such as the retina, the spinal cord
and brain stem, and is responsible for facilitating inhibitory neurotransmission. Similar to
other members of its family, GlyR is a hot-spot for small molecule interactions, many of
them have a potentiating effect on the receptor. GlyR is also modified by post-translation
modification (PTM) that leads to further diversity and modulations of the receptor.
Mutations or malfunctions of the receptor contributes to diseases and disorders, such as
hyperekplexia, chronic pain as well as others.
The link between protein structure and protein function is important towards
developing a full understanding of the structure and dynamics of a particular protein.
Understanding the interactions between small molecules, as well as the modifications that
happen naturally to the receptor in vivo, also lead towards this greater volume of knowledge
that helps define the importance of a protein of interest.
More importantly, however; obtaining more complete structural knowledge can
lead to the development of novel therapeutics that can specifically target the receptor and
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treat these channelopathies. Various conditions linked to a protein can be treated more
effectively once there is a more complete understanding of protein dynamics and structure.
Designing therapeutics that are specific to a protein of interest can also help mitigate offtarget binding which causes many of the side effects seen in pharmaceuticals.
2.3.1 Small Molecule Targets of GlyR
The glycine receptor has several allosteric and orthosteric modulators that bind the
receptor and affect its function. Strychnine, a plant alkaloid found most commonly in the
seeds of the Strychnos nux-vomica tree, is a competitive antagonist to GlyR, and due to its
toxicity is used as a rodenticide. It can be fatal to many mammals, even humans, if a high
enough dosage is ingested. Clinical signs and symptoms of strychnine poisoning appear
first as nervousness, muscle twitching, and stiff neck, before progressing to convulsions in
skeletal muscles. Death results due to asphyxia caused by paralysis of respiratory muscles.
The effect on GlyR is the blockage of chloride current, as strychnine binds in the LBD of
the receptor.454 Also, strychnine binds much tighter to GlyR than does its ligand, glycine,
as represented by the dissociation constants (Kd), 2 – 4 nM and 25 μM, respectively.455
Because of this extremely tight binding, strychnine can be used experimentally to
distinguish between it and other members of the pLGIC family, particularly between GlyR
and GABAAR;236 though studies have shown that strychnine can also bind, with much
lower affinity, to nAChRs.456
Another toxin derived from plants is the convulsant alkaloid picrotoxin (PTX)
which is used to discriminate between glycinergic and GABAergic currents.236 GABAARs
are highly sensitive to the toxin (at a range of about 1 – 10 μM), whereas; GlyRs are much
less sensitive.236 Furthermore, heteromeric αβ-GlyRs are less sensitive than homomeric α-
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GlyRs.457 PTX, therefore; is an important pharmacological tool to distinguish if there is a
heteromeric or homomeric GlyR present. Studies have also shown PTX can be used to
inhibit GlyR, by blocking chloride current.458
Ivermectin is a member of the avermectin family of compounds and is a
macrocyclic lactone.281,459,460 It is widely used to treat parasitic worm infections in
ruminant animals, and pinworms, threadworms and whipworms in mammals, including
humans.459,460 It is also an effective treatment against river blindness.461,462 There is
ongoing research that shows ivermectin has antiviral properties against positive-sense
single-stranded RNA viruses, such as SARS-CoV-2.463–465 Relevant to this work,
ivermectin, at low concentrations, is a potentiator of GlyR, that binds in the TMD, and does
not allow desensitization of the receptor, and at higher concentrations (≥0.03 μM),236,466
ivermectin is an activator of GlyR.236 Using ivermectin at lower concentrations can
effectively trap the receptor in the open state, and thus, allows for study of the open
conformation.
Other common small molecules that interact with GlyR are ethanol and caffeine.
Ethanol was first shown to cause glycine sensitivity in spinal neurons by Celentano et al.
in 1988.236,467 Studies by Lobo et al.468 showed that channel gating allows accessibility to
M1, M2 and M3, which are targeted by alcohols. Other studies showed that ethanol, as well
as other long chain alcohols, potentiate the receptor.469–472 Caffeine, on the other hand, is a
structural analog of strychnine, and thus an orthosteric modulator, targeting the LBD of
GlyR.473 It has been shown that caffeine inhibits current in both GlyRs and
GABAA Rs.473,474
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Medically relevant compounds that affect GlyR function are anesthetics,
benzodiazepines and members of the cannabinoid family. Anesthetics have traditionally
been thought to be non-specific drugs that acted by disordering lipid bilayers,236,281 but
since the 1990s, research has shown that ion channels are a specific target of these
drugs.475–480 Like alcohols, anesthetics target GlyR in the TMD;468 specifically I299 in M1,
S267 in M2 and A288 in M3.396,468,481–485 Volatile anesthetics, such as isoflurane, nitrous
oxide, propofol, thiopentone, pentobarbitone, ketamine, among others, have potentiating
effects on the receptor, as well as on other members of the pLGIC family.471,476,477,479,486–
489

Benzodiazepines are used to treat channelopathies present in GlyR and GABAA R
such as hyperekplexia and epileptic disorders.281,373,401,490 Studies analyzing the effects of
several benzodiazepines on GABAA R have shown that these drugs target the N-terminal
domain of the receptors, and the effects of diazepam in particular, are diminished if a
H101R mutation occurs.482 GlyR studies, analyzing the effects of diazepam, flunitrazepam,
flurazepam, among others, have also shown that these drugs target the LBD, specifically
involving the interactions made by strychnine.490,491 By binding in the LBD, and thus
mimicking glycine, they are able to produce anti-anxiety, anti-convulsant and musclerelaxant effects for which they are prescribed.490
Cannabis, which contains a psychoactive component Δ9 -tetrahydrocannabinol
(THC), is often prescribed and used to treat chronic pain.282,492,493 Though most of the
effects of THC and other members of the cannabinoid family are mediated through the
cannabinoid type 1 receptor (CB1),282,494–496 some of its effects are due to binding to GlyR,
specifically the analgesic effects.497,498 THC, as with many other important molecules,
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potentiates the receptor and provides an anesthetic effect.497,499,500 Both α1-GlyR and α3GlyR are linked to cannabis-induced analgesia.280,447,501–504 These cannabinoids interact
with GlyR in the TMD, specifically S296 and S307 in α1 and α3-GlyR.500
In summary, GlyR is a target for a wide variety of small molecular compounds,
many of them with important medicinal and pharmacological relevance. Most of them are
commonly used to treat disorders such as hyperekplexia, seizure disorders and pain. Some,
caffeine, ethanol, and THC are used for daily consumption.
2.3.2. Post-Translational Modifications (PTMs) and Regulatory Aspects of GlyR
Post-translational

modifications

(PTM)

that

target

the

M3-M4

loop

(phosphorylation and ubiquitination) have already been discussed in Section 2.2.4., but
there are others that occur in other regions. N-glycosylation, which is the attachment of
glycans to an Asn residue, occurs at N-X-S/T motifs. α1-GlyRs have one consensus
sequence, 38NVS40 in the ECD, and β-GlyRs have two N-glycosylation sites, at position 32
and 220. α2-GlyRs and α3-GlyRs also have similar consensus sequences.505 These Nglycosylation sites play a role in GlyR trafficking, particularly the exit from the
endoplasmic reticulum (ER), as studies have shown that when this consensus sequence is
mutated, GlyR cannot exit.506,507
There are also several sequences located in the ECD known as assembly boxes that
were determined through site-directed mutagenesis to promote pentameric assembly of the
receptors. In α1-GlyRs, these are
125NVLY128 .506,508

35PPVNVSC41,

74 AYNEYPDD81, 90LDSI93 ,

and

There are also sequences within M1, M3 and M4 that also promote

pentameric assembly.409
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Similar to the discussion of PTMs occurring in the M3-M4 loop, there was also
mention of intracellular binding partners in said loop. However, extracellular proteins do
interact with the ECD of GlyRs as well, in particular, calnexin. Calnexin is a chaperone
protein and a member of the lectin family that binds to mono-glycosylated and N-linked
core glycans.506,509 Coimmunoprecipitation studies showed the interaction between these
two proteins, and mutations to the ECD loop β2-3 and to M4 showed increased interaction
compared to WT GlyR.411
Another important regulatory molecule that interacts with GlyR outside of its M3M4 loop is zinc. Zinc is thought to reach a concentration of >100 μM during synaptic
stimulation,236 and is able modulate many post-synaptic and pre-synaptic ion channels,
including GlyR.236,510 High concentrations of zinc (> 10 μM) inhibit glycinergic current,
whereas; lower concentrations of zinc (0.1 – 10 μM) potentiate the receptor.236,511–514 Zn2+
ions can be coordinated by nitrogen, sulfur or oxygen atoms that are in the side chains of
histidine, cysteine, aspartate and glutamate residues.515 Studies have shown that in GlyRs,
Zn2+ ions coordinate to D80,516,517 studied extensively as D80A is a prominent
hyperekplexia mutation.401,516 Zinc coordinating to this site also increases ethanol
potentiation.517 Zn2+ ions also coordinate with several His residues, including H107, H109,
H210, H215, and H419,518,519 though most prominently at H107 and H109, as studies have
shown that the latter His residues fail to prevent inhibition of the receptor when H107 and
H109 were mutated.518
There are other molecules and other regulators that modulate the receptor. Calcium
ions cause elevation in the magnitude of glycinergic current that may be mediated by
calcium activation of calmodulin-dependent protein kinase II and calcineurin.236,520–522
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Also, pH appears to play a role in increasing the glycine EC50, shown by studies that
mutated various ECD residues, H109A, T112A and T112F.236,523
2.3.3. The Channelopathies of GlyR
2.3.3.1. Hyperekplexia
Hereditary hyperekplexia, also known as familial/human startle disease, is
characterized by extreme startle responses due to unexpected auditory or tactile
stimulations.400,401 It is further marked by prolonged muscle hypertonia, mostly in infancy,
which can lead to infant death, due to apnea or asphyxia. Furthermore, gross motor
development is delayed in the first two to three years of life.400 As patients age, hypertonia
is still present, though not as severe as during infancy, and injuries due to falling are most
prominent. There can also be delayed speech acquisition and intellectual disability.401
Onset of the startle response results in forceful closure of eyes, rising of bent arms over the
head and a stiffness or flexion of the neck, trunk, hips as well as elbows and knees.400,401
Consciousness is maintained during these episodes, which distinguishes this disorder from
epileptic seizures seen due to mutation and malfunction of GABAARs.373,401 The disorder
is rare, affecting about 1 in 40,000 people in the United States.524
Benzodiazepines are most often used to treat this disorder, including clonazepam,
and

diazepam,525

divalproex

sodium,

valproic

acid,

and

the

anticonvulsant

levetiracetam.525,526 These drugs work effectively to treat hyperekplexia,527,528 however;
side effects of these drugs vary widely, and include, increased concentration and energy,
sleeplessness, loss of control, aggression, and suicidal thoughts.529–531
Hyperekplexia is primarily caused due to mutations in α subunits in GlyRs and in
the presynaptic glycine transporter, GlyT2.400,401,532 As of 2014, a study by Bode and Lynch
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reported 55 mutations in α1-GlyR that cause the disorder.401 There are also mutations of
the β-subunit, but these are not as common or as numerous. The mutations are located
throughout the receptor. There are many mutations found in the ECD and TMD regions
(see Bode and Lynch),401 and there are some notable ones in the interface, which along
with those located in M2 are most often dominant mutations.388 There are also
hyperekplexia causing mutations in the ICD; one in the short M1-M2 linker, P250T, which
has been studied extensively,357,358 and several in the M3-M4 loop; R316X, G342S,
E375X, D388A and R392H,388,401 which are important to this work as structure of this
region is not well-resolved.
The dominant mutations (located primarily in M2, the ECD-TMD interface as well
as P250T) cause functional issues, such as spontaneous activation,358,401 reduced single
channel conductance,533 impaired channel gating, an overall lower maximal current, a
decrease in ligand binding efficacy533 and enhanced desensitization (caused primarily by
P250T).358,534 Some examples of spontaneous activation are: Q226E, located at the top of
M1 which also causes reductions in surface expression;401,532,535,536 V280M in the M2-M3
loop which causes drastic enhancement of glycine sensitivity; this may be due to
destabilization of the closed channel,401,535,536 and R414H, which is located in the M4
domain and the mechanism to which it may cause activation is currently unknown.401,535
Impaired channel gating is most often caused by two common dominant mutations,
R271Q and R271L.356,400,401,458,537 Both cause a significant decrease in glycine sensitivity,
but do not cause reduced surface expression. The most likely cause of the decrease in
channel gating and conductance is due to the loss of the positive Arg residue.356,401
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The recessive-type mutations, which are located throughout the receptor are
responsible for affecting receptor biogenesis, surface expression, trafficking and receptor
stability.388,401,402,411,444 Reduced surface expression is caused by recessive mutations that
are located primarily in the TMD; S231R and I244N in M1, R252H in M2 and R392H in
M4.401 However, there are also mutants located in the M3-M4 loop (see above) that also
contribute to reduced surface expression as well as decreased receptor stability.388,532,536,538–
540

Two of them, R316X and E375X lead to truncated receptors, and results in significantly

decreased surface expression due to protein misfolding and abnormal receptor
trafficking.388 A similar truncation in the M3-M4 loop is also seen in γ2 subunits in
GABAA Rs, which leads to epileptic disorders.375,541
According to Bode and Lynch, these mutations, either dominant or recessive can
be grouped into three categories: dominant mutations located in or around M2 that do not
impair expression but do cause misfunction of the receptor, recessive missense mutations
located throughout the receptor that cause a decrease in surface expression, and recessive
nonsense and deletion or frameshift mutations that result in disruption of full length
receptor formation.401
Despite understanding much about the many mutants and categories of mutant that
cause this disease, and regardless of the advancements modern medicine has made in
treating this disease, there is still work to be done. A complete structure of this receptor,
particularly focusing on unresolved areas, such as the M3-M4 loop, will enhance the ability
of targeted drug design, leading to fewer negative side effects and a more normal life for
those that have hyperekplexia.
2.3.3.2. Chronic Pain
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Chronic pain is a complex disorder that affects approximately 50 million
Americans, according to a 2016 study.542 It is found widespread over many conditions,
prevalently featured in diagnoses such as fibromyalgia,543,544 vulvodynia,545–547 trigeminal
neuralgia,548,549 irritable bowel disorder,550,551 arthritis,552,553 nerve damage,554,555 and many
others. It is also often associated with cancer patients.556,557 Symptoms, too, vary widely,
depending on the area most affected; but often are joint pain, burning pain, and fatigue;
depression and anxiety are comorbidly linked as well.546,558–560
Pain, because it is often a part of the innate immune response to a plethora of
different underlying conditions – tissue damage, infections, inflammatory disease, cancers
and others561–564 – chronic pain syndromes are often difficult to diagnose, and there is
stigma associated with the disease as the chronic pain patients suffer may not always be
believed.565–567 Treatment, traditionally, is limited to over-the-counter treatment such as
ibuprofen, naproxen and acetaminophen560 or prescription drugs such as opioid
painkillers,566 which are stronger, and thus more effective. However, these latter drugs are
habit-forming, and can lead to dangerous overdose.568–570 Other less traditional treatment
options recently seeing more widespread use, include acupuncture,571–573 low-level laser
therapy574 and THC and CBD as inhalants, oils or pills.282,492,493,575–577
The link between chronic pain and GlyR exists through its connection to the
cannabinoid family potentiating the receptor.280,447,501–504 As noted in Section 2.3.1., most
of the effects of the cannabinoid family are mediated through the cannabinoid type 1
receptor (CB1),282,494–496, but evidence shows that some of the effects are also mediated
through GlyR, specifically the analgesic effects.283,497,498,578,579 Furthermore, studies by
Goss et al. in 2011, and Harvey et al. in 2004, also show a unique link between GlyR and
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pain. In the former study, a gene therapy was established that used a herpes simplex virus
vector to express GlyR to manage pain in nociceptive neurons.284 In the study by Harvey
et al., α3-GlyRs were inhibited by prostaglandin-E2 (PGE) induced phosphorylation and
results showed that this mechanism is important in inflammatory-based pain
sensitization.388,447 This study also resulted in a pharmacological study that further delved
into α3-GlyRs as a potential therapeutic target.580
The implications of this link between GlyR and pain are exciting, and given the
shifting of opinions on alternative therapy for pain management, this could lead to better
therapies and a more normal way of life for so many that struggle with chronic pain.
2.3.3.3. Other Implicated Diseases and Disorders
Though hyperekplexia and chronic pain are the most well-studied in the context of
GlyRs, other diseases and disorders have been linked to the receptor, including, stiff person
syndrome (SPS) and progressive encephalomyelitis with rigidity and myoclonus (PERM),
autism spectrum disorders, panic and anxiety disorders and epileptic disorders.
SPS and PERM are glutamic acid decarboxylase (GAD)-positive disorders581,582
that share similarities with hyperekplexia in that these disorders also have muscle rigidity
and spasms as symptoms.402,582–584 SPS also is characterized with heightened sensitivity to
touch and sound.581,582 Both conditions are rare, but PERM is a much more severe diagnosis
as it is also marked by brain stem and autonomic dysfunction and breathing problems.583,585
The most effective treatment for both SPS and PERM is immunotherapy; Rituximab, a
drug used in immunotherapy has been used to treat both disorders.586–588 Though effective,
patient relapses are common, and thus, these disorders are still incurable.402,589
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Autism spectrum disorders (ASD) are a group of neurological disorders that affect
both behavior and communication and usually the first signs of development are within the
first two years of life. Though the underlying mechanism of the disorder is unknown, it is
thought that there is a multifaceted response with various genes influenced by the
environment to cause the disorder. One of the genes affected is GLRA2, a gene that codes
for the α2 subunit of GlyRs. A missense mutation, R153Q, reported in patients with ASD
caused a decrease in surface expression of GlyRs. This research suggests that there is a link
between social and cognitive impairment and GlyRs, and also that α2-GlyR may play a
role in learning and memory.590 Another study has connected a mutation in a protein
neuroligin-3, R451C, to increased inhibitory neurotransmission. This study proposes that
this gain-of-function mutation caused impaired social interactions, a hallmark of ASD, and
also unexpectedly showed increased inhibitory neurotransmission without affecting
excitatory transmission. The link to GlyR is unknown at this time.591
Panic disorders, including anxiety disorders and agoraphobia have also been linked
to GlyRs. One study found allelic variations in GLRB, the gene encoding for the β subunit
of the glycine receptor, in patients with panic disorders.592 Another study looked at GlyRs
in the hippocampus and found that decreased excitatory inhibition due to gain-of-function
of GlyR lead to an anxiety phenotype in mice.442
Epileptic disorders, commonly linked to GABAARs, can also be found in GlyRs.
Temporal lobe epilepsy, in particular, is linked to specific glycine receptors with high
affinity located in the hippocampus.593 These gain-of-function glycine receptors contribute
to increased glycinergic transmission and cause epileptic seizures.592,594 Glycine receptors
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located in the supramedullary region of the brain are also thought to contribute to
hyperexcitability disorders, such as epilepsy.595
A study by van den Eynden et al.279 in 2009 researched the non-neuronal locations
of GlyRs, and showed the presence of the receptor in immune cells, endothelial cells, renal
cells and hepatocytes. Though it is not yet known why GlyRs are found here, it does suggest
that this receptor may prove to be a crucial piece of other diseases and disorders in the
future.
2.4 Summary
The glycine receptor is a pLGIC which plays an important biological role in
inhibitory neurotransmission, and is strongly linked to pain and analgesia. The structure of
the receptor is lacking details of certain areas important in surface expression, trafficking,
and gating of the receptor. There is also a lack of understanding of protein dynamics
associated with channel gating and protein mobility. By using CX-MS (detailed in Chapter
1) and applying it to structure-function studies using a developed network of single, sitespecific cysteine mutations (see Chapter 3), the body of knowledge surrounding GlyR can
grow and be applied to the future development of more specific therapeutics.
Overexpressing GlyR with designated single Cys mutants, purifying and
reconstituting the receptor into a native-like lipid environment, enriching the receptor into
its allosteric states and then crosslinking it with a heterobifunctional crosslinker will
provide information on structural details in the vicinity of mutants chosen. This
information, when placed in the context of a network of various protein-protein interactions
can refine the structural details that are missing in crystal structures as well as give
information about protein dynamics as the receptor allosterically shifts between its states.
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CHAPTER 3. MATERIALS AND METHODS
3.1 Introduction
This chapter will discuss the materials and methods outlined for both Chapter 4
(resting state) and Chapter 5 (open and desensitized states). Though much of what is done
for resting state mutants is also done for open and desensitized state mutants is identical,
any changes will be noted.
3.1.1 Preparation and Overexpression of Mutant GlyR using the Baculovirus
Overexpression System
The following methodologies as described below contribute to the overexpression
of a single site-specific cysteine mutated GlyR from our network into Spodoptera
frugiperda (Sf9) cells.
3.1.1.1. Introduction of Single Site-Specific Cysteine Mutations via Mutagenic Primer
Design
Primers were designed according to site-directed mutagenesis protocols (purchased
from Operon). Both mutagenic primers (forward and reverse) were designed to contain the
desired mutation and to allow for annealing to the same sequence on opposite sides on the
plasmid (see Table 1). Each primer was designed to be 25-45 base pairs in length, have a
minimum guanosine/cytosine (GC) content of 40%, terminate with a G or a C and have a
melting temperature of approximately 78⁰C. The following equation was used to determine
each primer’s melting temperature:
Tm = 81.5 +0.41(%GC) – (675/N) - %mismatch,
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where N is the length of the primer in base pairs (Quikchange Lightning Site-Directed
Mutagenesis Kit, Instruction Manual).
Table 1. Forward Oligo Sequences. The forward oligo sequences for each mutation in the network,
M287C, K116C and K206C are detailed in the table below.

Mutation
M287C
K116C
K206C

Sequence 5’ to 3’
GCCATTGACATTTGGTGCGGAGTTGCCCTGCTCTTTGTG
ATCACCACAGACAACTGCTTGCTAAGGATC
TACAACACAGGTTGCGCCACCTGCATTGAGGCC

3.1.1.2. Mutant Strand Synthesis Reaction (PCR Cycling) and Digestion of Amplified
Products
In thin-walled PCR tubes, the following reaction mixtures were prepared in two
tubes: 10x reaction buffer (5 μL), pWhitescript 4.5 kb control primer (5 μL), oligo control
primers 1 and 2 (1.25 μL) each, dNTP mix (1 μL), Quik solution reagent (1.5 μL), and
deionized (dI) H2O to bring total volume to 50 μL. In the positive control tube, Quikchange
Lightning Enzyme was added, and forward and reverse primers were substituted for the
control primers. The temperatures to allow denaturation, annealing and elongation were
optimized by the Cascio Lab (Veeramachaneni) and are as follows: 95⁰C (2 cycles, 30 sec),
55⁰C (1 cycle, 1 min), 68⁰C (1 cycle, 7 min). The cycle was repeated 16 times. The desired
mutation was then filtered out using Dpn 1 restriction enzyme (2 μL) to digest the nonmutated parental DNA.
3.1.1.3. Transformation of XL10-Gold Ultracompetent Cells
XL10-Gold cell aliquots (45 μL, Agilent) were pipetted into Falcon tubes. 2 μL βmercaptoethanol as well as Dpn-treated DNA from control and samples were also added.
pUC 18 control was used to test transformation efficiency. Tubes were incubated on ice
and then heat-pulsed for 30 sec at 42⁰C. After subsequent ice incubation, liquid SOC media
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was added and the tubes were incubated at 37⁰C with gentle shaking for one hour. 10 μL
of each mixture was plated using the spread-plate method onto LB-ampicillin agar plates
and incubated overnight at 37⁰C. Plasmid DNA of colonies were isolated by miniprep using
UltraClean Standard Mini Plasmid Prep Kit (MO Bio, Short Protocol), and after
determining the concentration of the DNA in the samples via Nanodrop, a 0.8% agarose
DNA gel was run, stained and imaged. The presence of mutation was verified by
sequencing.
3.1.1.4. Transformation of DH10α Cells and Extraction of Recombinant Bacmid DNA
DH10α cells (100 μL aliquot per mutation, Manufacturer) was pipetted into a 14
mL round bottom Falcon tube. 5 μL mutated plasmid and/or 2 μL control plasmid (pUC
19) were added to the cells. After 30 min of ice incubation, the cells were heat-pulsed for
45 sec at 42⁰C. Samples were then chilled on ice for 2 min before addition of 900 μL of
SOC media was added. Serial dilutions were made into two other tubes using 100 μL of
the original, more concentrated sample. 100 μL of each tube (original and diluted tubes)
were plated via spread-plate method onto LB-kanamycin-gentamycin-tetracycline-X-gal
(5-bromo-4-chloro-3-indoyl-β-D-galactopyranoside) plates. The plates were then
incubated for 40 hr at 37⁰C to allow formation of blue and white color. An isolated, large
white colony was removed from the plates with a pipette tip and placed into a round bottom
Falcon tube containing 2 mL LB media, 10 μL kanamycin (10 mg/mL), 1.4 μL gentamycin
(10 mg/mL) and 1.66 μL tetracycline (12 mg/mL). The samples were incubated for 16 hr
at 37⁰C. 1 mL of sample was transferred to 2 mL collection tube and centrifuged for 2 min
at 13,000 x g. The remaining contents were added to the collection tube and centrifuged.
The supernatant was discarded and the pellet was treated with 300 μL Solution 1: 15 mM
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Tris (pH 8), 10 mM EDTA, 100 μg/mL RNAse A; and 300 μL of Solution 2: 0.2 M NaOH,
1% SDS. The samples were incubated at room temperature until the solution turned
translucent at which time 300 μL of potassium acetate was added slowly and the solution
was mixed gently to produce a white precipitate. Samples were incubated for 5 min at 20⁰C and centrifuged for 10 min (13,000 x g). The supernatant was transferred to a
collection tube containing chilled isopropanol and incubated overnight at -20⁰C. Samples
were centrifuged for 15 min at 13,000 x g. The supernatant was discarded and the pellet
was washed with ethanol (repeated twice). Samples were again centrifuged (5 min, 13,000
x g), supernatant was discarded and once again centrifuged for an additional minute. Pellets
were air dried with lids open, and the resulting recombinant DNA was dissolved in TrisEDTA buffer before determining concentrations via Nanodrop.
3.1.1.5. Transfection of Sf9 Insect Cells with Recombinant Bacmid DNA
2 mL of Sf9 cells (approximately 3 x 105 cells/mL) were added to a 6 well plate and
incubated at 27⁰C to allow for cell adhesion. The following was added to two 1.5 mL
centrifuge tubes; Tube 1: 100 μL Grace’s insect media and 1 μg of bacmid DNA; Tube 2:
100 μL Grace’s insect media and 6 μL of cellfectin. The two solutions were then mixed
together slowly before 15 min incubation at room temperature. The media was removed
from the 6 well plate carefully so as not to disturb the cells and 2 mL of supplemented
Grace’s insect media (+ 10% FBS, + 2% penicillin/streptomycin) was added. 800 μL of
Grace’s insect media was added to the Grace’s/cellfectin/bacmid mixture to dilute and 160
μL of that was then transferred to the well plate with the cells. The cells were incubated
overnight to allow the bacmid DNA to enter the cells. The media was removed from the
wells containing cells carefully and 2 mL of supplemented Grace’s insect media (+ 10%
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FBS, + 2% penicillin/streptomycin) was added. This was incubated for approximately 72
hours.
3.1.1.6. Determination of a Viral Titer
In a 96-well plate, 50 μL of poly-D-lysine (5 mg in 50 mL) was added to necessary
wells. For each mutation, 2 rows and all wells within those rows was utilized. The well
plate was incubated for 30 minutes at 28⁰C before removal of excess poly-D-lysine. 10 μL
of sterile PBS was added to each well and the plate was tapped gently to evenly distribute
the PBS. The excess was removed and the plate was allowed to dry in a sterile hood for an
hour. Sf9 cells were added to the wells at a concentration of 3 x 105, approximately 300 μL
of cells was added per well. The plate was covered with parafilm and incubated for 45
minutes to an hour at 28⁰C. The excess cells were carefully removed, so as not to scratch
the bottom of the well plate and disturb adhered cells.
In separate 15 mL conical tubes, the following mixtures were prepared,
corresponding to the wells used:
A1: 990 μL Grace’s Insect media supplemented with FBS and penicillin and streptomycin
(referred to as complete media).
A2: 990 μL complete media + 10 μL control virus (WT GlyR can be used here).
A3/A4: 990 μL complete media + 10 μL of virus to be tested
A5: 990 μL complete media + 10 μL virus from tube 3
A6: 990 μL complete media + 10 μL virus from tube 4
A7: 900 μL complete media + 100 μL virus from tube 5
A8: 900 μL complete media + 100 μL virus from tube 6
A9: 900 μL complete media + 100 μL virus from tube 7
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A10: 900 μL complete media + 100 μL virus from tube 8
A11: 900 μL complete media + 100 μL virus from tube 9
A12: 900 μL complete media + 100 μL virus from tube 10
100 μL of the mixture was added into the corresponding wells and incubated at room
temperature for an hour before removal. 200 μL of fresh complete media was added to each
well, the well plate was sealed with parafilm and placed into a zip-closure bag with a moist
paper towel to prevent evaporation. This was stored at 28⁰C in an incubator, overnight.
The following day, 4% paraformaldehyde (PFA) in PBS solution was prepared or
thawed from the freezer in a water bath. The well plate was checked for the presence of
adhered cells. The liquid media was removed gently from the well plate and 50 μL of PFA
was added to each well, without touching the bottom of the plate and was incubated for 20
minutes at room temperature. The PFA was removed from the wells and 50 μL of blocking
buffer containing 0.05% Tween (10% stock), 5% normal goat serum (NGS), and PBS was
added to each well, and incubated at room temperature for 1 hour. In a 1.5 mL centrifuge
tube, 1.5 mL of blocking buffer and 1.5 mL of primary antibody (mouse anti-gp64,
ab91214, Abcam) was added. After incubation, blocking buffer was removed from all wells
and replaced with 50 μL of primary antibody solution (1:1000 dilution) and incubated at
room temperature for an hour. A wash buffer containing 1% NGS and 0.05% Tween in
PBS was used to wash the wells three times. 100 μL of secondary antibody solution from
a solution containing 2.5 mL blocking buffer, 2.5 mL goat-anti-mouse chain B
galactosidase was added to each well and incubated at room temperature for an hour. After
washing wells three times as before, 100 μL of prepared color solution containing 6 μL Xgal (0.05 g in 1 mL N,N dimethylformamide, DMF), 6 μL PNBT (0.083 g in 1 mL DMF),
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500 mM magnesium chloride and PBS was added to each well, incubated at 37⁰C and
checked every 10 minutes for color production. The cells containing color were counted
and the viral titer was calculated.
3.1.1.7. Infection of Sf9 Insect Cells
After determining a viral titer of a particular mutation, the following equation was
used to determine how much of the amplified virus (resulting from transfection and
subsequent amplification of virus) should be added to a volume of approximately 750 –
1000 mL of Sf9 cells at a concentration of 1 x 106.
Inoculum required (mL) = (desired MOI) x (cells)/(pfu/mL virus);
where the desired MOI (multiplicity of infection) is greater than or equal to 5, the cells are
greater than 1 x 108, and the viral titer results (in plaque forming units (pfu)/mL should be
approximately, or greater than, 1 x 107.
3.1.2. Purification of GlyR from Sf9 Insect Cells
The glycine receptor was prepared through purification following published
protocols.605 Sf9 cells were harvested three days post-infection, cultured, washed witch icecold PBS (pH 7.4), suspended for 1 hr in hypotonic solution containing 5 mM Tris (pH 8),
5 mM ethylenediamine tetraacetic acid (EDTA), 5 mM ethylene glycol-bis(βaminoethylether)-N,N,N’,N’-tetraacetic acid (EGTA), 10 mM dithiolthreitol (DTT) to
cause cells to swell. Before lysis an antiproteolytic cocktail was added such that final
concentrations were 1.6 microunits/mL aprotinin, 100 mM phenylmethylsulfonylfluoride
(PMSF), 1 mM benzamidine, and 100 mM benzethonium chloride. Probe-tip sonication
(15 sec pulse intervals at 50% duty cycle with 30 sec rest in between) was used to lyse the
cells, and then the sample was centrifuged using a Beckman Coulter Ultracentrifuge for 30
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min at 290,000 x g606 (at 4°C). The resulting supernatant, the cytosolic fraction, was stored
and the protein pellet was placed in a resuspension buffer (hypotonic solution and 640 μL
300 μM NaCl) and sonicated and centrifuged as before. The pellet was added to a
digitonin/deoxycholate buffer containing: 1% digitonin; mixed lipids (9:1 plant extract
(95% phosphatidycholine purity): egg extract (60% phosphatidycholine purity) at 1.5
mg/mL; 0.10% deoxycholate; 25 mM potassium phosphate monobasic; 25 mM potassium
phosphate dibasic; 1M potassium chloride; 5 mM EDTA; 5 mM EGTA; 10 mM DTT and
the antiproteolytic cocktail previously used; to solubilize the membrane proteins, sonicated
as before and incubated overnight (4°C). After centrifugation as before, the resulting
supernatant was added to a 2-aminostrychnine resin (approximately 3 – 5 mL of resin was
used) to bind the GlyR and incubated overnight. To remove the GlyR from the resin, an
elution buffer containing: mixed lipids as before, 1% cholate, 25 mM potassium phosphate
monobasic; 25 mM potassium phosphate dibasic; 1 M potassium chloride; 5 mM EDTA;
5 mM EGTA; and 2 M glycine was added and equilibrated for 48 hr. The resulting slurry
was pelleted and the supernatant containing the eluted, purified GlyR was collected.
For open state mutants, which contain two additional mutations (Cys null +
A288G/F207G) to allow binding to IVM, the elution step differs. The double mutation
causes IVM to act as an agonist, but decreases GlyR binding affinity for glycine466,605 and
thus mobile strychnine (1.5 mM) rather than glycine, is used to elute purified GlyR from
the 2-aminostrychnine resin. This was incubated during affinity chromatography for at
least 48 hr and the resulting slurry was pelleted and the supernatant containing the eluted,
purified GlyR was collected. The purification process for desensitized states is identical to
resting state mutants.
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3.1.3. Reconstitution of GlyR into Lipid Vesicles
Reconstitution of eluted, purified GlyR was completed using protocols described
in previous study428 . Briefly, mixed lipids (9:1 plant extract (95% phosphatidycholine
purity): egg extract (60% phosphatidycholine purity) at 15 mg/mL, stored as suspended
vesicles) were added to purified GlyR/lipid/detergent micelles to yield a final concentration
of 1.5 mg/mL. Cholesterol (15.07 mM in methanol) was included to yield approximately
33 mol percent. GlyR/lipid detergent mixture was placed into a dialysis cassette (3500 MW
cutoff, Thermo) and the resulting protein/vesicle pellet was dialyzed against 3 x 1 liter
volumes of 25 mM potassium phosphate (KPi, pH 5.8). GlyR purification was verified by
Coomassie staining and Western blotting analysis, and GlyR concentration was quantitated
using a Modified Lowry assay.
3.1.4. GlyR-MTS-Benzophenone Crosslinking
100 μL of purified protein was used for crosslinking studies. 5mM of MTSbenzophenone crosslinker was added to the protein sample and allowed to bind for one
hour at 4⁰C with rotation. The sample was placed into a quartz cuvette and exposed to highintensity UV light (200-300 nm) for two ten-minute increments; the cuvette was flipped in
between to expose both sides, and the sample was allowed to rest in between exposure for
ten minutes. Non-reducing SDS-PAGE (15% resolving, 5% stacking) was performed with
the sample and gel plugs were excised from the gel above the 66 kDa BSA migration line
and between the 37 and 66 kDa migration line to encompass the oligomeric and monomeric
fractions of GlyR, respectively.
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Specific to the M287C mutation, 1 μL of glycine was added to allow the crosslinker
to bind. The sample was dialyzed against 3 x 1 liter volumes of 25 mM potassium
phosphate (KPi, pH 5.8) in the dark to remove the glycine before flash photoactivation.
To study GlyR in the open state (Cys null + IVM protein), 30 nM IVM was added
to the sample. To study the protein in the desensitized state, excess glycine (10 mM) was
added to the protein sample. 5 mM of MTS-bzp crosslinker (Figure 7) was added to the
protein sample and allowed to form disulfide crosslinks for one hour at 4⁰C with nutated
mixing. The sample was placed into a quartz cuvette and exposed to high-intensity UV
light (200-300 nm) for two ten-minute increments; the cuvette was flipped in between to
expose both sides, and the sample was allowed to rest on a bed of ice in between exposure
for ten minutes. Non-reducing SDS-PAGE (15% resolving, 5% stacking) was performed
with the sample and gel plugs were excised from the gel above the 66 kDa BSA migration
line and between the 37 and 66 kDa migration line to excise the oligomeric and monomeric
bands of GlyR, respectively.
3.1.5. In-Gel Trypsin Digestion
Both the monomeric and oligomeric gel plugs were placed into labeled, non-stick
microcentrifuge tubes and 100 mM ammonium bicarbonate (ambic, pH 7.8) and 50%
acetonitrile (ACN) was added to each tube (enough to cover the plugs) and incubated on a
nutator (VWR Thermal Shake Touch) at 37⁰C for fifteen minutes. This was repeated three
times. The supernatant was removed and 10mM of DTT was added to each tube and
incubated at 56⁰C for one hour. After removing the supernatant, 100 mM ambic and 200
mM iodoacetamide (IAM) was added to each tube and incubated at 37⁰C for one hour in
the dark. After washing the plugs with 100 mM ambic, 100% ACN was added to each tube
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and dried in an Eppendorf vacufuge for 15 to 20 minutes, depending on plug size. Enough
ambic was added to cover the plugs and 1 mg/mL liquid trypsin was added to each tube
and incubated on the nutator overnight. The supernatant, which contains the eluted,
crosslinked peptide pieces, was removed and placed into new, labeled non-stick tubes. To
the gel plugs, elution buffer (0.1% formic acid, and ultrapure water) was added to each
tube and incubated for 30 minutes before removal and being placed into newly labeled
tubes containing the eluted, crosslinked peptide pieces. The tubes containing the total
volume of eluted, crosslinked peptide pieces were placed on the Eppendorf vacufuge and
dried.
3.1.6. Mass Fingerprinting of Crosslinked MTS-Benzophenone to GlyR Peptides
50 μL of 0.1% formic acid in ultrapure water was added to tubes containing dried
tryptic fragments and incubated on the nutator for at least 2 hours and vortexed. Samples
were filtered using PhenexTM-NY Syringe Filters (4mm diameter, Phenomenex) before
being placed into MS vials (Agilent). Electrospray ionization quadrupole time-of-flight
mass spectrometry (ESI-Q-TOF-MS) measurements were taken using an Agilent 6530 QTOF-MS equipped with an Agilent HPLC-Chip II G4240-62006 ProtID-Chip-150, with a
40 nL enrichment column and a 75 μm x 150 mm separation column packed with Zorbax
300SB-C18 5 μm material. The mass spectrometer was run on positive mode using internal
standards (1221.9906 and 299.2944, Agilent) for calibration. Mobile phase compositions
were Solvent A (95% H2O, 5% acetonitrile, 0.1% formic acid) and Solvent B (95%
acetonitrile, 5% H 2O, 0.1% formic acid). The nanoflow elution gradient was developed as
follows at 0.50 μL of Solvent A (minute: percent A): 0.00:95%, 4.00:10%, 6.00:70%,
9.00:50%, 11.50:95%, and 13.00:95%. Data were processed using Agilent Qualitative
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Analysis Software v6.0. MTS-Benzophenone crosslinked peptides within a 10 ppm
accuracy window were identified, accounting for possible peptide modifications
(oxidation, acrylamidation, alkylation).
For MS/MS studies, crosslinked samples were run again on the Agilent 6530 QTOF-MS, targeting the specific m/z ratio, charge, and retention time (RT) of crosslinked
peptides identified in previous runs. Collision-induced dissociation (CID) was used for
MS/MS fragmentation following a linear increase in collision energy by m/z using the
formula: y = 3.7x + 2.5. CID was performed at ±0.2 min from the initial MS scan RT of
each crosslinked precursor ion identified. Data were processed using Agilent Qualitative
Analysis Software v6.0 in conjunction with ProteinProspector v5.14.3 (University of
California, San Francisco) and a python script utilized to match exported spectra data
(kindly provided by Amanda Dumi). The list of benzophenone masses, depending on
whether protonated, potassiated, sodiated, or alkylated are as follows: benzophenone m/z
shift, +312.391823, 350.482184, 334.373652, 370.452009, 408.542369, 392.433838 amu.

79

CHAPTER 4. PROTEIN-PROTEIN INTERACTIONS WITHIN THE RESTING
(APO-) STATE NETWORK
4.1 Introduction
The coupling of CX-MS to a network of single, site-specific Cys mutations can
provide a network of protein-protein interactions within GlyR which will help elucidate
and refine structure. In this chapter, this network will be applied to analyze the structure of
this receptor in its resting state. GlyR, like other pLGICs, transitions from a closed state to
a short-lived open state after ligand binding, in which the gate is open and conducting ion
flow, and then transitions to a longer-lived desensitized state, where the pore is closed, and
ligand is more tightly bound. The dynamics of ligand binding, and the structural changes
to accommodate this will be discussed in the next chapter.
4.1.1. The Resting State
Structures of α1-GlyR and α3-GlyR homopentamers have been crystallized in the
presence of their competitive antagonist, strychnine.296,297 These structures represent a
closed channel, as indicated by constriction points in the pore and unfavorable interactions
between hydrophobic regions and water, thus leading to a large energy barrier that ions
cannot overcome.243,596 In the α1-GlyR structure, the ion channel pore shows two sites of
constriction, at position 2’ (Pro 266) and 9’ (Leu 277).296 The 9’ position is narrowest in
the strychnine bound state, at a radius of 1.4 Å, which is too small to allow for a hydrated
chloride ion to pass through.296 However, though both are closed structures, they may not
represent a true apo-state, as ligand is bound to the orthosteric site. Other non-mammalian
pLGICs have been successfully crystallized in their apo-states, including GLIC (at pH
7)308,309,314 and GluCl.312,315 However, it is unclear if any known structure represents a good
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homolog of apo GlyR, and thus, structural information of a true apo-state is necessary
(details of the transition from the resting state to the active state and comparison to other
pLGICs can be found in Chapter 5). Furthermore, as with many crystal structures of
pLGICs, the large intracellular loop is truncated in known structures, resulting in a gap in
structural knowledge. Even if a true apo-state of GlyR were to be determined, this gap
would still exist. Since the loop is important in affecting function, is a structure of a pLGIC
lacking the intracellular loop reflect the physiological state of the full-length receptor?
Another concern is the role membrane lipids play in structure, stability and
function. Current crystal structure data is developed from analyses in a delipidated
environment, or in lipid nanodiscs, and thus, may not represent a native receptor
environment, and possibly affect the structure of the receptor. Lipid interactions are
common to the TMD region of pLGICs. According to Unwin et al.303,304,332,597 and
others,598 a three-ring organization of the TM α-helices exists. The M2 region makes up
the innermost ring and has no contact with membrane lipids. The second ring is composed
of M1 and M3, and in the outermost ring lies M4. These three helices contact the bilayer
and may bind selective lipids.598
Analyses of binding general anesthetics to various pLGICs showed the importance
of lipids. Many general anesthetics bind in the TMD region, and displace bound lipids. For
example, cannabinoids are thought to form direct contacts with an exposed Ser residue in
M3 of GlyRs as well as with lipids.283,598 Propofol and desfluorane, which were crystallized
with GLIC, appear to compete for binding with lipids that are bound to apo-state GLIC
structures.413,598 This is also seen in the binding pocket for IVM.598
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Lipids also appear to play a role in gating, conformational dynamics and stability.67,598–600
Cholesterol has been shown to provide supports between the agonist-binding domain and
the pore of nAChRs.394 A molecular modeling study has shown that the displacement of
lipids in the cavities from motions by M2 and M3 shows that the shape and volume of the
cavities are coupled to gating.413 Cholesterol, PA and PC also have an influence on function
and transitions between conformational states in both nAChRs and GlyRs.14,320 When
nAChRs are in the presence of PC alone, they tend to favor a desensitized state, but in the
presence of PA and cholesterol, a resting state is favored.601 For α1-GlyRs, the
concentration of cholesterol distinguishes two distinct apo-states.14 The biggest implication
from these studies, as pertaining to this work, is that the apo-state of GlyRs is flexible,
dependent on lipids for stabilization, function and conformation, and cannot be studied by
crystallized methods in a conformational manner. The studies outlined in this chapter
focuses on methodology that allows the analysis of the native receptor, in a lipidenvironment, without any truncations, functioning as a true resting state receptor.
4.1.2. Network Rationale
The Resting State Network built in this work (and used in subsequent
conformational states as well) is composed of three site-specific single cysteine mutations:
M287C, K116C and K206C. Each mutation was inserted into a plasmid that contained
GlyR cDNA that had been modified; three cysteines were mutated (C41S/C290A/C345S),
that do not participate in disulfide bridges when the protein is folded; this is referred to as
Cys null GlyR. Cys null GlyR has similar activity to WT GlyR.602 After overexpression,
the mutant GlyR was purified and crosslinking studies with MTS-bzp (Figure 7) were
conducted.
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Figure 7. Methanethiolsulfonate (MTS) – benzophenone crosslinker. This heterobifunctional crosslinker is
used in all studies. The MTS group (bracketed in yellow) acts a leaving group, and the remaining S atom
makes a disulfide bond with the only available Cys residue in the protein. After photoactivation, the
carbonyl group on the benzophenone group (bracketed in purple) forms a diradical. After hydrogen
abstraction, a new C-C bond is formed between the Cα of a proximal residue within the length of the
crosslinker spacer. The alkyne tag (bracketed in red) was added as a way to perform click-chemistry, but
these studies proved to not allow proper ionizability of the peptides.

These three sites were chosen for their potential to study areas of the receptor not
well-resolved, and due to ease of analysis. The extracellular mutants, positions 116 and
206, were analyzed previously in the Cascio lab, using lysine-lysine crosslinking.32
Position 116 is located on the interior of the receptor, on a loop behind beta sheet 8 (Figure
5, 8) and position 206 is located on beta sheet 10, which is on the exterior of the receptor;
and so the inclusion of both of these locations in the network was valuable. Furthermore,
position 206 is located within the C-loop region, which is theorized to cap over bound
agonist during ligand binding (Section 2.2.1.1).
The TMD mutant, position 287 is located in M3, but not far enough into the
membrane that it cannot be reached by the crosslinker in the presence of glycine.603,604 A
study by Williams et al.604 showed accessibility of M3 in a state dependent manner. The
failure of previous studies conducted at 290C were attributed to inaccessibility.
Furthermore, it was hypothesized that studying a TM mutant may lead to information about
the elusive M3-M4 loop region, and since this region is truncated in current crystal
structures and models, insights from crosslinking studies would prove to be useful when
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refining the structure. It was also hypothesized that
the crosslinker used, once bound to the thiol, would
be hydrophobic enough to penetrate the membrane
and thus, access the intracellular M3-M4 loop.
These three site-specific points will later be

Figure 8. Network of Mutations. The
three mutations chosen as primary
attachment sites for MTS-bzp are M287C,
K116C and K206C, represented as
colored spheres on a single subunit of
GlyR (PDB: 3jad). M287C is in blue, and
resides in M3. K116C is in pink and is
located on a loop behind beta sheet 8.
K206C is colored green and is on beta
sheet, which is a constituent of the Cloop.

combined with several other positions that are either
completed (A41C and H419C)602 or are currently in
progress (K6C, G23C I412C; see future work). It is
hypothesized that these mutants will provide vital
information to discuss receptor dynamics as well as
complement high-resolution techniques which will
lead to more complete structures, with a particular
focus on the regions in the receptor that are currently
not well resolved.
4.3. Results and Discussion
Crosslinking-mass spectrometry (CX-MS) is a sensitive and useful tool to
characterize spatial relationships of proteins, and by mapping these distance restraints,
more highly resolved and accurate molecular models can be obtained.5,8 This, in turn, can
be used to complement other high-resolution structures and will help bridge the gap of
understanding between protein structure and modulation of function.5 The designed
network contains one mutant located in the transmembrane region (M287C) and two
mutants located in the extracellular domain (K116C, K206C). In each of these cases, the
Cys mutation was introduced in a Cys null background – a GlyR mutated to remove all free
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thiols such that each subunit in the pentamer only has a single reactive thiol. Each will be
discussed separately, relating to the results found in the resting state and then integrated
together in terms of refining structure and analyzing dynamics of the resting state. In
Chapter 4, the open and desensitized states will be discussed separately, integrated
together, and then will include the resting state to discuss the dynamics of the receptor
relative to each position.
After purification of each single Cys receptor, respective GlyRs were reconstituted
into lipid vesicles with the addition of cholesterol, which is an essential membrane
component and important to the function of pLGICs.14,394,601,607,608 The purified,
reconstituted receptor was then crosslinked in the dark with only the addition of MTS-bzp
(Figure 7), ensuring the receptor was in its apo-state, allowing the formation of a covalent
disulfide to the heterobifunctional crosslinker at the site of insertion of the single reactive
Cys residue. After photoactivation, the reactive benzophenone non-specifically forms
another covalent crosslink with the area proscribed by the length of the crosslinker (~ 25
Å). Non-reducing SDS-PAGE was run and bands containing crosslinked GlyR, both
monomeric and oligomeric, were separately excised. Bands were then reduced before
trypsinolysis to release the crosslinker from its known original site of disulfide linkage.
Bands were alkylated and extracted for MS and MS/MS analysis. This was repeated for
an n ≥3 independent infections/preparations and mass shifted peptides are reported for an
n≥2 for all states and subsequent mutations. Each of these biological replicates were
subjected to at least two technical replicates.
Unique peptides found in samples where no ligand was added, IVM was added or
excess glycine was added correspond to unique areas that are approximately 25 Å from the

85

single cysteine mutation in the resting, open or desensitized state, respectively. Peptides
that were found in oligomeric band (intramolecular + intermolecular crosslinks) that were
identical to peptides found in monomeric bands (intramolecular crosslinks) were identified
as intramolecular crosslinks. This is because non-reducing SDS-PAGE was utilized, to
only separate GlyR oligomers from monomers; membrane proteins commonly run as both
single subunits and oligomeric subunits even without crosslinking.602 Also, due to the
inability to distinguish between five potential crosslinking events per pentamer this results
in crosslinks identified from oligomeric bands can be either intra- or intersubunit, and thus,
only those found in oligomeric bands that were not in monomeric bands were considered
to be intermolecular and reported as such in the tables.602
For MS analysis, two missed cleavages were allotted as crosslinking at Lys or Arg
sites may result in reduced trypsin proteolysis.7 Mass ions consistent with MTS-bzp
crosslinking from the initial MS run were identified using a 10ppm mass cutoff. The
sequence coverage for all mutations had a large range of about 40 – 80%, averaging about
60% sequence coverage; therefore, though the tables are expansive, they may not represent
all of the crosslinked peptides in the receptor. Peptides that were shifted by MTS-bzp were
targeted for a second run if they met the following conditions: only one MTS-bzp was
identified in a particular retention time, the peptide was greater than three amino acids in
length and it did not match with a m/z found in the blank, gel blank or control runs. In order
to refine the crosslinking results to a specific area within the peptide, ideally a single amino
acid residue, a second round of MS was run, which targeted the identified precursor ion by
its mass, retention time and charge.
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Using collision induced dissociation (CID), each product ion was fragmented,
resulting in b, y or a product ions (Figure 1). These resulting fragment masses were
extracted from each spectra obtained and placed into a matching program, which matched
theoretical results from ProteinProspector to results found. Match parameters were within
Figure 9. MS and MSMS Representative Spectra. The top spectra represents a precursor ion spectra at
retention time 3.555 minutes, from a monomeric fragment of K116C resting state data. The inset spectra
represents the elution of a particular peptide that has been mass-shifted by the mass of MTS-bzp,
60
VNIFLRQQWNDPR72 (peak is denoted by an asterisk). The bottom spectra is the CID spectra of the
mass of the precursor peptide, 666.6653. Using a theoretical list of fragmented peptides and comparing
them to extracted data, the b and y ions were mapped onto the peptide to refine the crosslinker position to
67
QQ67. Each product ion spectra produced from the fragmentation of the product ion mass at various
retention times is mapped onto the peptide to produce an overall crosslinker position refinement.

0.1 Da. Any identified b, y, or a ion was plotted onto the peptide to refine the crosslinking
position (Figure 1). Depending on how many times the particular peptide ionized it could
be found in multiple retention times, meaning either isobars are linked at different sites or
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different m/z but same chemical structure, and thus, could have various crosslinking events
within it. After n ≥3 trials were completed, the refined crosslinking results that were found
in at least two trials were tabulated and mapped onto the crystal structure determined by
Du et al.296 The strychnine-bound version (PDB: 3JAD) was used, as it represents a nonconducting state, and it avoided using the crystal structure bound with glycine and
ivermectin because it is not certain whether that structure represents an allosterically
modulated desensitized state or a partially open state.296 It was subsequently used for all
mutations in all states for uniformity purposes, as this would allow for easier detection of
mobile regions and changes between the states.
Distance measurements were taken between the Cα of the mutation site and the Cα
where the crosslinker bound. If only a single site was resolved in MSMS studies as the site
of attachment, the measurement was recorded with no standard error measurement. If
crosslinking could not be resolved to a single site, but rather to a stretch of continuous
amino acids, an average of the respective Cα distances were reported with its standard
error. These distance measurements can be used to examine the accuracy of the model used
as well as the model consistency or lack thereof. It also can be used as a means of
interrogating dynamics and receptor mobility.
4.3.1. Position 287
A total of 39 sites of crosslinking relative from 287C have been identified; 24 of
these are intramolecular crosslinks (Table 2). These sites are distributed throughout most
of the receptor but are primarily located in the intracellular M3-M4 loop region and the
TM domain (with the exception of M1). There are also crosslinking sites in the preM1
region of the ECD and the M2-M3 loop, found in the ECD-TMD interface (Figure 10,
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Table 2). The C-terminal tail, which is also not resolved in crystal structures has also been
crosslinked intramolecularly (Table 2).
Table 2. M287C Resting State Crosslinks.
The table shows intramolecular and intermolecular mass-shifted peptides from ≥3 separate trials,
compiling only what was found in ≥2 trials. The blue underlined areas represent the sites of refinement.
The average distance ± standard error measurement (SEM) column shows the distance from the site of
mutation to the refined areas. Areas that are refined to a single amino acid are represented by a single
distance; whereas, refinement to multiple amino acids is represented as a mean and the standard error.
Residues from 310-377 are not resolved in crystal structures, and thus no measurement data is available.
Note that the distance between Cα of the residue crosslinked to the Cα of the mutation is approximately
25 Å.

M287C Resting State
Intramolecular
17

LMGRTSGYDARIRPNFK33
VNIFLRQQWNDPR72
66
QQWNDPRLAYNEYPDDSLDLDPSMLD
SIWKPDLFFANEK104
105
GAHFHEITTDNKLLRISR122
60

Location
Pre M1

EEKDLRYCTK200
HYNTGKFTCIEARFHLER218

201

ASLPKVSYVK281
AIDIWCAVALLFVFSALLEYAAVNF
VSRQHK312
321
RRHHK325
356
GANNSNTTNPPPAPSKSPEEMRK378
378
KLFIQRAK385
387
IDKISR392
415
REDVHNQ421
Intermolecular
34
GPPVNVSANIFINSFGSIAETTMDYR59
120
ISRNGNVLYSIRITLTLACPMDLK143
253
VGLGITTVLTMTTQSSGSR
ASLPKVSYVK281
310
QHKELLRFRRK320
326
EDEAGEGRFNFSAYGMGPASLQAK
DGISVK355
350
ISVKGANNSNTTNPPPAPSK371
372
SPEEMRKLFIQR383
390
ISRIGFPMAFLIFNMFYWIIYK411

73±1,72, 61
45
63±3, 35

43±2, 49, 50,
54±9
37±2, 41
50±1, 48±1, 30±2

191

272

Avg. Dist.
±SEM

M2-M3 loop 15±2
16, 34
M3

282

M3-M4 loop 25±1, 22±0.3

C-term tail
Pre M1

N/A
34, 30±0.2
25
N/A

63±2, 32±0.4
64±2, 26
19±0.3

M2, M2-M3
loop
M3-M4 loop N/A
N/A

M4

89

N/A
N/A, 39±1
32±1, 26

Given the position of the mutation, in M3, it was hypothesized that crosslinking to
this site might allow crosslinking to regions deeper, or even across the membrane. It was
considered possible that once the disulfide bond is made to the ionized thiolate at position
287, the crosslinker is no longer membrane impermeable and its benzophenone group and
spacer are hydrophobic enough to penetrate the cell membrane. Other studies have also
shown the hydrophobicity of the MTS-bzp crosslinker and its ability to penetrate the
membrane.609,610 This proves to be the case in this study as well, as a large proportion of
the crosslinking sites, 38% of them, are in the M3-M4 loop. This is particularly noteworthy
as previous studies have not been able to visualize crosslinking data to this region,602 and
this loop is truncated in current crystal structures, and thus this work provides new
information relating to structural details and dynamics of this elusive region. The
approximately 70 residue long loop, which is characterized by its sequence and length
diversity among pLGICs, and is not resolved in current structures of any pLGIC, shows
crosslinking throughout, but is mostly seen in the beginning and the end of the loop, as
represented by the peptides, 310QHKELLRFRRK320 and 387IDKISR392, respectively (Table
2, Figure 10).
Another area that was anticipated to be crosslinked was the TMD region and the
loops in the interface as they are in close proximity to position 287. M3 was crosslinked
intramolecularly, and M4 and M2 were crosslinked intermolecularly (Table 2, Figure 10).
The fragmentation data based on the different retention times led to the inability to refine
this region to any particular area. The M2-M3 loop was also crosslinked heavily. The Cysloop, the loop located in the ECD-TMD interface, the hallmark loop of the pLGICs, was
crosslinked at position K143. The Cys-loop, and the other loops that make up the ECD-
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TMD interface are predicted to be mobile, and so, it is hypothesized that seeing these
regions in other states, refined at different positions indicate mobility of these regions (see
Chapter 4).
Of particular note, it was unexpected that crosslinking would occur at the top of the
ECD, seen in the peptide

17 LMGRTSGYDARIR 33.

This could be indicative of the

“bloomed” appearance used to describe the resting state, because the ECD is wider at the
Figure 10. M287C Resting State Crosslinks. Two subunits of GlyR
(PDB: 3jad) are shown to visualize both intramolecular crosslinks (left
subunit) and intermolecular crosslinks (right subunit) to position 287
(represented as a yellow sphere). All crosslinked sites are highlighted
in blue (see Table 2). The bead model below the structure shows the
unresolved M3-M4 loop, both intra- and intermolecularly. The
unresolved C-terminal tail is not shown.

top, and more flexible as an
apo-state protein, there could
be the possibility that it would
come into close proximity of
the

membrane,

and

thus

position 287. This may also
be due to local unfolding
events of the protein in this
region, a concept that will be
discussed more thoroughly in
later

sections.

Previous

studies showed that affinity
purification of homomeric
GlyRs was functional after
reconstitution.428
Given the dimensions
of
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MTS-bzp

and

its

flexibility, the distance between the Cα at position 287 to the crosslinked sites should be
approximately 25 Å. The measured distances using the available crystal structure bound to
strychnine (PDB: 3jad) shows a large discrepancy from this number, with an overall range
of 14.5 to 72.5 Å. It is important to note that there is no available measurement data for the
crosslinks to the M3-M4 loop region or C-terminal tail, as those features are not present in
available crystal structures. It is also relevant that these distance measurements are taken
on a static image based on a dynamic experimental study, and so, they are most useful to
show dynamics and protein flexibility, and to visualize what is most congruent with
available crystal-based structural data. These seemingly excessive crosslinking lengths
have been seen in other crosslinking studies and is still a phenomenon that requires more
analysis. In a CX-MS study analyzing the entire human mitochondria, approximately 10%
of the crosslinks found exceeded their 30 Å Eulerian crosslinker distance.20 This study used
lysates and thus were not purified, so it became difficult to distinguish intra- from
intermolecular crosslinks. They also allowed up to 20 ppm error cutoff. Our studies, in
contrast, uses purified protein and minimizes the potential for protein aggregates, and thus,
distinguishing both intra-subunit and inter-subunit crosslinks is made more manageable.
Also, the error cutoff in this work is 10 ppm, allowing more stringency. The major point
here is that currently, without a true set of standards for conducting CX-MS studies, each
study sets its own standards for what is a confident match, what is an artifact, and what
error cutoff should be used.5,7,180 This will change in time as CX-MS becomes a more
widespread technique.
Overall, with respect to position 287 in the resting state, there are a few important
discoveries. This is the first look at the M3-M4 loop in the context of a full-length protein
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in a native environment. These studies suggest that the loop is intimately associated with
the membrane when the protein is in an apo-state. Also, the protein appears to be quite
flexible, which is expected, as there is crosslinking seen throughout the protein, and in the
upper ECD. The lack of contact to M1 may mean that M3, or the top of it, is more closely
associated with M4 and M2 in this state. Finally, due to the diversity of structures observed
in cryo-EM studies, this too, suggests flexibility.296,297
4.3.2. Position 116.
Position 116 is located on a loop behind β-sheet 8, on the β5-5’ loop, in the ECD
(Figure 5). Previous studies using Lys-Lys crosslinking suggests its surface accessibility.32
The study by Liu et al.32 examined intra- and intermolecular crosslinking in GlyBP (a
truncated form of GlyR consisting of its ECD), with dimethylsuberimidate (DMS), an
amine-reactive reagent. GlyBP has a total of 11 Lys that could be potentially crosslinked
with DMS, 12 intramolecular and 2 intermolecular Lys-Lys crosslinks were identified.
Similar to our studies, intermolecular crosslinks were only considered to be between two
subunits if they were not identified in monomeric bands. Importantly, the top portions of
the subunits (residues 1-33), including the α-helix were found to be flexible, as shown by
the crosslinking between K6 and K166.32
In this work, crosslinking results after n≥3 trials, resulted in 29 crosslinking events.
Similar to what was seen in crosslinking studies to position 287, some sites could be refined
to single sites of attachment. Quantitation studies that examine the propensity for various
sites attached and how often will help to further understand the significance of these sites
to position 116 and others. Of the 29 individual crosslinking sites, the majority of them
were found intramolecularly. Most of the crosslinks were found in the preM1 region of the
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receptor which is expected as position 116 is located in the ECD. In comparison to position
287, crosslinking data to position 116 crosslinks to more of the top of the ECD, including
the
1

peptide

seen

in

287,

LMGRTSGYDARIR33

17

as

well as

the

peptide

ARSATKPMSPSDFLDK16 (Table 3, Figure 11). Position 116 also crosslinks to the C-

loop, which when analyzed in the context of all three states will give better perspective on
how the C-loop may be moving relative to this position (Chapter 4). Crosslinking identified
in regions containing K6 and the C-loop have also been found in the study by Liu et al.,32
Table 3. K116C Resting State Crosslinks.
The table shows intramolecular and intermolecular mass-shifted peptides from ≥3 separate trials,
compiling only what was found in ≥2 trials. The pink underlined areas represent the sites of refinement.
The average distance ± standard error measurement (SEM) column shows the distance from the site of
mutation to the refined areas. Areas that are refined to a single amino acid are represented by a single
distance; whereas, refinement to multiple amino acids is represented as a mean and the standard error.
Residues from 310-377 are not resolved in crystal structures, and thus no measurement data is available.
Note that the distance between Cα of the residue crosslinked to the Cα of the mutation is approximately
25 Å.

K116C Resting State
Intramolecular
Location
1
16
ARSATKPMSPSDFLDK
Pre M1
17
LMGRTSGYDARIRPNFK33
60
VNIFLRQQWNDPR72
132

143

ITLTLACPMDLK
DLRYCTKHYNTGK206
214
FHLER218
253
VGLGITTVLTMTTQSSGSR271
272
ASLPKVSYVK281
310
QHKELLRFRRK320
322
RHHK325
372
SPEEMRKLFIQR383
378
KLFIQRAK385
384
AKKIDK389
386
KIDKISR392
Intermolecular
1
ARSATKPMSPSDFLDK16
120
ISRNGNVLYSIR131
123
NGNVLYSIRITLTLACPMDLK143
191
EEKDLR196
253
VGLGITTVLTMTTQSSGSR271
272
ASLPKVSYVK281
194

94

M2
M2-M3 loop
M3-M4 loop

Pre M1

M2
M2-M3 loop

Avg. Dist. ±SEM
20±1 (9-14 only)
23±1, 20±1, 25±1
12
39±2
30±1
31±2
51±1
40±1, 40, 44
N/A
N/A
91 (378 only)
85±1
78±1
76±1
N/A
30±2, 24±1
31±2, 20±1, 27±2
31±2
58±2
43, 38±1

but K16 to K116 was not found. The ECD-TMD interface is also crosslinked, though in a
different pattern than seen in position 287. The Cys-loop has more crosslinking to it, but
Figure 11. K116C Resting State Crosslinks. Two subunits of GlyR
(PDB: 3jad) are shown to visualize both intramolecular crosslinks
(left subunit) and intermolecular crosslinks (right subunit) to
position 116 (represented as a yellow sphere). All crosslinked areas
are highlighted in pink. The bead model below the structure shows
the M3-M4 loop, both intra- and intermolecularly. The C-terminal
tail is not shown.

the M2-M3 loop has fewer
sites of attachment. In both
position 287 and 116, the M2M3 loop is crosslinked both
intramolecularly

and

intermolecularly, meaning that
loops from adjacent subunits
can interact with both the
middle of the ECD where 116
is and the top of M3 where 287
is. Again, in the context of
multiple conformational states,
it will be clearer as to how
these loops may be moving.
The

crosslinking

results in the TM domain is
very different compared to
what was seen in 287. Only M2
is crosslinked to position 116, and as seen previously, the fragmentation data for this region
does not allow for refinement to a single amino acid. This may be due to how well this
peptide ionizes, or because multiple isobars are not chemically distinct enough to be
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separated by LC and precluding product ion assignment. This will be better resolved once
quantitation studies are conducted.
The most unexpected result for this position is the crosslinking that is seen in the
M3-M4 loop. The intracellular loop is expected to be too far away from the ECD to
crosslink to it, and yet in every trial conducted these crosslinking events were reproducibly
observed. Crosslinking to this area is only seen intramolecularly, and mostly at the
beginning and the end of the loop, so very close to the inner membrane surface. Many of
the peptides crosslinked have a number of Lys and Arg residues, including;
310

QHKELLRFRRK320 , 378 KLFIQRAK385 , and

386

KIDKISR392 (Table 3, Figure 11). The

significance of this is that poly-Lys and poly-Arg peptides have been shown to penetrate
the cell membrane,611–621 which might be the reason that these peptides are able to be
crosslinked from position 116 in the ECD. This will be discussed in more detail in the next
chapter.
The range of distance measurement are even larger here than what was seen for
position 287, considering crosslinks were identified in the M3-M4 loop (Some peptides
from this region are part of the crystal structure though shifted to be included in M4) and
M2 (Table 2 and 3). However, it is likely that the apo-state is highly flexible, perhaps more
so than other states,238,243,598 and thus, seeing a large amount of out-of-bounds crosslinking
is not that concerning.
Overall, with respect to position 116, the ECD appears to be flexible as much of it
is crosslinked. Areas reported to be mobile, such as the C-loop, the Cys-loop and the M2M3 loop are crosslinked. The TMD region, however, is not heavily crosslinked, which
indicates that position 116 does not come into contact with the TM, with the exception of
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M2. It could also mean that crosslinking to this region was detected by the MS. This too
can be better explained in the context of the open and desensitized states.
4.3.3. Position 206.
Table 4. K206C Resting State Crosslinks.
The table shows intramolecular and intermolecular mass-shifted peptides from ≥3 separate trials,
compiling only what was found in ≥2 trials. The green underlined areas represent the sites of
refinement. The average distance ± standard error measurement (SEM) column shows the distance
from the site of mutation to the refined areas. Areas that are refined to a single amino acid are
represented by a single distance; whereas, refinement to multiple amino acids is represented as a mean
and the standard error. Residues from 310-377 are not resolved in crystal structures, and thus no
measurement data is available. Note that the distance between Cα of the residue crosslinked to the Cα
of the mutation is approximately 25 Å.

K206C Resting State
Intramolecular
Location
1
ARSATKPMSPSDFLDK16
Pre M1
132
143
ITLTLACPMDLK
272
ASLPKVSYVK281
M2-M3 loop
372
SPEEMRKLFIQRAK386
M3-M4 loop
Intermolecular
17
LMGRTSGYDARIRPNFK33
Pre M1
105
GAHFHEITTDNK116
117
LLRISRNGNVLYSIR131
253
VGLGITTVLTMTTQSSGSR271
M2
272
ASLPKVSYVK281
M2-M3 loop
310
320
QHKELLRFRRK
M3-M4 loop
321
RRHHK325
334
FNFSAYGMGPASLQAK349
350
DGISVKGANNSNTTNPPPAPSK371
372
SPEEMRKLFIQR383
384

AKKIDKISR392
412
IVRREDVHNQ421

C-term tail

Avg. Dist. ±SEM
39±1 (9-16 only)
27±1, 34
45±1, 38±1
84 (378 only)
31±2, 35±0.1
19±1
20±1
69±1, 61±1
44, 48
N/A
N/A
N/A
N/A
88±1
(378-388
only), 84±2
77±1
45±2
only)

(412-413

Position 206 is located on the C-loop and so gaining perspective on what is
crosslinking to this site is advantageous to analyzing its movement during gating and
channel activation. Studies have shown this area to be quite mobile, moving about 7 Å, to
cap over the bound ligand.238,317,318,343,344 There were 26 individual crosslinking sites
identified, and unlike those for positions 287 and 116, most of these were intermolecular
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crosslinks. Similar to 116, position 206 comes into contact with the upper preM1, in
residues 1-16 and residues 17-33. It also crosslinked to position 116 intermolecularly
(refined from 105GAHFHEITTDNK116 to 113TDNK 116). This is not reciprocated by results
seen in 116, either intra- or intermolecularly. The loops in the ECD-TMD interface, the
M2-M3 loop and the Cys-loop are also crosslinked. The proximity of position 206 to these
loops could be significant in triggering downstream channel activation.
Similar to position 116, very little crosslinking is seen in the TM domain, and is
only seen in M2 (Table 4; Figure 12 shows crosslinking to M4 but this area is actually M3M4 loop peptides). The
significance of the ECD
mutants being in closer

Figure 12. K206C Resting State Crosslinks. Two subunits of GlyR
(PDB: 3jad) are shown to visualize both intramolecular crosslinks (left
subunit) and intermolecular crosslinks (right subunit) to position 206
(represented as a yellow sphere). All crosslinked areas are highlighted in
green. The bead model below the structure shows the M3-M4 loop, both
intra- and intermolecularly. Again, the crosslinking data is highlighted
in green. The C-terminal tail is not shown. Refer to Table 3.

proximity to the pore and
not the other α-helices,
may have something to do
with how the α-helices
align themselves into a
three-ring
system.304,332,389,598
also

similar

And
is

crosslinking to the M3M4

loop.

What

is

interesting though, is the
peptides crosslinked do
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not have an abundance of poly-R/K regions, and thus, membrane penetration, seems less
likely, unless the poly-R/K regions pull other parts of the loop into the membrane as well.
Two of the peptides, 334FNFSAYGMGPSLQAK349, refined to the last three amino acids,
and 350DGISVKGANNSNTTNPPPAPSK371 are in the middle of the loop (See Section 4.5
for discussion of the M3-M4 loop).
4.3.4. Integration of Network in the Resting (apo-) State
Analyzing the resting state as a whole, with respect to the network of mutations can
provide some unique perspectives into its structure and dynamics. All three mutations
crosslinked to the top of the ECD, to the peptide 17LMGRTSGYDARIR33 , position 287 to
residues 20-21, 23, and 27; position 116 to residues 19-24, 27-28 and 31-32; and position
206 to 18-19 and 27-28 (Tables 1-3). K116C and K206C crosslinked to the peptide
1ARSATKPMSPSDFLDK16,

but M287C did not. It is expected that the ECD mutants may

crosslink to the upper ECD, given the approximate distance of the crosslinker of 25 Å, but
it was unexpected that position 287 would. This is indicative of protein flexibility in the
resting state. In order for the receptor to contact these three mutants in its apo-state it must
be sampling other energy wells as it searches for the lowest resting state conformation. To
confirm these movements, future work involves analyzing two upper ECD mutants, K6C
and G23C. If these mutants crosslink to all three mutants in this network, it is more
definitive of protein flexibility.
Another part of the ECD, 105GAHFHEITTDNKLLRISR122 which contains position
116, was crosslinked to both 287 and 206, but was not seen in 116 results. This could be
due to crosslinker length. However, what is interesting is that this network of mutations is
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able to “see” one another, and thus provide a sense of reciprocity that increases the
confidence of the results.
The ECD-TMD interface is known to play an important role in transducing the
effects of ligand binding to the TMD region, particularly the M2-M3 loop and the Cysloop,238,304,363,371,622 the hallmark loop of these channels. An analysis of the resting state
alone cannot provide enough details into the dynamics of this region, but what is apparent
is that all three mutants are crosslinking to this region, and thus, this network provides
important vantage points. The Cys-loop in α1-GlyRs is

138

CPMDLKNFPMDVQTC152.

Position 287 only crosslinks to K143 on the complementary subunit; whereas, position 206
crosslinks to K143 intramolecularly. Position 116 sees the most crosslinking to this loop,
at residues

DLK143 intramolecularly, and

141

CPM140 , intermolecularly. All of the
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residues that are crosslinked are on the exterior part of the loop, and primarily near the
bottom, closest to the TMD region, except for position 116, which also crosslinks to the
top of the exterior loop. It is important to note that 287 is crosslinking to the complementary
Cys-loop at the bottom, whereas; both ECD mutant are crosslinked to the bottom of the
principle Cys-loop. Position 116 crosslinks to the top of the complementary loop. It is
thought that the Cys-loop displaces outward during activation,238 so this might show a
different pattern of interaction in the active state, perhaps to the other side of the loop.
However; given the length of the crosslinker used, it may be too large to detect subtle
changes that are taking place, as there is mostly likely only a 2-3 Å difference in their
displacement.304 The M2-M3 loop interacts with these three mutations slightly differently,
as there is no clear indication of where the loop is relative to these positions. However,
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analyzing this loop in the context of other conformational states may be more helpful in
explaining the dynamics of this loop.
The C-loop, as stated previously, has a larger displacement during activation, as
much as 7 Å,304 though still much smaller than the length of MTS-bzp. With respect to
position 206, there is no crosslinking seen in either the principle or complementary subunit.
This could be due to crosslinker length. However; the other two mutants, which are not
located on the C-loop as 206 is, do crosslink to the principle subunit. Position 116
crosslinks to residues 195LRYCTKHYN 203, 198-203 are part of the loop; and position 287
crosslinks more sporadically, to C198, 203 NT204, and 206 KF207.
Crosslinking results in the TM domain were also somewhat surprising, as both ECD
mutants only crosslinked to M2, the α-helix that lines the pore; whereas, 287 located in
M3, had more uniform distribution of crosslinking results in this region. The results for
287 are expected as 287 is located in this region, but it is interesting to see that position
116 and 206 are similar in what they contact.
The C-terminal tail, which is not resolved in crystal structures is crosslinked to
positions 206 on the complementary subunit and 287 on the principle subunit, but not to
116. This is somewhat expected as 116 is quite far away, and hypothesized to be in a less
mobile region than 206.
The M3-M4 loop is also unresolved in crystal structures, and what was most
surprising to see crosslinked to all three mutants. Both positions 287 and 206 crosslinked
more so than position 116. Most of the crosslinking sites were located at the beginning and
ends of the loop, but the middle of the loop was crosslinked to 287 and 206. In the context
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of resting, open and desensitized states, a better perspective can be gained about what role
this loop may play in gating and desensitization.
The distance data for all mutations shows that PDB:3jad, a strychnine-bound nonconducting state,296 has inconsistencies in terms of receptor flexibility. With respect to all
of the mutants, a maximum of 32% of the crosslinks were found within an expected range
of ≤30 Å (Table 11). These numbers can only take into account the distances able to be
measured on the crystal structure, and thus, M3-M4 loop and C-terminal tail crosslinking
were omitted. Based on this data, it can be interpreted that this non-conducting crystal
structure cannot truly represent an apo-state GlyR structure.
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CHAPTER 5. PROTEIN-PROTEIN INTERACTIONS WITHIN THE OPEN AND
DESENSITIZED STATE NETWORKS
5.1. Introduction
Representing protein dynamics is difficult to do with high-resolution techniques
such as cryo-EM and x-ray crystallization. The majority of current structural knowledge
comes from NMR and x-ray structures; the popularity of cryo-EM is increasing, and more
structures determined by this technique are being added to the Protein DataBank (PDB).
However, cryo-EM and x-ray structures cannot represent protein dynamics. NMR does
have this capability, but it lacks the ability to analyze large membrane proteins. Thus, using
CX-MS to help refine the particularly dynamic parts of a membrane protein, as well as
provide information on proteins in near-native environments in various conformations is
essential. Available crystal structures have helped to speculate how the receptor may
transition from one state to the next, and CX-MS experiments can provide additional details
as to whether these speculations have merit.
5.1.2. Receptor Activation and Desensitization
The Monod-Wyman-Changeux (MWC) theory was originally used to model the
behavior of allosteric enzymes.623 It is also an accepted theory to explain the agonistinduced activation seen in pLGICs.623 It is based on the idea that the receptor spontaneously
shifts between pre-existing states, and that ligands shift the equilibrium towards high
affinity states.623 It also provides an explanation for reorganization of multiple subunits,
meaning that two states; a low-affinity resting state and a high-affinity ligand bound state
are shifted towards the higher bound state as more ligand binds. This theory works well for
active and resting states, but less so for desensitization.324
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The transition between the resting state and the active state, according to available
structures shows that an apo-state is less rigid, especially in the ECD region. The interface
between subunits at the ECD is larger, and more flexible, resulting in fewer interactions
and creating more solvent-exposed areas.238,314 As ligand binds to the receptor, the βsandwich folds in each subunit are postulated to move as a rigid body in response, which
results in the ECD to become closer together.314 There is an overall anti-clockwise twist of
the ECD, and it is referred to as ‘un-blooming’.243 The C-loop caps over the orthosteric
site,317 and the tip of the loop appears to move with the complementary subunit.243,314 This
un-blooming and anti-clockwise twist is observed in transitions of GLIC, GluCl and GlyRs
though there are some differences in mechanisms. GluCl does not appear to have much
movement of the C-loop in the same manner as GLIC, but does show tightening of loops
A, B and C, pushing them towards the complementary subunit which allows for ligand
binding.243 A residue important for binding agonist in the F loop, K171, also shifts from a
downward to an upward position for better hydrogen binding.243 In the crystal structure of
α1-GlyRs, since they are already bound to strychnine, they appear already un-bloomed,
instead of going through an un-blooming conformation as it shifts to the active state.243,296
It is important to note, that GlyRs are not crystallized in a true apo-state, and so the
competitive antagonist may be locking the receptor in this un-bloomed configuration. The
transition of an apo-state GlyR may in fact, resemble the transitions seen in GLIC or GluCl.
The C-loop of GlyRs, however; moves similarly to what is predicted in GLIC structures.243
The transition at the level of the ECD-TMD interface in GLIC involves mostly the
M2-M3 loop. There is a revolving motion towards M3 resulting in a 4Å shift.243 This shift
appears to suggest that there is allosteric coupling of the movements in the ligand-bound
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ECD region to the TMD gate region. The interface in GluCl structures also involves the
M2-M3 loop, but it moves differently, in a lateral motion, instead of a revolving motion.312
The result here causes a tilt in the M1 and M3 helices to allow IVM to bind.312 Because the
GlyR structure is already bound at the orthosteric site with strychnine the resulting
transitions to the active state are blunted. What is interesting is that the transitions in the
TMD differ between α1 and α3-GlyRs. The former behaves similarly to what is seen in
GluCl, but α3-GlyRs have a more radial twist. A voltage-clamp fluorometry study in 2009
showed that the addition of strychnine caused conformational changes to the ECD, but did
not open the pore which indicates that the dynamics caused by strychnine binding are
different than the dynamics caused by glycine binding.624 The movement of M2 is similar
among pLGICs, as it responds to the displacement of the Cys-loop, and the M1-M2 loop.
The top of the helix rotates outward, towards the M1 and M3 helices.596
According to the structure determinations from Du et al.,296 there is a 4-5 Å
difference between the strychnine-bound structure and the glycine and glycine/IVM-bound
structures in the pore, due to the rotation of the 9’ Leu position. Du and colleagues also
conducted two-electrode voltage clamp electrophysiology experiments to analyze these
conditions (glycine v. glycine/IVM) in a physiological context. They concluded that the
glycine-bound structure was an agonist-bound open state, and they suspected that the
glycine/IVM-bound structure was an allosterically modulated desensitized state or a
partially open state.
As previously mentioned, current crystal structures lack dynamics information and
are missing pieces of the receptor, particularly the intracellular M3-M4 loop. But another
concern based on these available structures is the source of the protein and the lack of a
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lipid bilayer. Du et al.296 crystallized GlyR from zebrafish, and not human, and the main
difference between the two is how they respond to the binding of IVM. Human α1-GlyR
is potentiated by IVM and it prevents the channel from desensitizing, whereas; in zebrafish
GlyR, IVM may shift the receptor towards desensitization.466 This difference in interaction
could implicate minor structural or mechanistic details that need to be better understood.
In this work, IVM will be used to analyze the open state as the binding keeps the receptor
from desensitizing. This is possible due to a double mutation in GlyR, A288G/F207G,
which allows IVM to bind GlyR with higher affinity.466 A similar mechanism for
preventing desensitization has also been shown in α1-GlyRs with the use of picrotoxin.324
Similarly, as previously discussed, the role of lipids is extremely important in membrane
protein structure and function.67 All of this leads to uncertainty in proposed mechanistic
insights provided by high-resolution structures and thus, the need for complementary
information from CX-MS studies.
It is now understood that in addition to an active, open state, there are also preactive states, a ‘flipped’ state, which exhibits only partial agonist stabilization and
response, and a ‘primed’ state that results in a shorter-lived open state.238,243,324 Neither of
these pre-active states have been investigated structurally, and so it is unknown how they
contribute to the dynamics of an open state configuration.
Further speculation and controversy arise when understanding the transition from
the open, active, state to a desensitized one. Desensitization is defined by a closed, ligandbound state that is refractory to any activation and decreases ion flow. It is thought to
prevent over-activation.324 Much of the information regarding desensitization came from
early experiments studying nAChRs. Kinetic studies showed that there are both ‘fast’ and
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‘slow’ desensitization states,324,625–627 and that desensitization happens when fully ligandbound.324,628,629
Original theories suggested a single gate opened and closed, but in the 1950s, Del
Castillo and Katz630 proposed a dual-gate model, one that opened after ligand binding to
produce an open channel, and another that closed as the channel desensitized.324,631–633 The
activation gate, sometimes called the hydrophobic gate, is proposed to be located near the
center, at position Leu 9’, and the desensitization gate is proposed to be near the
intracellular end of the TMD.243,324,631,632 Many crystal structures of resting states or
agonist-bound closed states have shown constriction at the central position in the
pore,243,296,297,308,309,311,312 giving evidence towards this activation gate. The dual-gate
model also proposes that a desensitized state would have a widening of the upper part of
the TM α-helices and a constriction at the intracellular end.324,632 NMR studies of ELIC
have shown a contraction at the intracellular end of the TMD in an apparent desensitized
state.632 Some suggest that several crystal structures (GLIC, GluCl, and α1-GlyR)296,324,634
may also represent desensitized states; whereas, others suggest that only the crystal
structure of β3-GABAAR is a true representation of a desensitized state.243
Based on the experiments analyzing desensitization rates thus far, some
mechanistic details have emerged. Site-directed mutagenesis experiments showed several
residues in pLGICS have an effect on desensitization. The 9’ residue that is the
hydrophobic gate for activation, is conserved among pLGICS (often a Leu), when mutated
almost completely suppresses desensitization.324,635,636 Several mutations in the ECD and
the ECD-TMD interface also affect desensitization.637,638 Relevant to α1-GlyRs, mutations
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in the intracellular M1-M2 loop, near the selectivity filter, I244A and P250T, strongly
increase desensitization and lead to loss-of-function phenotype.354,357,387
Analysis of phosphorylation sites in the intracellular loop have also provided
insight into desensitization. In nAChRs and GABAARs, the desensitization rate was
decreased in the presence of phosphorylation of the M3-M4 loop.639,640 The loop also seems
to play a role in desensitization in α1-GlyRs, as splice variations and mutations have
shown,388,414 though this has not been shown due to effects of phosphorylation.
Despite the wealth of kinetic data that exists for desensitization, there is still a gap
in knowledge regarding the dynamics and structural configuration of α1-GlyRs and other
pLGICs. There are countering ideas on which available crystal structures represent a truly
desensitized state; this ambiguity can likely be resolved with more structural experiments.
In these studies, we propose to examine allostery by CX-MS. Open and
Desensitized State Networks are composed of three site-specific single cysteine mutations:
M287C, K116C and K206C. Each mutation was inserted into a plasmid that contained
GlyR cDNA that had been modified, the resulting protein is referred to as Cys null GlyR
(C41S/C290A/C345S, Chapter 4). In addition to using Cys null GlyR described previously,
to study the desensitized state, two additional mutations are needed to study the open state
(A288G/F207G), by allowing IVM to bind, and keep GlyR from desensitizing. After
overexpression, the mutant GlyR was purified and crosslinking studies with MTS-bzp
(Figure 7) were conducted. After MS and MS/MS analysis, sites of crosslinking were
refined for each mutation in open and desensitized states and were then compared to resting
state crosslinking data to gain insight into receptor dynamics. These three site-specific sites
were chosen for their potential to study areas of the receptor not well-resolved, and due to
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ease of analysis. It is hypothesized that these mutants will provide vital information to
discuss receptor dynamics as well as complement high-resolution techniques which will
lead to more complete structures, with a particular focus on the regions in the receptor that
are currently not well resolved.
5.2. Results and Discussion
The use of CX-MS and site-specific single cysteine mutations can provide useful
information on protein structure as it can complement high-resolution techniques and study
proteins in native environments.5,7 It also has the ability to provide information of protein
dynamics, as the protein is studied as a fully-functional protein and multiple
conformational states can be compared.10 The site-specific network of Cys mutations is
identical to what was proposed in Chapter 3: one mutant located in the transmembrane
region (M287C) and two mutants located in the extracellular domain (K116C, K206C).
Each of these mutant-containing GlyR is purified, reconstituted into lipid vesicles (+
cholesterol) which is essential for the function of pLGICs,14,394,601,607,608 and then enriched
in either resting, open or desensitized states before being crosslinked with MTS-bzp. By
using MS and MS/MS analysis, both intra- and intermolecular sites of crosslinker
attachment are identified. By comparing crosslinking results from open and desensitized
states to crosslinking results identified in resting states, dynamic information regarding
conformational changes in GlyR can be determined. Furthermore, by comparing the
resting, open and desensitized networks as a whole, with respect to each of the mutants in
the network gives structural information about the receptor in each state.
5.2.1. Position 287
5.2.1.1. Open and Desensitized State Results
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Analysis of the open state revealed 25 individual sites of crosslinking. There is
distribution throughout the receptor, as was seen in the resting state, though the top of the
ECD is not observed to be crosslinked (Table 5, Figure 12). There were much fewer
crosslinks identified in the desensitized state (11 overall), but the distribution of
crosslinking in the ECD is similar to the open state, in that the top of the ECD (residues 133) are not detected as being crosslinked (Table 6, Figure 12). The ECD interface is
crosslinked in both open and desensitized states, mostly the M2-M3 loop, though the Cysloop is crosslinked in the open state. In the open state, the M2-M3 loop is crosslinked
Table 5. M287C Open State Crosslinks.
The table shows intramolecular and intermolecular mass-shifted peptides from ≥3 separate trials, compiling
only what was found in ≥2 trials. The blue underlined areas represent the sites of refinement. The average
distance ± standard error measurement (SEM) column shows the distance from the site of mutation to the
refined areas. Areas that are refined to a single amino acid are represented by a single distance; whereas,
refinement to multiple amino acids is represented as a mean and the standard error. Residues from 310-377 are
not resolved in crystal structures, and thus no measurement data is available. Note that the distance between
Cα of the residue crosslinked to the Cα of the mutation is approximately 25 Å.

M287C Open State
Intramolecular
60

VNIFLRQQWNDPR72
105
GAHFHEITTDNKLLR119

Location
Pre M1

117

LLRISRNGNVLYSIR131
NGNVLYSIRITLTLACPMDLK143
272
ASLPKVSYVK281
356
GANNSNTTNPPPAPSKSPEEMRK378
379
LFIQRAK385
384
AKKIDK389
387
IDKISR392
Intermolecular
34
GPPVNVSANIFINSFGSIAETTMDYRVNIFLR59
66
QQWNDPRLAYNEYPDDSLPLDPSMLD
SIWKPDLFFANEK104
191
EEKDLRYCTKHYNTGK206
282
AIDIWCAVALLFVFSALLEYAAVNFVSRQHK312
310
QHKELLR316
393
IGFPMAFLIFNMFYWIIYK411
123
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M2-M3 loop
M3-M4 loop

Pre M1

M3
M3-M4 loop
M4

Avg.
±SEM

Dist.

47±1, 62±2
40, 49, 51±1,
58±1
66, 57±1
45, 36±0.3, 24±2
14±1, 15±0.4
N/A
32±1
26±0.3
23±2
32, 48
64±2
50±0.3, 55±0.4
24±0.4
N/A
28±0.3

intramolecularly to the beginning of the loop 272 ASLP275, and the middle, 278 SY279, and not
at all to the complementary subunit.
Table 6. M287C Desensitized State Crosslinks.
The table shows intramolecular and intermolecular mass-shifted peptides from ≥3 separate trials,
compiling only what was found in ≥2 trials. The blue underlined areas represent the sites of refinement.
The average distance ± standard error measurement (SEM) column shows the distance from the site
of mutation to the refined areas. Areas that are refined to a single amino acid are represented by a
single distance; whereas, refinement to multiple amino acids is represented as a mean and the standard
error. Residues from 310-377 are not resolved in crystal structures, and thus no measurement data is
available. Note that the distance between Cα of the residue crosslinked to the Cα of the mutation is
approximately 25 Å.

M287C Desensitized State
Intramolecular
Location
253
VGLGITTVLTMTTQSSGSR271
M2

Avg. Dist. ±SEM

384

M3-M4 loop

29, 29, 25

Pre M1

37, 56±2
48±1
39±1
22, 18±1

AKKIDK

389

Intermolecular
VNIFLRQQWNDPR72
105
GAHFHEITTDNKLLR119
191
EEKDLR196
272
ASLPKVSYVK281
310
QHKELLR316
60

M2-M3 loop
M3-M4 loop

13±

N/A

The desensitized state shows intermolecular crosslinking to this region primarily
near the end, 277 VSYV280, and also to P275. Though it is difficult to determine whether the
differences seen in these two states is indicative of this region’s involvement in gating, it
does show mobility, which is congruent with what is seen in the literature.238,304,310
The TM domain is heavily crosslinked in both M3 and M4 in the open state and in
M2 in the desensitized state, as seen previously, M2 appears to be a region of GlyR that
does not ionize well, and thus, the lack of fragmentation data leads to the inability to refine
the position to a smaller area of amino acids. This is evident due to the number of counts
seen in peptides from M2 in comparison to other peptides. Furthermore, the amount of
fragmentation spectra is also fewer; we allow refinement data for a peptide that has four or
more fragmentation ions per spectra. In both M3 and M4, there was evidence of multiple
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binding sites, each species had different matched product-precursor sites at a particular
retention time, and thus led to the entire region not resolving well.
The M3-M4 loop region, with the exception of the peptide 359NSNTTNPPPA368 in
the open state, is mostly crosslinked at the beginning and end of the loop, regions which
were discussed previously, contain poly-R/K regions. The C-terminal tail is not crosslinked
in either of these states, which differs from what was seen in the resting state, relative to
position 287.
5.2.1.2. Dynamics Relative to Position 287.
Dynamic information can be revealed by analyzing the resting, open and
desensitized states relative to position 287. Starting at the region furthest from the
extracellular membrane surface (and using Figure 10 and 13), residues 1-33, are
crosslinked much more so in the resting state than in ligand-bound states. It is likely that
this is because in a true apo-state, GlyR is “bloomed”, and thus the ECD is wide at the top,
perhaps bringing the top of the ECD closer towards the membrane, and 287C. It may also
be due to relatively increased flexibility of the resting state; as this unliganded state may
have a shallow energy profile and sample more conformational space. The peptides
60VNIFLRQQWNDPR72 ,

and the beginning of 66QQWNDPRLAYNEYPDD…ANEK104 ,

which is part of β-sheet 2, is found crosslinked in all three states. In the resting state, it is
found intramolecularly at L64 and

69

intramolecularly at

69NDP71

62IFLRQQ67

and

NDPR72; whereas, in the open state, is found
and intermolecularly at

69NDPR72.

In the

desensitized state it is only seen intermolecularly, at N61, and 67QW68. Non- conducting
states interact with this area on different subunits, and the open state has the most contacts
to this area. One explanation could be the that the receptor, in its active state, has ‘un-
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bloomed’ and thus brought the middle β-sheets, where this peptide is, closer to position
Figure 13. M287C Resting, Open and Desensitized State Crosslinks. All states are represented by two
subunits of GlyR (PDB: 3jad). The left subunit of each visualizes intramolecular crosslinks, and the
right subunit, intermolecular crosslinks to position 287 (represented as a yellow sphere). All
crosslinked areas are highlighted in blue. The bead models below each structure represent the M3-M4
loop, both intra- and intermolecularly. The C-terminal tail is not shown. Refer to Tables 2, 4 and 5.

113

287, then it would be in the resting state or the desensitized state, especially since both the
principle and complementary subunits are crosslinked in the open state but not in nonconducting states.
The C-loop, which is known to be an area that is particularly mobile,238,331 also
shows dynamics relative to position 287. In the resting state, the C-loop on the principle
subunit is crosslinked. In the ligand-bound states, the complementary subunit’s C-loop is
crosslinked. This could be indicative of the C-loop closing over the ligand in these states.
Also, in the ligand-bound states, the position of crosslinking changes; in the active state,
the very tip of the C-loop is crosslinked,

200

KH201 and

204

TG205, and in the desensitized

state, the middle and bottom of β9 is crosslinked. Because the length of the crosslinker is
approximately 25 Å, small details are difficult to elucidate, but this does show the dynamics
of this particular region, and though speculative, the tip of the C-loop moves closer to M3
in the open state. Another area known to be dynamic is the interface between the ECD and
the TMD.238 Differential crosslinking patterns in the M2-M3 loop and the Cys-loop
between the conformational states indicate mobility. The Cys-loop appears to be moving
away from M3 as ligand binds, and the M2-M3 loop of principle and complementary
subunits is closer to the pore in the resting state, as there is much more crosslinking to this
loop in the resting state.
The TM domain also indicates movement when comparing the conformational
states. In the resting state, M2 is crosslinked intermolecularly, and there is minor
crosslinking seen in M3 in the principle subunit. In the open state, there is an increase in
crosslinking seen in M3, and also the addition of crosslinking seen in M4. This suggests
that relative motions in M3 and M4, as M4 is either moving closer to M3, or regions
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become accessible to crosslinking upon channel gating, which correlates to other studies
by Han et al.641 and Ferraro et al.14 Since this study is measuring Euclidian distances,
connecting residues by a straight line, it does not take into account regions that are blocked
sterically. Because of this assumption the actual distances between residues may differ. In
the desensitized state, M2 is crosslinked to the principle subunit. This may suggest that the
pore in the desensitized state could be wider than it is in the resting state, since in the resting
state, the complementary subunit’s M2 α-helix is closer to position 287. The difference,
according to structures determined by Du et al.296 suggests a change of 4-5 Å between a
closed state and a possible desensitized state; however; the desensitized state is not well
characterized. Also, the desensitized state, according to the dual-gate model, predicts that
the TMD is wider at the top in the desensitized state. Based on these crosslinking results,
there is no evidence to support or refute this.
The importance of using position 287 is highlighted in its ability to examine the
intracellular M3-M4 loop. Crosslinking patterns during conformational changes can
provide details into the role this loop may play in gating and desensitization. In the resting
state, the loop is intimately associated with the membrane, more so than in any other state.
The beginning of the loop,

310QH311

and

315LRFRRK320

are crosslinked in the

complementary subunit, and 321RR322 and 324HK325 in the principle subunit. The end of the
loop, including the part of the loop that is part of M4 in available crystal structures is also
crosslinked in the resting state, at 369PSKSPE374, Q382, 384 AK385 and D388 to the principle
subunit and K371,

374EEMR377 ,

and

381IQR383

to the complementary subunit. These

crosslinks to the beginning and the end of this intracellular loop are within reach of the
crosslinker, however; what is also seen in the resting state are crosslinks to the middle of
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the loop; at 361NT362 (intra-), R333, 352ISVK355, and 356GAN358 (inter-). This suggests that
the middle of the loop is associating closer to the membrane as well in order to come close
enough to interact with 287C. In the open state, there is intersubunit crosslinking to
359

NSNTTNPPPA368, which is close to residues seen in the resting state. All of the other

crosslinks seen in the open state are at the beginning or the end of the loop. The desensitized
state only has minimal crosslinking to the loop, at A384, K386, and K388 on the principle
subunit and 311HK312 on a neighboring subunit. These data suggest that as GlyR transitions
from its resting state to the open state, the M3-M4 loop moves away from the membrane.
It also suggests that with respect to position 287, there is not much change in the
desensitized loop structure from what is seen in the open state. It could also be because one
of the desensitized state samples had a lower sequence coverage and thus, might have not
included parts of the M3-M4 loop.
In summary, position 287 provided a look into the M3-M4 loop, an unresolved area
in current crystal structures. The apo-state receptor is flexible, ‘bloomed’ and its
intracellular loop is associating with the membrane. The conformational shift as the
receptor transitions to a high-affinity ligand bound state involves ‘un-blooming’ of the
ECD and capping of the C-loop. The ECD-TMD interface is dynamic and may move away
from the pore. In the TMD region, M4 moves closer to M3. The open state to desensitized
state transition is represented by mobility of the C-loop and mobility of the M2-M3 loop.
With respect to position 287, there may not be much change detected during this transition.
5.2.2. Position 116.
5.2.2.1. Open and Desensitized State Results
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Position 116 is located on the loop between β5 and β5’ in the ECD, and was chosen
to be part of this network because it has been previously studied in Lys-Lys crosslinking
studies and so has proven to not hinder the functionality of the receptor when crosslinked.32
There is a decrease in the amount of crosslinking data in the open state in comparison to
the resting state of position 116. This could either be due to data matching protocols or
perhaps the ionizability of the non-identified peptides, but it could represent that the apoTable 7. K116C Open State Crosslinks.
The table shows intramolecular and intermolecular mass-shifted peptides from ≥3 separate trials,
compiling only what was found in ≥2 trials. The pink underlined areas represent the sites of refinement.
The average distance ± standard error measurement (SEM) column shows the distance from the site of
mutation to the refined areas. Areas that are refined to a single amino acid are represented by a single
distance; whereas, refinement to multiple amino acids is represented as a mean and the standard error.
Residues from 310-377 are not resolved in crystal structures, and thus no measurement data is available.
Note that the distance between Cα of the residue crosslinked to the Cα of the mutation is approximately
25 Å.

K116C Open State
Intramolecular
Location
1
20
ARSATKPMSPSDFLDKLMGR
Pre M1
60
VNIFLRQQWNPDR72
123

NGNVLYSIRITLTLACPMDLK143
DLRYCTKTGKATCIEAR213
214
FHLER218
272
ASLPKVSYVK281
310
QHKELLRFRRK320
321
RRHHK325
378
KLFIQRAKK386
384
AKKIDK389
386
KIDKISR392
Intermolecular
60
VNIFLRQQWNDPR72
191
EEKDLR196
194

M2-M3 loop
M3-M4 loop

Pre M1

Avg. Dist. ±SEM
N/A, 20±1, 20±2
11±1, 20±1
6, 16±2, 32±2
27±2, 24±2
28±1
41±1, 45±1
N/A
N/A
84±1
80, 76
75±1
22±1
31±1

state is more flexible than the open state and/or the attached crosslinker has greater
conformational flexibility.
A total of 19 intramolecular sites and 2 intermolecular sites were identified. The
majority of them are found in the ECD, but as seen in the resting state, there is also
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crosslinking identified in the M3-M4 loop. The Cys-loop, the M2-M3 loop and the C-loop
are crosslinked; since all of these areas are known to be mobile, these crosslinks provide
Table 8. K116C Desensitized State Crosslinks.
The table shows intramolecular and intermolecular mass-shifted peptides from ≥3 separate trials, compiling
only what was found in ≥2 trials. The pink underlined areas represent the sites of refinement. The average
distance ± standard error measurement (SEM) column shows the distance from the site of mutation to the
refined areas. Areas that are refined to a single amino acid are represented by a single distance; whereas,
refinement to multiple amino acids is represented as a mean and the standard error. Residues from 310-377
are not resolved in crystal structures, and thus no measurement data is available. Note that the distance
between Cα of the residue crosslinked to the Cα of the mutation is approximately 25 Å.

K116C Desensitized State
Intramolecular
Location
1
ARSATKPMSPSDFLDKLMGR20
Pre M1
60
72
VNIFLRQQWNDPR
123
NGNVLYSIRITLTLACPMDLK143
194
DLRYCTKHYNTGK206
253
VGLGITTVLTMTTQSSGSR271
M2
272

ASLPKVSYVK281
QHKELLR316
317
FRRK320
321
RRHHK325
378
KLFIQRAKK386

M2-M3 loop
M3-M4 loop

310

384

AKKIDK392
KIDKISR392
393
IGFPMAFLIFNMFYWIIYK411
Intermolecular
21
TSGYDARIRPNFK33
191
EEKDLR196
201
HYNTGKFTCIEAR213
350
DGISVKGANNSNTTNPPPAPSKSPEEMR377
412
IVRREDVHNQ421
386

M4
Pre M1

Avg. Dist. ±SEM
N/A, 17
14, 10, 12±1, 19±1
29
34, 30±1
59±2
41, 40, 43, 44
N/A
N/A
N/A
87±1, 83
80±1, 76
78±1, 71
52
21±1
30±1
22±1

M3-M4 loop
C-term tail

N/A
45±1
only)

(412-413

insight into dynamics. In the desensitized state, there are 32 identified crosslinks, and are
more evenly distributed throughout the receptor, similar to the resting state though there is
more crosslinking seen in the M3-M4 loop, primarily at the beginning and end of the loop.
As seen in the open state, there are also identified crosslinks to the Cys-loop, M2-M3 loop
and the C-loop. M2 and M4 are crosslinked which was not present in the open state.

118

5.2.2.2. Dynamics Relative to Position 116.
Figure 14. K116C Resting, Open and Desensitized State Crosslinks. All states are represented by two
subunits of GlyR (PDB: 3jad). The left subunit of each visualizes intramolecular crosslinks, and the
right subunit, intermolecular crosslinks to position 116 (represented as a yellow sphere). All crosslinked
areas are highlighted in pink. The bead models below each structure represents the M3-M4 loop, both
intra- and intermolecularly. The C-terminal tail is not shown. Refer to Tables 3, 7 and 8.

Resting
Open
Desensitized
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Comparing the resting state to the open and desensitized states highlights some
important information regarding receptor transitioning. The non-conducting states are
more alike than the open state in the upper part of the ECD, residues 1-33. Resting state
crosslinks include intramolecular 6 KPMSPSDFL14, 19GRTSGY24 , 27RI28, and 31 NF32 ; and
intermolecular 1 ARS3. In the desensitized state, there is crosslinking to A4, M18,
intramolecularly and 21TSGYDARIRPNFK33 intermolecularly. In the open state, there is
only intramolecular crosslinking, 3 SATK6 , 9 SPS11,

15

DK16 . The lack of intermolecular

crosslinking in the open state suggests that position 116 is farther away from the
complementary subunit in the open state and then moves closer to that subunit in the
desensitized state.

60

VNIFLRQQWNDPR72 , of β2, is crosslinked within and between

subunits, and is only observed intramolecularly in non-conducting states (Figures 11 and
14, Tables 3, 7 and 8).
Crosslinking to the C-loop is consistent with observations that this region is
mobile.238,304,318,343,344,348,642 In the resting state, β9 and half of the C-loop connected to it
Figure 15. C-loop Crosslinking Comparison in K116C. On the left is the crosslinking results for the resting
state, the middle, the open state, and the left is the desensitized state (all shown in pink). The β-sheets are
labeled in the resting state. β9 and β10, as well as the loop in between constitutes the part of the receptor
that caps over glycine once bound. Crosslinking results show consistency in mobility of this region, as in
the resting state β9 is closer to K116C, the open state crosslinks to β10, and the desensitized state only has
crosslinking to the tip of β10 and the C-loop itself.

120

are crosslinked to position 116. In the open state, crosslinking to β10 and the connecting
part of the C-loop are identified. In the desensitized state, crosslinking is only found at the
end of β10, closest to the C-loop and throughout the C-loop (Figure 15). This suggests that
the C-loop does move during ligand binding and may cap over the ligand in the open state.
The shift in crosslinking in the desensitized state may be due to better refinement of the
region in this state or that the bottom of β10 is no longer close enough to crosslink to
position 116.
The ECD-TMD interface also shows dynamic changes between the states. In the
resting state, both the Cys-loop and the M2-M3 loop are crosslinked intramolecularly and
intermolecularly (Table 3). In the ligand-bound states, however; there is solely intrasubunit
crosslinks to both loops. With respect to the Cys-loop, in the open state,

CPMD141 is

138

crosslinked, and in the desensitized state, P139 is crosslinked. The resting state is shifted
slightly to

141DLK143,

but also includes

138CPM140

on the complementary subunit. In the

M2-M3 loop, the lack of crosslinking to the complementary subunit in both ligand-bound
states, suggests that either position 116 has moved farther away from the loops or the M2M3 loop has moved farther away from position 116. Han et al.643 analyzed taurine and
glycine binding to α1-GlyRs and showed near-identical motion of the M2-M3 loop in
response to binding of either agonist, and they concluded that the loop moves in a predetermined fashion, regardless of the ligand bound.
M2 is heavily crosslinked in the resting state, on both principle and complementary
subunits. M2 is crosslinked in the desensitized state, as is M4. However, in the open state,
there is no crosslinking to the TMD (Figure 14 shows M4 being colored in the open state,
but those residues are technically M3-M4 loop residues). This crosslinking pattern could
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suggest that position 116 is not able to contact the TMD in the open state, due to the ‘unblooming’ conformation that results. Since position 116 is an interior mutant, in may be in
a position that is somehow blocked from reaching the TMD.
Another difference seen between the states is the involvement of the C-terminal
tail, 412 IVRREDVHNQ421. This is an important region, since it is not resolved in current
crystal structures and is involved in the modulation of activity by Zn2+.644 It is only
intermolecularly crosslinked in the desensitized state. In position 287, this region was only
crosslinked in the resting state and position 206 sees this in the resting and desensitized
state. Future work involves analyzing I412C, so this mutant might help to reciprocally
discern allosteric motions in this C-terminal tail of the receptor. However, the fact that it is
never seen in the open state may have something to do with the ‘un-blooming’
conformation, or the lack of involvement of the tail in gating.
The intracellular loop also involves the desensitized state more than the other states,
as it has crosslinking to this region both intra- and intermolecularly. All states show
crosslinking to the beginning of the loop. The non-conducting states also show crosslinking
to the end, but on different subunits. A detailed discussion of the intracellular loop can be
found in Section 5.4.
Position 116, since it is located in the interior of the ECD, provides a unique
perspective into what may happen as ligand binds. This data is consistent with C-loop
mobility, and suggests that as glycine binds, the C-loop may cap over it. The open to
desensitized state transition also shows mobility of this region. The receptor has higher
affinity to glycine in the desensitized state,236,631,637 and interactions made with the C-loop,
as well as the other loops in the LBD may contribute to this. A shorter crosslinker, as well
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as the examination of position 206 may help to provide more details into the differences
between the open and desensitized state in terms of movement of the C-loop region.
5.2.3. Position 206
5.2.3.1. Open and Desensitized State Results
Table 9. K206C Open State Crosslinks.
The table shows intramolecular and intermolecular mass-shifted peptides from ≥3 separate trials,
compiling only what was found in ≥2 trials. The green underlined areas represent the sites of refinement.
The average distance ± standard error measurement (SEM) column shows the distance from the site of
mutation to the refined areas. Areas that are refined to a single amino acid are represented by a single
distance; whereas, refinement to multiple amino acids is represented as a mean and the standard error.
Residues from 310-377 are not resolved in crystal structures, and thus no measurement data is available.
Note that the distance between Cα of the residue crosslinked to the Cα of the mutation is approximately
25 Å.

K206C Open State
Intramolecular
Location
3
SATKPMSPSDFLDKLMGR20
Pre M1
105
122
GAHFHEITTDNKLLRISR
123
NGNVLYSIRITLTLACPMDLK143
321
RRHHK325
M3-M4 loop
378
KLFQRAKK386
Intermolecular
17
LMGRTSGYDARIRPNFK33
Pre M1
132
143
ITLTLACPMDLK
201
HYNTGCATCIEARFHLER218

Avg. Dist. ±SEM
41±1 (9-12 only)
33±1
27±1
N/A
80±1
34±1
28±2
41±2, 30

Similar to position 116, there are less crosslinks identified in the open state than in
the other two states. Only 9 crosslinks were identified in the open state, compared to 31 in
the desensitized state and 25 in the resting state. In the open state, the crosslinking is
primarily located in residues before M1, in the ECD and ECD-TMD interface. The upper
part of the ECD, residues 1-33 are crosslinked. The region where 206 is located is also
crosslinked,

HYNTGCATC209, though only to the complementary subunit (Table 9).

201

The only other crosslinks identified are found in the M3-M4 loop. With respect to the
distance measurements, there are none that were found less than the crosslinker length,
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which suggests that the open state is not well-represented by the crystal structure. Results
from the desensitized state are more consistent to what was seen in the resting state, as
Table 10. K206C Desensitized State Crosslinks.
The table shows intramolecular and intermolecular mass-shifted peptides from ≥3 separate trials,
compiling only what was found in ≥2 trials. The green underlined areas represent the sites of refinement.
The average distance ± standard error measurement (SEM) column shows the distance from the site of
mutation to the refined areas. Areas that are refined to a single amino acid are represented by a single
distance; whereas, refinement to multiple amino acids is represented as a mean and the standard error.
Residues from 310-377 are not resolved in crystal structures, and thus no measurement data is available.
Note that the distance between Cα of the residue crosslinked to the Cα of the mutation is approximately
25 Å.

K206C Desensitized State
Intramolecular
Location
1

ARSATKPMSPSDFLDKLMGR20
TSGYDARIRPNFK33
105
GAHFHEITTDNKLLRISR122

Pre M1

21
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ISRNGNVLYSIRITLTLACPMDLK143
191
EEKDLRYCTK200
272
ASLPKVSYVK281
310
QHKELLRFR318
321
RRHHKEDEAGER333
334
FNFSAYGMGPASLQAK349
350
DGISVKGANNSNTTNPPPAPSK371
372
SPEEMR377
378
KLFIQRAKK386
384
AKKIDKISR392
412
IVRREDVHNQ421

M2-M3 loop
M3-M4 loop

C-term tail

Intermolecular
ARSATKPMSPSDFLDKLMGR20
Pre M1
191
200
EEKDLRYCTK
253
VGLGITTVLTMTTQSSGSRASLPKVSYVK281 M2, M2-M3
loop
321
325
RRHHK
M3-M4 loop
1

Avg.
±SEM

Dist.

N/A, 40, 32±1
22±1
32±2
26±1, 25±1
20±2
38±1
N/A
N/A
N/A
N/A
84
81, 79±1, 73
73±1, 67±1
37
(412-413
only)
N/A, 32±2
36±1
64±2, 48±1, 49
N/A

more regions of the receptor are represented. Similar to the resting and open states, the
upper part of the ECD (residues 1-33) is crosslinked. Again, as seen in the open state, the
C-loop is crosslinked to the complementary subunit. This is interesting, as the resting state
does not crosslink to this area, so there is similarity between the ligand-bound states. In
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Figure 16. K206C Resting, Open and Desensitized State Crosslinks. All states are represented by two
subunits of GlyR (PDB: 3jad). The left subunit of each visualizes intramolecular crosslinks, and the right
subunit, intermolecular crosslinks to position 206 (represented as a yellow sphere). All crosslinked areas
are colored green. The bead models below each structure represents the M3-M4 loop, both intra- and
intermolecularly. The C-terminal tail is not shown. Refer to Tables 4, 9 and 10.

Resting
Open
Desensitized

terms of the ECD-TMD interface, the desensitized state is more similar to the resting state
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than to the open state. Both non-conducting state show intramolecular crosslinking to the
Cys-loop, and crosslinking to the M2-M3 loop, though the desensitized state interacts with
both subunits in this area. As mentioned previously, the C-terminal tail is crosslinked to
the principle subunit. With respect to position 116, the C-terminal tail of the
complementary subunit was crosslinked in the desensitized state. And unlike position 116,
the tail is also crosslinked in the resting state, similar to position 287. The most striking
result from this state, though, with respect to this position are the unique crosslinking sites
identified in the M3-M4 loop region. There are regions crosslinked here that are not found
in any other state or mutant in the analyzed network (See Section 4.5).
5.2.3.2. Dynamics Relative to Position 206
Position 206 is located on β10, part of the β-sheets that connect the C-loop, and cap
over the ligand once bound. Thus, it is hypothesized to be a highly mobile region, and so
there was an expectation for visualizing protein dynamics. The first 16 residues,
1

ARSATKPMSPSDFLDK16 are crosslinked to the principle subunit in all three states;

unrefined to any particular residues in the resting state, 3 SATKPMSPSD12 in the open state
and 7 PM8 , and P10 in the desensitized state. The complementary subunit only has
crosslinking to this region in the desensitized state, at
17LMGRTSGYDARIR33 ,

resting and open states,

1 ARSA4.

The peptide

is seen crosslinked to the complementary subunit in both the
MG19,

18

31

RI32 and 17-32, respectively; but in both principle

(17LMG19, 21TSGYD 25) and complementary subunits ( 18MGR20) in the desensitized states.
Though this region has not been reported to be mobile, it is consistently seen interacting in
various patterns with all of the analyzed mutants. Position 206 is in a mobile location, but
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positions 287 and 116 are not and so, this region is hypothesized to be an area that may
have mobility (Section 5.5).
Another important part of the ECD is position 116. Position 206 crosslinks to 116
in the complementary subunit of the resting state and the principle subunit of the open state,
but is not seen in the desensitized state at all. An explanation for this might be the length
of the crosslinker; perhaps in the desensitized state, and the principle subunit of the resting
state, the two residues are too close to one another. This may also be why the C-loop, the
region where position 206 is located is not seen in the resting state, but is crosslinked in
the complementary state in both ligand-bound states. According to studies involving the
transition between the resting state to the pre-active state, the ‘flip’ state, the motions of
the C-loop extend to the β1-β2 loop (50 SIAETT55) in the ECD-TMD interface in
GlyRs.238,352 What is interesting is that none of the mutants analyzed crosslink to this area;
though position 287 comes closest, crosslinking to 57DYR59 and Y58 in the complementary
subunit of the resting and open states, respectively. And so, there is no evidence from this
data to show involvement of this loop in the transition between resting and open states.
The absence of crosslinking in the open state to the TMD is similar to what was
seen with respect to position 116. Because both ECD mutant do not contact the TMD in
the open state, this suggests that the orientation of these mutants is somehow blocked from
reaching the TMD or is out of the reach of the crosslinker. The interaction to the TMD in
non-conducting states, for both positions 116 and 206 suggests that there is a
conformational change from resting to open and from open to desensitized that involves
the accessibility and inaccessibility of the TMD with respect to these mutants.

127

The M3-M4 loop, though unexpected to be crosslinked to, may suggest an
interesting role for the loop. Like position 116, there are few crosslinks in the open state.
However, dissimilar to position 116, there is more crosslinking found in the nonconducting states. More so, the crosslinking found is not just at the beginning and end of
the loop, which may make since to be crosslinked given a larger tolerance of the crosslinker
length, but is found in the middle, in unique areas not seen when analyzing other mutants.
The resting state crosslinking sees the most unique areas, and is primarily crosslinked
intermolecularly. In the desensitized state, the crosslinking is primarily found to the
principle subunit. In position 287, the majority of crosslinking was found in the resting
state, leading to the suggestion that the loop’s intimate association with the membrane in
this state may play a structural role in a non-conducting receptor. Position 206 seems to
suggest similarly, that the non-conducting states involve the loop, more so than the active
state does.
5.2.4. Distance Data
After the crosslinking data was mapped onto the crystal structure (PDB:3jad), the
distance between Cα of either position 287, 116 or 206 to the Cα at the site of crosslinking
was measured. This information was useful in determining model accuracy with respect to
the mutations analyzed. Using the same crystal structure for all states and all of the
mutations provided uniformity, however; the structure used was the strychnine-bound
closed state, and so it is unlikely to match entirely to the data, as the structure is not a true
apo-state. The measurements were grouped into three categories: <20 Å, 20 – 30 Å, and
>30 Å, to show crosslinks that were less than the length of the MTS-bzp crosslinker, within
a suitable range based on the approximate 25 Å length, and greater than the length of MTS-
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bzp, respectively. Generally, a tolerance of approximately 3-5 Å is applied to the length of
the crosslinker used to account for molecule flexibility.5,128,645,646 A measurement that was
out of the range of the crosslinker, the third category, is perceived to show model
inaccuracy, and also protein dynamics.
What was immediately obvious was that many of the crosslinks were out of the
range of the crosslinker’s length (Table 11), greater than 40% of them for all positions and
states. While it is expected that some of the distances would be out-of-bounds due to the
capability of CX-Ms to study protein dynamics, it was unexpected that the majority of the
Table 11. Distance Data. The table represents the percentage of distance measurements within certain ranges
for each mutation M287C, K116C and K206C, in all three states, resting (R), open (O) and desensitized
(D). The distance data was split into three categories: (1) <20 Å (less than the reported length of MTS-bzp),
(2) between 20 to 30 Å (the length of MTS-bzp with molecule flexibility accounted for) and (3) >30 Å
(larger than the reported length and expected to show model inconsistency). Of the total measurements, a
percentage was calculated that fit into the three categories and tabulated. All distances are from Cα of the
site of mutation to Cα of the crosslinking site.

measurements (in most cases) would be. However, studies by Merkley et al.,646 Kahraman
et al.123 and Ryl et al.20 have noted a considerable range of out-of-bounds crosslinking
distances in their studies. According to these studies, it is likely the out-of-bounds
crosslinking is due only to protein dynamics that are unable to be detected in experimental
structures and not the formation of protein aggregates.20,123,646,647 It is also suggested that a
larger length tolerance should be considered, thus decreasing the out-of-bounds
crosslinking percentage.646
Since the structure used does not adequately define any of the analyzed states, but
is closest, perhaps, to the resting state, the data was expected to closely fit this structure.
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However, that was not the case. The resting states of all analyzed mutations had the highest
percentage of out-of-bounds crosslinks. This is most-likely due to the resting state being a
more flexible state than the ligand-bound states.243 Because the structure is bound to
strychnine, it is far less flexible than it would have been.
By totaling up the crosslinks that are <20 Å and those that are between 20 – 30 Å,
the desensitized states, of all mutants has the highest percentage. Again, this is not to say
that the structure used to map these results is a desensitized structure, but that the results
from the desensitized state crosslinks have the best fit. What this could mean is that a
desensitized state, from the perspective of position 287, 116 and 206 best fits an antagonistbound closed state, which is what PDB:3jad is representative of. Though studies have
shown that dynamics due to glycine versus strychnine binding differ,642 there may be a
similar end result that was captured conformationally in the crystal structures, and so, an
antagonist-bound state may be similar to what can be visualized by the positions analyzed.
The most important point is that the high percentage of out-of-bounds crosslinks is
indicative of protein dynamics and that dynamic information cannot be properly mapped
onto a static image. Crystal structures cannot represent dynamics, and thus, to understand
how a protein is transitioning between its states, structural studies that include dynamics
should be performed.
5.3. Network Integration
In Chapter 3, the resting state was integrated with respect to position 287, 116 and
206. Of note, the resting state showed contacts to the upper part of the ECD, residues 1-33
with respect to all mutants, lending credibility that this region may be especially mobile,
or that the resting state is more flexible. Analysis of regions where the ECD mutants were
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located showed that they were crosslinked by each other and by 287, but not themselves.
This is most likely due to crosslinker length, but it also is indicative of a network that
provides an important perspective into studying structure, and a good starting point.
Investigating the resting state with CX-MS showed compatibility with what is
reported in the literature of dynamic areas. The C-loop, Cys-loop and M2-M3 loop show a
difference in refinement patterns that is consistent with the mobility of these loops. The
resting state also showed similarity in the TMD region from the ECD mutants, and the
identified crosslinking found in the unresolved M3-M4 loop region suggest an intimate
association with the membrane. Integrating the open and desensitized states will provide
more context into overall receptor dynamics.
5.3.1. Open State
Analysis of the open state reveals several important differences from what was seen
in the resting state. The upper ECD, residues 1-33, are no longer crosslinked with respect
Figure 17. Comparison of Open State Crosslinking. To show the differences between crosslinking data the
open state crosslinking results for network mutants is shown. On the left, in blue, are crosslinking data for
M287C. In the middle, in pink, are the results from K116C, and on the right in results from K206C. Larger
images with detailed explanation can be found in Figures 13, 14 and 16, respectively.
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to position 287, but are still crosslinked to the ECD mutants. It is speculated that the
‘bloomed’ configuration of the resting state changes to an ‘un-bloomed’ configuration as
glycine binds, and this may mean that the top of the ECD is no longer close enough to
crosslink to M3, where 287 is located.
There are also differences seen in the TMD and the M3-M4 loop. M2, M3 and M4
were crosslinked to position 287 in the resting state, but positions 116 and 206 only saw
crosslinking to M2. In the open state, there is still heavy crosslinking to position 287 to M3
and M4, but not M2. From the perspective of the ECD mutants, however, there is no
crosslinking to the TMD. It is unclear why these mutants are able to crosslink to the helix
that lines the pore in an apo-state, but not in an active state. Could it be that somehow the
crosslinker is blocked from reaching the pore in an active state? Further work must be
conducted to gain more insight. It is also interesting that position 287 no longer crosslinks
to M2, but is heavily crosslinked to the complementary M3 and M4. According to studies
that proposed mechanisms for channel opening, there is a tilting of the M2 helices to widen
at the top to allow ion flow.238,308,309 The ability for the pore to widen from approximately
2 Å to 6 – 7 Å is due to limited contacts M2 makes with M1 and M3, and a cavity in
between the helices that holds water or cholesterol.238,304,360,389,394,395,648 One perspective
from this data, with respect to position 287, could be that if M2 is widening at the top and
also removing the water and/or cholesterol from the cavity to make room for ion flow, the
distance between the top of M2 and the top of M3 becomes so small that the crosslinker is
unable to crosslink; where in the resting state, the crosslinker was able to crosslink to M2.
Specific studies should be conducted on MTS-bzp to see both the minimum and maximum
distance it can reach.
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The M3-M4 loop shows major differences also. In the resting state, there were
many crosslinks to this region, from all mutants in the network, and there is a dramatic
decrease in the amount of crosslinking to the loop in the open state. With respect to the
ECD mutants, there is crosslinking to the loop only at the beginning of the principle loop;
311HKELL315

and 321 RRHH324 in position 116, and 321RRH323 in position 206. Position 287

sees more crosslinking than the ECD mutants but still much less than it did in the resting
state; to the end of the loop in the principle subunit, and the beginning of the loop in the
complementary subunit. It appears that the loop is moving away from the membrane as the
receptor is activated. Whether this means that the loop does play a role in the structural
stability of an apo-state receptor is unclear. Further work on this loop is necessary to discern
its importance in stability, gating and activation.
The ECD-TMD interface, because it is known to play a role in transducing signal
from the LBD to the TMD, is an important area for visualizing dynamics in an active state.
The Cys-loop, with respect to the ECD mutants, shows a decrease in crosslinking from the
resting state to this region. In fact, position 206 does not crosslink to this region at all in
the open state. Position 116 interacts with both the principle and complementary loops in
the resting state, but only the principle loop in the open state. Position 287 only sees the
principle subunit in both states. The M2-M3 loop shows a similar decrease in crosslinking
from the resting to open states for all positions. It is unclear whether this is indicative of
transducing signal, but it does show an overall mobility of this region.
Lastly, studies have shown that the β-sheets of the ECD move as rigid bodies
pulling the ECD closer together as the receptor is activated.314 Examination of β-sheets 1
through 6 of the ECD in both resting and open states does show movement of these regions,
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but it is inconclusive if the ECD is becoming closer together. With respect to position 287,
crosslinking is identified in β2, β4 and β5 in the principle subunit, and β1, β2 and β5 in the
complementary subunit. In the open state, however; there is crosslinking only to β2, β5 and
β6 in the principle subunit and β2 in the complementary subunit. This could suggest that
the ECD is coming closer and thus, the crosslinker length, being approximately 25 Å is too
long and thus insufficient to crosslink to these sheets, but it could mean these areas were
not identified in these studies. Similar results can be seen for both position 116 and 206,
and thus, this shows mobility of the region, but is not conclusive towards a constriction of
the ECD.
Overall, the major changes between the resting and open states are found in the
upper ECD, the TMD and the M3-M4 loop. Fewer contacts are made to these regions, with
respect to all mutants. This may suggest an ‘un-bloomed’ conformation due to the changes
in the upper ECD with respect to position 287. This may also suggest that the M3-M4 loop
moves away from the membrane during the active state.
5.3.2. Desensitized State
Analysis of the desensitized state reveals similarities to the open state, which is
interesting as both are ligand-bound states, for instance, the upper ECD, residues 1-33, are
crosslinked only to positions 116 and 206, but not position 287. This may suggest that with
respect to this region, there is not much change as the receptor transitions between the open
and desensitized state.
An area that was expected to change overall would be the C-loop, and the β-sheets
that surround it, β9 and β10. This region consists of
198CTKHYNTGKFTC209

185PGFILKEEKDLRY197

for β9,

for the loop, and 210IEARFHLER 218 for β10. In the resting state,
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there were multiple contacts in the principle subunit for both positions 287 and 116;
193

KDLR196 , C198,

203

NT204,

206

KF207 ,

213

RFH215 and

195

LRYCTKHYN203 ,

215

HLER218 ,

respectively. However, there was no contact in position 206, though this could be because
K206 resides in this region. Only position 116 crosslinked to the complementary subunit,
at 192 EKDLR196 in the resting state. In the open state, where it is proposed that the C-loop
caps over the ligand, there was no change seen by position 206. For 287, however; all the
contacts seen in the resting state were no longer present, but the complementary subunit
saw crosslinking to

200

KH201 and

204

TG205. In position 116, the complementary subunit

crosslinking is identical, but in the principle subunit, there are subtle differences,
204

TGKATC209 (note that position 207 is one of two mutations that are added to allow IVM

to bind and thus trap GlyR in its open state), 212 AR213 and 214 FHLER218. In the desensitized
state, GlyR has a higher affinity to its ligand,386,649 and so it is expected that there may be
some change in proximity of certain residues in the loop with respect to the ligand resulting
in stronger hydrogen bonding. According to Brejc et al.,417 the ligand makes contacts at
Y202, and close to K200. With respect to position 116, crosslinking is seen to both
principle and complementary subunits, at N203,

205GK206,

and

191 EEKDLR196, 210IE211,

respectively. In 287, similar to the open state, no contacts are made to the principle subunit,
but there is intermolecular crosslinking found at

191 EEKDLR196 .

The biggest change is

position 206 which crosslinks both intra- and intermolecularly, which wasn’t seen in the
other two states, at 193 KDLRY197 and 198 CT199. Though these data cannot provide evidence
of minute changes that might result in higher affinity binding, the fact that there is a
difference in crosslinking patterns does show this loop is moving in all states.
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The ECD-TMD interface also shows dynamics in this state as well. In the open
state of position 206, there was no crosslinking seen in the Cys-loop or the M2-M3 loop,
but in the desensitized state, there is contact to both. In contrast, for position 287, the Cysloop crosslinking is no longer present, and in the M2-M3 loop, there is a shift in
crosslinking seen from the principle subunit to the complementary one. Position 116 shows
only subtle changes in both loops. The ability to crosslink to these regions, particularly
from 206 and 287 is closer to what was seen in the resting state. This may suggest that the
interface, with respect to this network, looks similar in non-conducting receptors, despite
the fact that the ligand is still bound. Perhaps, the energy added due to ligand binding
initially causes the loops in the interface to move, but then they revert back to a more
original location once the receptor desensitizes.
Figure 18. Comparison of Desensitized State Crosslinking. To show the differences between crosslinking
data the desensitized state crosslinking results for network mutants is shown. On the left, in blue, are
crosslinking data for M287C. In the middle, in pink, are the results from K116C, and on the right in results
from K206C. Larger images with detailed explanation can be found in Figures 13, 14 and 16, respectively.
K206C
M287C
K116C

This similarity to the resting state is also seen in the TMD. Once again, there is
crosslinking to M2, which was seen earlier. In the open state, the ECD mutants did not
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crosslink to the TMD at all. In context of all the conformational states, it is interesting that
M1 was never able to be crosslinked, by any of the mutants in the network. Is it because
the region doesn’t ionize well? If a mutation could be placed here, and result in a functional
receptor, it would be valuable to expand the network to include this region.
What is most striking about the desensitized state are the unique crosslinking
patterns seen in the M3-M4 loop region. Position 206 sees unique sites in the loop that are
not identified in any other state or by any other mutant. The reasons for this are currently
unknown, but will be further discussed in the next section.
Integrating the network in all of the states has identified dynamic regions within
the receptor, The M3-M4 loop, the C-loop, the loops in the ECD-TMD interface, and
perhaps even the upper residues of the ECD. This integration has also provided proof that
this methodology is able to show dynamics. As the receptor transitions between resting,
open and desensitized states, unique patterns emerge for each conformation, even in the
resting state. This shows that the receptor can be effectively trapped in each state.
5.4. The Intracellular Loop
The M3-M4 loop is multifaceted in terms of its functions and modulations; it
mediates specific interactions with intracellular binding partners,381 is targeted by
PTMs,381,395 modulated by positive allosteric ligands, and it plays a role in channel
structural integrity,396 gating,397 desensitization398-400 and receptor surface expression.395 It
distinguishes the pLGICs from one another, and determines the specific ion channel
properties.388,414–416 Because this loop is truncated in crystal structures, its structure and the
interaction it may have with the rest of the receptor is lacking. This work has been able to
visualize the loop in resting, open and desensitized states, and this information can be used
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to help better understand how the loop interacts with the receptor, as well as with the
membrane in its conformational states.
The M3-M4 loop of α1-GlyR is approximately 70 residues, which is about 20% of
the total mass of the receptor (Figure 19). Each of the mutations in the network was able
to crosslink to the loop in all states. From the perspective of position 287, this was expected.
However, the crosslinking of the ECD mutants to this loop was surprising. One explanation
of the results could be due to poly-R/K regions. Studies have shown that peptides
containing Arg and Lys residues have the ability to penetrate the membrane.614,616,619–621,650
These peptides have been classified as cell-penetrating peptides (CPPs),613,616,617,619–621 and
are commonly grouped into three classifications; protein derived CPPs, which are
sometimes also called protein transduction domains; model CPPs and designed CPPs.616
With respect to this work, only protein-derived CPPs will be discussed here, for
information on other types see Zorko et al.,616 Lindgren et al.651 and Gräslund et al.652.
Protein-derived CPPs come from short sequences within proteins that have translocation
Figure 19. Intracellular M3-M4 Loop of α1-GlyR. The bead model depicts the amino acid residues that
makes up the intracellular loop of α1-GlyR. The loop is not resolved in available crystal structures. The
blue lines represent commonly found peptide pieces, with the exception of 317FRRKRRHHK325 which
has multiple R and K residues and thus, multiple tryptic pieces could result. It is important to note that
there are other peptide pieces that could produce different tryptic pieces, as well. The last two peptides,
KLFIQRAK and KIDKISR are represented on structure determinations PDB: 3jad, 3jae and 3jaf
(strychnine-bound, glycine-bound and glycine/IVM-bound) but are part of the M4 helix and not as part
of the loop due to a 16 amino acid shift of the sequence. Because of this, the bead model for the
crosslinking results seen in M287C, K116C and K206C resting, open and desensitized results only
include up to residue R377.
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properties.616,617,653 The significance of CPPs, other than providing a path for information
to be brought into the cell, has evolved into a method for drug delivery.614,617
A wealth of knowledge regarding CPPs came from studying the HIV-Tat protein.
Tat (trans-activator of transcription) is a protein that is known to be involved in the
replication of human immunodeficiency virus type-1 (HIV-1).654 In order for the virus to
replicate itself it needs a way to enter the plasma membrane and the nuclear membrane of
the cell, and studies have shown that the Tat protein is responsible for facilitating cell
uptake.654–657 The specific sequence is, CGRKKRRQRRRPPQC.616,617,653,658 Another early
identified CPP was derived from Antennapedia homeodomain of Drosophila, called
penetratin; its sequence is RQIKIWFQNRRMKWKK.616,659 Note that both peptide
sequences contain Arg and Lys residues, but do not have any other specific motif. This
holds true for all protein-derived CPPs; they are all short (< 30 residue) peptides that are
both basic and amphipathic, but other than these two characteristics can be quite
variable.616
The mechanism of how these basic, amphipathic sequences penetrate the
membrane is unclear, but analysis of both Tat and penetratin suggests that the positively
charged peptide interacts with negatively charged phospholipids and that creates an
inverted micellar structure that then opens the membrane inward or outward.616,650,659 Other
researchers have proposed that poly-R groups interact more strongly than poly-K groups
with phospholipid bilayers, particularly those containing PC and PG.618 This may be due
to the guanidinium group and its ability to form up to five strong hydrogen bonds to
carboxyl,

phosphoryl

and

sulfuryl

groups

phosopholipids.653,660–662

139

that

are

in

carbohydrates

and

Keeping this is mind, the crosslinking results for the M3-M4 loop suggest the
possibility that sequences within the loop may act as CPPs. If the loop is divided purposely
into commonly digested trypsin fragments, there are a total of 9 peptides (Figure 18), but
two have been put together and referred to as the poly-R/K region; they are as follows: (1)
310QHKELLR316,

(2)

317FRRKRRHHK325

334FNFSAYGMGPACLQAK349,

(5)

(poly-R/K region), (3)

350DGISVK355 ,

(6)

326EDEAGEGR333

(4)

356GANNSNTTNPPPAPSK371,

(7) 372SPEEMR 377, (8) 378 KLFIQRAK385 and (9) 386 KIDKISR392. Note that peptides 8 and
9 are part of M4 in available crystal structures. Also, though peptide 2 shows the highest
concentrated area of Arg and Lys residues, there are other peptides that also have these
basic residues and thus, may display cell-penetrating behavior.
Figure 19 plots the distribution of crosslinking seen in the M3-M4 loop in resting,
open and desensitized states for M287C, K116C and K206C, with respect to each
commonly trypsin-digested peptide fragment. Relative to all mutants, there was the least
amount of crosslinking seen in the open state, which could be due to the loop moving away
from the membrane as the receptor activates. There was the most crosslinking seen in the
resting state; this could be due to the loop providing stability to an apo-state receptor.
Analyzing the results with respect to each mutation identifies differences between
patterns seen. Crosslinking results for K206C is broadly distributed throughout the loop,
and is seen at least once in each peptide region. M287C crosslinking results are skewed
more towards the resting state, but it does crosslink uniquely to two regions in the open
state, (356-371 and 372-377) which are not seen with respect to the other mutants. K116C
sees the fewest crosslinking results overall, but most of them are found in the desensitized
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Figure 20. Total Intracellular M3-M4 Loop Crosslinks. This chart represents the total number of crosslinks
found in the M3-M4 loop and the distribution pattern of the crosslinking results. Each commonly trypsindigested peptide region is represented by residue number on the x-axis, as are resting, open and desensitized
states. The colored bars indicate where crosslinking sites were identified, blue for M287C, pink for K116C
and green for K206C. The bar size indicates how much crosslinking was identified per region and per
mutation. If the crosslinking was identified in either the principle or complementary subunit, the bar is
shorter; if crosslinking was identified in both principle and complementary subunits, the bar doubled in size.
The maximum count a region could receive is 6, for both subunits having crosslinking for all mutations. If
crosslinking was not seen in a particular region at all, that state received a ‘zero’. Figure 18 identifies the
residues for all peptide regions.

state. It is likely that position 116 is in a less mobile region that position 206, and this could
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be why it sees less crosslinking to the intracellular loop.
With respect to the peptide regions, there is a greater amount of crosslinking
identified at the beginning (310QHKELLR316 and 317 FRRKRRHHK325) and the end of the
loop (378 KLFIQRAK385 and 386 KIDKISR392), for all mutations and in all states. The regions
that have the highest amount of crosslinking overall is
378KLFIQRAK385.

372SPEEMR377

and

The reasoning behind this, based on the sequence, could be due to CPP-

like behavior. Peptide 2, in particular, consists of most of the basic stretch in α1-GlyRs,
316

RFRRKRR322 which according to Sadtler et al.,420 contains the NLS and binds to

intracellular proteins to allow its entry into the nucleus. It is also binds to the G-protein
subunit Gβγ, as does a di-Lys region, 385 KK386.388,422 Interestingly enough, this interaction
has been shown to enhance glycine induced current,423 and mutations to these residues
results in a non-functional receptor.419 The basic stretch also binds allosteric modulators,
like ethanol and cannabinoids.424–427 These modulators have also been proposed to bind to
the TMD region at M1, M2 and M3,390,462,475-479 and though this does not mean the M3-M4
loop is binding to these modulators in a hydrophobic environment like the membrane, but
it is interesting and requires further study. the TMD region at M1, M2 and M3,390,462,475479

and though this does not mean the M3-M4 loop is binding to these modulators in a

hydrophobic environment like the membrane, but it is interesting and requires further
study.
Another interesting peptide, parts of peptides 5 and 6, 358NNSNTTNPPPAPSK372
has been proposed to play a role in desensitization, and folding stability in α3-GlyRs.405
These

regions

are

also

identified

as

common

motifs,

the

poly-asparagine

(358NNSNTTN364),388 and the polyproline motifs (366 PPPAPS371), which may have helical
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structure387,428 and also forms the SH3 consensus sequence.429,430 Crosslinking to these
regions was identified by positions 287 and 206 in the resting state, only 287 in the open
state, and 116 and 206 in the desensitized state. It is unclear why these regions are
visualized in varying patterns by the network, and could simply mean due to poly-R/K
regions in the loop, they are brought into close enough contact.
K206C also saw crosslinking to two unique peptides,
334

326EDEAGEGR333

and

FNFSAYGMGPACLQAK349, not identified by any other mutant, and only seen in

desensitized state results. Those these two peptides do not have poly-R/K regions, they are
relatively close, sequentially to peptide 2, and that could be why they were able to be
brought into close enough proximity to crosslink to position 206. But why only in the
desensitized state? This is currently unclear and needs to be studied further.
Phosphorylation of the loop may also play a role in how the loop interacts with the
membrane and the rest of the receptor. α1-GlyRs have a phosphorylation site at S391.445
Studies that analyze phosphorylation of this site may shed light on how the loop changes
with the addition of a large negative charge. The addition of single site-specific cysteine
mutations to the M3-M4 loop may also increase the knowledge of how the loop is moving
as the receptor shifts allosterically and how it interacts with the membrane.
5.5. Mapping Mobility
CX-MS, because full-length, functional proteins are used in its analysis, can study
protein dynamics. This cannot be visualized with other high-resolution techniques and so
provides additional information that should be taken into account as current structural
models are refined, or as new ones are built. Multiple studies have shown dynamic areas
to be the C-loop, the ECD-TMD interface, and likely, the M3-M4 loop.238,304,388,389 This
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work is in agreement with these studies (Figure 21). The C-loop, and the β-sheets that are
Figure 21. Proposed mobile regions of α1-GlyR. Analysis of all regions with respect to all mutations and
conformational states reveals various regions that show mobility. In order to be scored as mobile, the
region had to be found in each mutation, and at least one state, and have a different pattern of crosslinking
refinement between the conformational states. These areas were then mapped onto PDB:3jad, in orange.
Represented below are clockwise from the right, the cartoon schematic of α1-GlyR, with the bead model
of the M3-M4 loop, the bottom-up view and the top-down view of the receptor.

Top-down

Bottom-up

connected to it show mobility with respect to all mutants in the network. The ECD-TMD
interface, but particularly, the M2-M3 loop, and the Cys-loop also show dynamic changes
as the receptor transitions between resting, open and desensitized states. The intracellular
loop, which is not resolved in crystal structures is likely mostly unstructured, but appears
to be dynamic at the beginning and the end of the loop. Lastly, the upper ECD may also be
a dynamic region, as it has varying crosslinking with respect to the mutants in this network.
Due to the considerable length of MTS-bzp, and that the length tolerance should most likely

144

be increased more than the additional 3-5 Å,20,123,224 it is difficult to fully describe the
dynamics on a static crystal structure. It also becomes difficult to truly understand how this
relates to model inconsistency. Does one structure fit the data more so than another? Is the
apo-state receptor more flexible? These questions can be better answered by using a larger
network, and the addition of varying-length crosslinkers.
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CHAPTER 6. SCIENTIFIC IMPACT AND FUTURE DIRECTIONS
6.1 Overall Conclusions
The major takeaways from this work can be split into five categories; (1) the utility
of CX-MS for protein structure studies, (2) the capability of the methodology to discern
various conformational states of resting, open and desensitized, (3) the compatibility and
complementarity of CX-MS to other high-resolution techniques, (4) the ability to resolve
missing pieces in current crystal structures, and (5) that protein dynamics and mobility can
be examined using CX-MS.
By using only small gel plugs excised from SDS-PAGE, and analyzing the sample
via MS, dozens of unique crosslinking sites were identified. CX-MS does not require large
concentrations of sample and can provide valuable information with only femtomolar
quantities.5 The analysis of three single, site-specific cysteine mutations led to the
identification of 145 intramolecular crosslinks and 80 intermolecular crosslinks.
Enriching the receptor in its conformational states: resting (MTS-bzp), open (MTSbzp + IVM) and desensitized (MTS-bzp + excess glycine) resulted in unique crosslinking
constraints for all states. It was originally thought that there would be carryover from
resting state data into the other conformational states and that the resting state would not
have unique sites, but that was not seen. Instead, each conformational state could be
effectively enriched and unique information for the three states could be identified. This is
of course, most important in terms of understanding the apo-state, since no crystal
structures accurately define this state for GlyR, but is also useful for studying the
desensitized state, as there is disagreement in what structurally defines a desensitized state.
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CX-MS, though low-resolution, has the ability to complement high resolution
techniques. The information gained from CX-MS studies is valuable as it has the ability to
examine a full-length, functional protein of any molecular weight in native conditions. It
cannot provide minute details, as cryo-EM and x-ray diffraction can, but it does provide
compatible data that helps understand a protein or protein complex in a dynamic way.
Furthermore, CX-MS is incredibly valuable for the study of membrane proteins.
Truncations, and mutations for stability often render a structure that has missing
pieces or unresolved regions. CX-MS can provide information on these regions, since fulllength, functional proteins are used in these studies. With respect to this work, the M3-M4
loop was able to be visualized, which gives valuable insight into its structure and position
in various conformational states of GlyR. It is known that the M3-M4 loop in pLGICs is
variable and distinguishes them from one another. It affects gating, desensitization,
trafficking, and degradation. Discovering what parts of the loop are interacting with the
membrane or with other parts of the channel can help better understand how this loop
modulates function of the receptor. It appears that non-conducting states, the resting and
desensitized states, involve a M3-M4 loop that is associated with the membrane, but the
open state seems to lack this involvement. Studies analyzing M3-M4 loop mutants may
help to clarify this.
Experiments on pLGICs have reported areas known to be mobile, including the Cloop, the M2-M3 loop, the Cys-loop and likely, also the M3-M4 loop. This work has come
to an agreement that these areas are indeed dynamic and contribute to the transitions
between resting, open and desensitized states. This work has also shown that the upper
ECD region may be mobile as well, though the reason behind this is unclear.
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6.2 Scientific Impact
Because the structure of a protein is fundamentally linked to its function, having a
complete understanding of the structure and all of its parts, as well as a deeper
understanding of how the protein is shifting allosterically as it transitions through resting,
open and desensitized states, will lead to advancement in therapeutics. Therapeutics are
derived from protein structural knowledge. For instance, chronic pain, a debilitating, and
quite common disorder, is linked to the glycine receptor. These studies are a step forward
towards understanding this receptor, developing drugs based on this knowledge and
alleviating chronic pain symptoms.
This methodology can be applied to all of the members of the pLGIC family, and
proteins in general, which will lead to similar discussions of other proteins in this family,
as well as other transmembrane proteins that are particularly difficult to purify and
crystallize. Transmembrane proteins make up the large majority of therapeutic targets but
are not represented well in crystal structures, as the majority of structures are of soluble
proteins. With the addition of CX-MS to the structural biochemist’s toolbox, a multitude
of diseases, disorders and conditions can see treatment improvements as structure
determinations improve.
6.3 Future Work
This work is an ongoing project. The network of mutants to which the structural
roadmap is built is increasingly getting larger. The three mutants analyzed (M287C, K116C
and K206C) will be added to two prior mutations, A41C and H419C602 in future
publications. And, currently, other mutants are being analyzed to grow the network further:
two upper ECD mutants K6C and G23C, and a C-terminal tail mutant, I412C.
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As addressed in Chapter 1, the utilization of different length crosslinkers can be
crucial to a more complete structure as they provide different radii in which various points
of interest are connected. They can help provide reciprocity; if A links to B, and B to C,
does A link to C? And if the crosslinking distance between A, B or C is shortened, are they
still interacting? A diazirine crosslinker is being proposed to crosslink to the network
already described (Figure 22). Using other crosslinker functionalities may also help
Figure 22. MTS-Diazirine Crosslinker. At a
length of approximately 12 Å, this crosslinker
is about half as long as MTS-bzp, and thus can
extend the information that each single, sitespecific mutation point is crosslinking to.
O

O

N

S
S

N

alleviate any binding bias the crosslinker may
have. One study has proposed that MTSbenzophenone crosslinkers have a tendency to
bind to Met at a higher rate,663 but there is no
evidence of this reported in this work.

Further work will also be conducted on the M3-M4 loop. Though this work has
made important discoveries into its mobility and dynamics, there is much more to address.
Analyzing mutants within the loop will help determine reciprocal linking between mutants
already in the network as well as provide new information into the dynamic positions of
the loop during conformational states. It may also help answer the question of membrane
permeability by the loop, given its poly-R/K regions.
Another important piece of studying membrane proteins like GlyR is its interaction
with various lipids within the membrane. CX-MS is a valuable tool to study protein-lipid
interactions. Studies have already been conducted analyzing cholesterol concentrations,14
and are currently ongoing with the intention of studying how varying concentrations of PC
and PA affect the structure of the glycine receptor.
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Lastly, quantitation of crosslinking is particularly useful. The peaks in MS spectra
do not give information on how abundant a peptide is, just its ability to be ionized.
Quantitation would aid in determining which sites of attachment are more favorable or
common than others versus which sites might be less abundant. This is also a currently
ongoing investigation in the Cascio lab.
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